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Autophagy is a catabolic process involved in homeostatic and regulated cellular protein recycling 
and degradation via the lysosomal degradation pathway. Emerging data associates Crohn’s Disease 
(CD) with an impaired ATG16L1 autophagy gene. Increased activity in the endocannabinoid 
system and up-regulation of suppressor of cytokine signalling (SOCS)-3 protein expression are 
evident in inflamed intestine. We accessed the impact of phyto-cannabinoid (CBD), synthetic 
cannabinoid (ACEA) and endocannabinoid (AEA) on autophagosome formation, and investigated 
the mechanisms involved. Our findings show that all three cannabinoids induce autophagy in a 
dose-dependent manner in fully differentiated CaCo2 cells. ACEA and AEA induced canonical 
autophagy, which was cannabinoid receptor (CNR)-l mediated. In contrast, CBD-induced 
autophagy is partially non-canonical and not CNR1 receptor mediated. Functionally, all three 
cannabinoids reduce SOCS3 protein expression. Blocking of autophagy reversed the cannabinoid- 
induced effect. In conclusion, CBD may have potential therapeutic application in CD where 
functional CNR1 receptor or autophagy is compromised and the regulatory protein, SOCS3, is 
itself regulated by the autophagy pathway.
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1.1 The gastrointestinal (GI) tract
The gastrointestinal (GI) tract is an organ whose major role is nutrient digestion and absorption. 
A single layer of intestinal epithelial cells line the entire GI tract layer and thus, provide a 
barrier for microbes in the intestine (Figure 1.1). This barrier exhibits the capability by the 
formation of intercellular tight junctions on the cell layer. Disruptions of the epithelial layer 
will lead to activation of inflammatory immune response as the host will be exposed to various 
















@  Fully differentiated cells 
0  Proliferative progenitors 
Stem cells 
A  Paneth cells
Figure 1.1. Schematic diagram for small and large intestine. (A) Structure of small intestine. 
Stem cells are located above the Paneth cells. Proliferation occurs and cells migrate towards 
villus. Progenitors stop proliferating at the villus-crypt junction and start to differentiate. (B) 
Structure of large intestine. Stem cells are located at the bottom of the crypt. Proliferation 
occurs at the bottom of the crypt and starts to differentiate when it reaches the top third of the 
crypt.
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The small intestine can be further segregated into duodenum, jejunum and ileum. The small 
intestine contains villi - finger like structures which project into the lumen of the intestine. This 
feature is crucial in the small intestine as it increases the surface area of absorption (Wilson, 
1962). Conversely, this feature is absent in the large intestine (Figure 1.1). Instead of having 
the villi structure, large intestine contains only crypts of Lieberkuhn and a flat surface of 
epithelial cells.
As the undifferentiated multipotent stem cells migrate from the bottom of the crypt to the apical 
surface of the crypt and villus structure, these cells are proliferation and differentiation into 
different epithelial lineages, which include Goblet cells, Paneth cells, and enterocytes. A 
Goblet cell is a flat shaped cell which is responsible for mucin production; mucin protects the 
epithelial surface from microbial invasion, as well as facilitating the movement of food along 
the GI tract (Kufe, 2009). Paneth cells, on the other hand, are responsible for secreting anti­
microbial proteins into the lumen of the gut (Klionsky, 2009; Radtke and Clevers, 2005). As 
for the enterocytes or intestinal absorptive cells, these cells form the majority of the intestinal 
epithelium. A microvillus brush border develops along the apical surface of the cells as cells 
differentiate along the upper crypts. The primary role of a brush border is to increase the area 
of adsorption and facilitate the transport of molecules and ions from the intestinal lumen.
1.1.1 Crosstalk between intestinal epithelium and intestinal microbes 
The intestinal epithelium forms a physical barrier between the intestinal microbes and the 
lymphoid tissue (Abraham and Cho, 2009). Under normal physiological conditions, 
intestinal microbes reside in the gut and contribute towards the regulation of basic 
physiologic functions, which include the metabolic and immune functions (Blaut and 
Clavel, 2007; Frazier et al., 2011; Flint, 2012). Microbiota composition may impact on 
individual differences in immune response towards immunological condition and such
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microbiota composition changes in accordance with age and external factors, such as 
environmental condition and diet (Hooper et al., 2002; Biagi et al., 2012). Research 
studies proposed that the host is capable of recognizing microbial presence in the 
intestinal epithelium by identifying the microorganism-associated molecular pattern 
(MAMPs) through specific pattern-recognition receptors (PRRs) and that this interaction 
contributes to the crosstalk between intestinal epithelium and intestinal microbes. PRRs 
are innate immune membrane-bound or cytosolic molecules that recognize bacterial 
MAMPs; for example, the un-methylated CpG (cytosine-guanine) motif which is well- 
conserved in bacterial DNA and the lipopolysaccharide (LPS) in gram-negative 
organisms (Rautava and Walker, 2007). Apart from recognizing bacterial structure, PRRs 
also identify the presence of protozoan, fungal and the single-stranded RNA characteristic 
of viral structure (Akira et al., 2006). One of most studied examples of PRRs is human 
Toll-like receptors (TLRs). TLRs have been shown to express on both intestinal epithelial 
cells and immune cells such as dendritic cells and macrophages (Didierlaurent et al., 2005; 
Sirard et al., 2006). Activation of TLRs by microbial ligands will initiate the host’s 
immune response, via the production of cytokines, chemokines or co-stimulatory 
molecules (Sirard et al., 2006; Rautava and Walker, 2007).
Despite various studies having been performed to investigate the interaction between 
intestinal epithelium and intestinal microbial, the mechanism which commensal microbes 
adopt to influence the host physiology and vice versa remains largely unknown. This may 
due to the effect commensal microbes have on host physiology is largely dependent on 
the microbe-microbe interaction in the GI tract, and such a dynamic ecosystem of 
commensal microbes is very difficult to recapitulate in the laboratory setting. To date, 
data relating to the crosstalk between the host and commensal microbes has been derived
mainly from studies with the use of germ-free or gnotobiotic animal models. As such, 
accumulating evidences has identified the role of commensal microbes in the 
development of the GI tract. For instance, commensal microbiota has been shown to 
affect the composition and thickness of the mucosal layer in the GI tract (Sharma et al., 
1995; Deplancke and Gaskins, 2001; Petersson et al., 2011). Sharma, et al.’s study 
revealed that germ-free rats possess fewer goblet cells, a thinner mucus layer and a higher 
percentage of neutral mucins in the colon as compared to conventionally raised animals. 
Interestingly, the conventional mucus properties can be re-introduced into the germ-free 
animal through the stimulation of microbial ligands, such as LPS and peptidoglycan 
(Petersson et al., 2011), suggesting an indirect role of commensal micoflora in inducing 
defence mechanisms against the invading pathogens via the formation of an intestinal 
mucosal layer. In addition, commensal microbes are also involved in the modulation of 
epithelial permeability in the GI tract. This was demonstrated through a study where 
gram-negative bacterium, Bacleroides thetaiotaomicron, increased the resistance of the 
gut to injury in the germ-free mice through the induction of small amounts of proline- 
rich protein 2A (SPRR2A), a protein involved in the maintenance of the epithelial 
junctional complex (Hooper et al., 2001). Such an effect is not limited to commensal 
microbes, several probiotics, strains such as Lactobacillus plantarum 299v and 
Lactobacillus reuteri R2LC, have also been shown to reduce intestinal epithelial 
permeability in the methotrexate-induced colitis rat model (Mao et al., 1996).
Considering the beneficial functional outcomes contributed by commensal microbes and 
the fact that the host is tolerant towards indigenous microbes, this suggests that the host 
may respond to the commensal microbes through a distinct pathway. However, the 
mechanism utilized by the host to discriminate between indigenous microbes and
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pathogens has long been a fascination. The host immune system has to be able to respond 
adequately to the recognition of pathogens that may act as a potential threat to the tightly 
regulated host immune response without invoking inflammatory activity, as the failure of 
such regulation may lead to the onset of chronic intestinal inflammation. An interesting 
study by Lee et al. (2006) showed that TLR9, a receptor which is expressed on both apical 
and basolateral surfaces of the intestinal epithelial cells, induces distinct inflammatory 
response despite both compartments express similar TLR9. In contrast to the basolateral 
TLR9, apical TLR9 stimulation fails to activate both the nuclear factor kappa-light-chain- 
enhancer o f activated B cells (NK-kB) and extracellular signal-regulated kinase (ERK) 
signalling pathways, or the secretion o f pro-inflammatory cytokine interleukin (IL)-8. 
cDNA microarray analysis revealed that both basolateral and apical TLR9 regulates a 
distinct set o f genes and only 40% of the ov erall induced-targets are shared between the 
apical and basolateral TLR9 stimulated response, suggesting that, even though TLRs fail 
to distinguish MAMPs which are present in both commensal microbes and pathogen, 
TLRs may still be able to act differentially in accordance to the location and induce 
inflammatory response against pathogens that penetrate through the intestinal epithelial 
cells barrier.
1.1.2 Inflammatory bowel disease
Inflammatory bowel disease (IBD) comprises two major types of intestinal disorders: 
Crohn’s Disease (CD) and Ulcerative Colitis (UC) (Abraham and Cho, 2009). Both of 
these diseases are chronic diseases associated with inflammation in the gastrointestinal 
(GI) tract. According to the Crohn’s and Colitis UK, IBD affects about 1 person in every 
250 in the UK population. They have shown that the common age for the diagnosis for 
IBD is between 10 and 40. For UC, between 6000 and 12000 new cases are being 
diagnosed in each year whereas for CD, the number of new cases is less compared to 
UC (between 3000 to 6000 new cases per year).
In CD, inflammation can occur anywhere in the digestive system, from mouth to anus. 
However, it mostly affects the small intestine and colon. CD leads to the growth of ulcers 
and presence of scars on intestinal wall. In contrast, for UC, inflammation occurs via tiny 
ulcers in the rectum and colon. The common features for CD include the fat wrapping, 
thickening of the intestinal wall and the formation of cobble-stoning on the intestinal wall 
(Figure 1.2). In contrast, the common features for UC include distortion of the crypt 
structure, the loss of mucosa and haustra and the formation of pseudopolyps on the 
intestinal wall (Figure 1.2).
The common symptoms associated with both of these diseases include pain, diarrhoea 
and general tiredness. One of the hallmarks for CD is severe weight loss in CD patients. 
One fifth of the adults in IBD clinic are 85% under their ideal body weight (Gee et al., 
1985). The failure in gaining weight can lead to anorexia and contribute to the increased 
secretion of several pro-inflammatory cytokines, for instance, tumor necrosis factor- 
alpha (TNF-a) and IL-1.
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Figure 1.2. Common features of Crohn’s disease and Ulcerative colitis.
Image source: John Hopkins Medicine Gastroenterology & Hepatology.
1.1.3 Role o f  intestinal microbes in pathogenesis o f  IBD
To date, accumulating clinical evidences suggest that the dysregulation of the immune 
response to commensal micoflora plays a role in the pathogenesis of intestinal 
inflammation, such as IBD in the GI tract (Frank et al., 2007; Abraham and Cho, 2009; 
Knights et al., 2013). Studies showed that the GI tracts of both UC and CD patients 
suffered from a depletion of commensal microbes, such as Firmicutes and Bacteroidetes, 
as compared to the non-IBD controls (Frank et al., 2007).
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Amongst Firmicutes, Faecalibacterium prausnitzii induces anti-inflammatory activities 
in the GI tract by enhancing the mucosal barrier function, increasing intestinal mucous 
production and stimulating the production of immunosuppressive cytokines such as IL-
10. This microbial population has also been shown to have a significant reduction in the 
biodiversity of intestinal microbiota in CD patients, as opposed to healthy controls 
(Sokol et al., 2008; Looijer-van Langen and Dieleman, 2009). Apart from Firmicutes, 
IBD patients also exhibit a decrease in the abundance of Bacteroidetes, in particular the 
Bacteroides fragilis (Swidsinski et al., 2005). In contrast to the decrease o f both 
Firmicutes and Bacteroidetes microbial populations in the inflamed gut, studies have 
reported an increase of Proteobacteria and Actinobacteria in patients with active IBD 
(Frank et al., 2007; Peterson et al., 2008; Chassaing and Darfeuille-Michaud, 2011). For 
instance, an increased number of mucosa-associated Escherichia coli (E.coli) has been 
shown in CD patients. These adherent-invasive E.coli (AIEC) invade the intestinal 
epithelium cell barrier by adhering to the epithelial cells, followed by the replication 
within these cells. The high prevalence of AIEC in CD patients may be the outcome 
from the failure of intestinal mucosa to limit microbial invasion, a consequence from the 
defect in Paneth cell function and the subsequent decreased secretion of antimicrobial 
peptides in the GI tract (Chassaing and Darfeuille-Michaud, 2011).
Overall, even though there are significant findings suggesting an association o f dysbiosis 
o f intestinal micoflora to the pathogenesis of IBD, it is still unclear as to whether the 
dynamic changes in the gut microbiota is a cause or a consequence of chronic intestinal 
inflammation.
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1.2 Cannabinoids
The therapeutic properties of cannabis are first described in Chinese pharmacopoeia dating 
back to 200A.D, whereas intensive studies with the compound only began in the western 
world from the 19th century onwards. Since then, research on cannabis has moved 
progressively from the plant to its components, the associated receptors and the endogenous 
counterparts in the mammalian system (Di Marzo, 2006). In the 1970s, Hans Kosterlitz and 
John Hughes, from Marischal College in Aberdeen, started to question the presence of 
morphine receptors in the mammalian brain and proposed that such receptors should not only 
be activated via the plant substances, but also via the ligands which are made in associate with 
the receptor within the mammalian system. Given this, together with Howard Morris, from 
London, they then discovered enkephalins, the endogenous agonist for the uncloned opiate 
receptors (Hughes et al., 1975). Based on the discoveries of endogenous “morphine-like” 
compounds, Raphael Mechoulam and his group from Jerusalem strongly believed in the 
presence of endogenous ligands for the cannabinoid receptor (CNR)-l, a receptor which is 
highly expressed in mammalian’s brain. In 1992, together with Roger Pertwee from Marischal 
College, they successfully isolated and chemically identified Anandamide (AEA), the first 
discovered endogenous cannabinoid (Devane et al., 1992). This was followed in 1995 by the 
discovery of a second endogenous CNR1 ligand, 2-arachidonoylglycerol (2-AG), by a 
Japanese team (Sugiura et al., 1995). Later, in 1998, with the discoveries and recognitions of 
various endogenous ligands for CNR, Vincenzo Di Marzo from Italy proposed the term 
“endocannabinoids” for all endogenous cannabinoid ligands and from this evolved the so- 
called “endocannabinoid system” which consists of the cannabinoid receptors, their 
associated ligands, the enzymes and the proteins which regulate the ligand concentration (Di 
Marzo, 2006).
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1.2.1 The endocannabinoid system
The endocannabinoid system (ECS) consists of endogenous cannabinoids, cannabinoids 
receptors and enzymes that are involved in either synthesizing or degrading endogenous 
cannabinoids. At first, it was thought that the action of ECS mainly occurred in the 
centre o f the brain, however, it was soon discovered that apart from the brain, GI tract, 
liver, pancreas, adipose tissue, and skeletal muscle are all involved in the network of 
the ECS (Cluny et al., 2012).
Endocannabinoids are endogenous lipid signalling molecules. Interestingly, 
endocannabinoids mimic the pharmacology activity of A9-THC, an active compound of 
marijuana, Cannabis sativa. A9-THC, as well as endocannabinoids is shown to be 
primarily regulated through the cannabinoid G protein coupled receptors: cannabinoid 
receptor CNR1 and CNR2. The finding of the cannabinoid receptors have led to the 
discovery of other THC-like compounds: A-arachidonoylethanolamine, or AEA and 2- 
AG (Bisogno, 2008; Cluny et al., 2012). Little was known of the endogenous role of the 
receptors until AEA, 2-AG and other endocannabinoids were identified. 
Endocannabinoids are formed by amides, esters, and ethers of long-chain 
polyunsaturated fatty acids. To date, five classes of endocannabinoids have been 
identified: AEA, 2-AG, Noladin ether, virodhamine and lastly TV-arachidonoyldopamine 
(NADA) (Bisogno, 2008; Piomelli, 2003). Unlike other modulators that are 
biosynthesized in advance and stored in intracellular compartments for later use, 
endocannabinoids are synthesized on demand through the regulation of the intracellular 
concentration of Ca2+ (Cluny et al., 2012).
12 | P a g e
XOjPO-
,0— P  = 0
PLA2
— P = 0
j PL(










Figure 1.3. Major biosynthesis pathway for endocannabinoid anandamide (AEA). The 
pathway is divided into two major enzymatic reactions. The first step is the formation 
of A-ArPE where the fatty acid chain from sn-1 position of glycerophospholipids is 
transferred to the amino group of phosphatidyl-ethanolamine. This step is catalysed by 
enzyme NAT. Next, there are four major pathways lead to AEA formation. A-ArPE can 
either be catalysed by PLC and PTPN22 via the formation of phospho-AEA or by PLA2 
and lyso-PLD via the formation of 2-lyso-A-arachidonoyl-phosphatidylethanolamine, 
or by Abh4 and phosphodiesterase via formation of glycerol-phospho-AEA or by 
NAPE-PLD.
*Redrawn from Bisogno, 2008.
Abbreviation: AEA, anandamide; N-ArPE, N-arachidonyl-phosphatidylethanolamine; NAT, trans-N- 
acyltransferase; PLC, Phospholipase C; PTPN22, Protein tyrosine phosphatase 22; PLA2, Phospholipase 
A2; lyso-PLD, Lyso-phsopholipase; Abh4, x ^ -^ r o la s e ;  NAPE-PLD, N-arachidonylphosphatidyl- 
ethanolamide phospholipase D.
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i. Biosynthesis and hydrolysis of Anandamide
Anandamide (AEA) is synthesized by three phospholipase in its biosynthetic pathway: 
N-arachidonylphosphatidylethanolamine phospholipase-D (NAPE-PLD) (Bisogno, 
2008; Ueda et al., 2005), a subtype of phospholipase C (PLC) and Phospholipase A2 
(PLA2) (Bisogno, 2008). Apart from those three phospholipases, enzymes such as trans- 
N-acyltransferase (NAT) and x//?-hydrolase (Abh4) are also involved in biosynthesis of 
AEA (Bisogno, 2008). The pathway for biosynthesis of AEA is shown in Figure 1.3.
NAPE-PLD, the major enzyme that catalyses the formation of AEA, has a distinct 
characteristic compared to other PHD enzymes. NAPE-PLD has no selectivity for the 
fatty acid moiety on sn-1, sn-2 or A-position of NAPEs (Okamoto et al., 2004). Even 
though NAPE-PLD is named as phospholipase D, its amino acid sequence shows that 
there is no shared homology between NAPE-PLD and other phospholipase D enzymes 
(Okamoto et al., 2004). AEA is the ligand for CNR1 and CNR2 receptors which are 
located in the surface of the target cells. In addition to its endocannabinoid activity, 
AEA is also an “endovanilloid”, which binds to the intracellular binding site o f the 
Transcient Receptor Potential Vanilloid type 1 (TRPV1) receptor (Van Der Stelt and 
Di Marzo, 2004).
AEA is rapidly hydrolysed and thus removed from the extracellular space by fatty acid 
amine hydrolase (FAAH). During hydrolysis, FAAH breaks the amide bond of AEA to 
yield arachidonic acid (AA) and ethanolamide (Ueda et al., 2005). By doing that, FAAH 
is controlling the cellular uptake of AEA by maintaining or creating the concentration 
gradient between the intracellular and extracellular space that facilitates diffusion of 
AEA.
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Studies suggest there is a membrane transporter that facilitates the diffusion of AEA 
from the extracellular milieu into extracellular space, named the AEA membrane 
transporter (AMT). Accumulation of AEA in FAAH knock-out mice gave the indication 
of the existence of additional mechanisms involved in the up-taking of AEA (Fegley et 
al., 2004). Additionally, discovery and development of several compounds such as 
AMI 172 inhibitor, which appeared to have the capability to inhibit cellular uptake of 
AEA but not the AEA hydrolysis via FAAH, also support the existence of AMT (Fegley 
et al., 2004). However, this is still under investigation and the existence of AMT will 
only be certain if further molecular evidences of AMT are found.
ii. Functional consequences of AEA
As for the functional consequences for AEA, this endocannabinoid has been shown to 
be greatly involved in the modulation of pain, anxiety, as well as the angiogenesis and 
apoptotic process during tumour progression (Luchicchi and Pistis, 2012; Portella et al., 
2003).
The role of AEA in anxiety modulation is demonstrated through the study where 
enhanced AEA successfully reversed the anxious phenotype in mice which had been 
exposed to stress and the AEA-induced effect was mediated via the CNR1 receptor. In 
agreement with that finding, the in vivo study also showed that by knocking out the 
FAAH gene in the system, the anxiety-like behavioural response was significantly 
reduced in mice and such effect was shown to be CNR1 mediated (Rossi et al., 2010). 
This implied that the AEA-induced effect on anxiety modulation is mediated through 
the CNR1 receptor and such outcome may possibly correlate to the inhibition of FAAH.
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Apart from the role of AEA in tumour progression, the study showed that administration 
of endocannabinoid analog 2-methyl-arachidonyl-2-fluro-ethylamide (Met-F-AEA) to 
mice with K-ras established tumours, dramatically reduced the tumour size, as 
compared to untreated mice. This effect, however, was significantly inhibited once the 
treatment was replaced by the CNR1 antagonist SR141716A (Portella et al., 2003). Met- 
F-AEA is also capable in inhibiting p21ras and subsequently, this can lead to the 
inhibition of angiogenesis by down-regulation of vascular endothelial growth factor 
(VEGF) (Portella et al., 2003). This implied that AEA may reduce tumour progression 
by inhibiting angiogenesis in the tumour cells and such an effect may be CNR1 mediated.
iii. The cannabinoid receptors
CNR1 and CNR2 are two of the well-studied examples of cannabinoid receptors. CNR1 
is proficient in coupling and activating Gj/Go stages in cell cycle, whilst CNR2 selectivity 
actuates Go (Glass and Northup, 1999). CNR1 was the first to be discovered and studies 
have shown that the expression level of CNR1 is high in the brain regions that associate 
with cannabinoids and low in regions where cannabinoids are not normally produced 
such as the respiratory centres of medulla (Herkenham et al., 1991). The binding of 
cannabinoids to CNR1 activates many important signalling pathways that control cell 
fate. These include phosphatidyl inositol-3-kinase (PI3K) and its downstream effector 
protein kinase B (PKB/AKT) signalling pathway, ERKs, c-Jun N-terminal kinase (c-JNK) 
and the p38 MAP kinase pathway (Guzman, 2003).
CNR2 was discovered much later than CNR1, as the expression of CNR2 in the cell is 
lower than that of the CNR1 receptor, resulting in difficulty in creating a highly selective 
antibody for the CNR2 (Van Sickle et al., 2005). Studies have shown that the CNR2 is
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expressed in immune cells, suggesting that CNR2 has a role in the human immune 
function (Demuth and Molleman, 2006).
1.2.2 Cannabidiol (CBD)
A9-THC is commonly viewed as the main component that contributes to the cannabis- 
induced effect but the presence of cannabidiol (CBD), another component which may 
constitute up to 40% of the cannabis extracts, has often been neglected (Zuardi et al., 
2006). CBD was first isolated from marijuana extract in 1940. However, there was a 
halt in the journey of discovery as no finding was reported for the following 25 years. 
The next CBD-related finding was published on 1963 by Mechoulam and Shvo where 
the chemical structure of CBD was revealed. Up to 1975, CBD was reported alongside 
other cannabis in the publications, but not many studies only concentrated on the action 
of CBD itself. Only recently (from early 2000’s), CBD research started to gain the 
attention of various research groups, as CBD is a non-psychotropic cannabinoid and 
exerts positive pharmacological effects in response to inflammation, cancer and even 
neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases (Antonio 
Waldo, 2008; Capasso et al., 2008; Izzo et al., 2009). To date, CBD has been used in 
combination with A9-THC in a 1:1 ratio in Sativex® drug for treating multiple sclerosis 
(Izzo et al., 2009).
i. CBD in Endocannabinoid system (ECS)
CBD, unlike A9-THC, possesses a low binding affinity for both CNR1 and CNR2 
receptors. Apart from the cannabinoid receptors (CNR1, CNR2), CBD also acts as the 
receptor antagonist for the orphan receptor, GPR55 (Antonio Waldo, 2008). 
Nonetheless, administration of CBD also stimulates the TRPV1 receptor (Bisogno et al.,
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2001), a receptor which also binds to the endocannabinoid, AEA. Furthermore, studies 
also showed CBD modulated ECS by inhibiting the FAAH-mediated hydrolysis of AEA 
(Capasso et al., 2008; Watanabe et al., 1996), suggesting that such effect may be 
mediated through TRPV1 receptor.
ii. Anti-inflammatory action of CBD
Various in vivo and in vitro studies have demonstrated that the phytocannabinoid, CBD 
acts as an anti-inflammatory agent by reducing the production of pro-inflammatory 
cytokines. CBD decreased the production of tumour necrosis factor (TNF)-a in LPS 
treated mice through an adenosine receptor activation (Izzo et al., 2009). Additionally, 
CBD has also been shown to reduce croton oil-induced hypermotility in mice and this 
was shown to be regulated through CNR1 and FAAH (Capasso et al., 2008). This 
finding implies that CBD may be a potential therapeutic drug to normalise motility in 
patients with inflammatory bowel disease (IBD).
1.2.3 Cannabinoids in IBD
Various studies have been performed to look into the role of the ECS in gut homeostasis 
and its relation to the occurrence of IBD. Overall, ECS is shown to be involved in the 
modulation of inflammation, motility, and permeability of the GI tract (Alhouayek and 
Muccioli, 2012; Di Marzo and Izzo, 2006; Izzo et al., 2001; Massa et al., 2004; Wright 
et al., 2005).
During intestinal inflammation, up-regulation of endocannabinoid levels and the 
increased expression of cannabinoid receptors will enhance the action of 
endocannabinoid system (Di Marzo and Izzo, 2006). This is shown by the increased 
CNR1 receptor expression in the colon of the intrarectal dinitrobenzene sulphonic acid
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(DNBS) treated mice (Massa et al., 2004). Apart from that, they also highlighted the point 
that by knocking out the CNR1 gene, it will lower the inflammatory score of the DNBS- 
treated mice. On the other hand, study showed that in healthy human intestinal epithelium, 
the CNR2 expression is weak. In IBD patients, there was an increased expression in 
CNR2 receptor (Wright et al., 2005). However, the actual function and mechanism 
regarding the increased CNR2 expression on the epithelial cells remains unknown. Most 
of the findings associated with the CNR2 receptor showed that activation of the CNR2 
receptor will lower the secretion of pro-inflammatory cytokines from immune cells. 
Consequently, this benefits the shift away from inflammation (Klein, 2005).
Next, ECS is also involved in the modulation of gastrointestinal motility. The 
hypermotility of the intestinal tract is often related to the onset of chronic IBD, which 
predominantly leads to the consequent effect of diarrhoea due to an increase in secretion 
and/or a decrease in absorption, with reduced colon contractility (Alhouayek and 
Muccioli, 2012). Studies showed that cannabinoid receptors are capable of inhibiting 
inflammation-induced hypermotility. The treatment of CP55940, an agonist for both 
CNR1 and CNR2 receptors delayed the intestinal motility in inflamed mice. The 
CP55940 induced effect was inhibited by CNR1 antagonist but not by CNR2 antagonist, 
suggesting that CNR1 but not CNR2 is involved in the modulation of hypermotility in 
the GI tract (Izzo et al., 2001). As previously stated, CNR1 is highly expressed during 
inflammation and with the finding of C N R l’s role in inhibiting gastrointestinal 
hypermotility, this suggests that the increased CNR1 expression may be beneficial to 
normalize the hypermotility observed in IBD.
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Increased intestinal permeability is implicated in IBD pathogenesis, as the presence of a 
leaky intestinal barrier will promote microbial invasion through the mucosal tissue, 
which subsequently leads to an increase in pro-inflammatory cytokine production, 
resulting in chronic inflammation. Study showed that both A9-THC and CBD are capable 
of modulating intestinal permeability by increasing the recovery time of EDTA-induced 
increased permeability in CaCo2 cell and such effect was CNR 1-dependent (Alhamoruni 
et al., 2010). Additionally, the treatment of A9-THC and CBD also increased the mRNA 
of tight junction protein zona occluden(ZO)-l in the cell model, suggesting that both of 
these cannabinoids may be beneficial for treating abnormally permeable intestinal 
epithelium (Alhamoruni et al., 2010).
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1.3 Suppressor of Cytokine Signalling (SOCS)
Innate immunity is the first defence mechanism induced by the body’s immune system in 
response to pathogen invasion. Activation of such defence mechanism leads to the release of 
pro-inflammatory cytokines, resulting in the recruitment of immune cells to the site of injury. 
Therefore, it is essential for the cytokine-mediated signal transduction to be tightly-regulated 
in the immune system and this is generally regulated by initiating a negative feedback 
regulatory process via the cytokine-bound-receptor (Dalpke et al., 2008). The importance in 
SOCS-induced cytokine regulation in the immunity response can be illustrated via a study, 
which demonstrated an elevated level of interferon (IFN)-y and IFN-y production activity, 
resulting from the loss of SOCS1 gene, could resulting in an overwhelming inflammatory 
response, which subsequently led to the development of complex fatal neonatal disease 
(Alexander et al., 1999).
SOCS protein acts as the negative feedback inhibitor towards the JAK-STAT-induced signal 
transduction, as the mechanism of action in regulating cytokine production. Binding of 
cytokines to the associated receptor initiates a conformational change on the receptor itself, 
resulting in the auto-phosphorylation of the tyrosine residues on Janus kinases (JAK). 
Consequently, the activated JAK kinases will recruit signal transducer and activator of 
transcription factors (STAT) via the phosphor-tyrosine-binding Src homology 2 (SH2) domain. 
In turn, the activated STAT will form STAT dimers with other phosphorylated STAT residue 
and the accumulation of activated STAT dimers in the cell nucleus will eventually initiate the 
transcription of SOCS gene (Dalpke et al., 2008; Piessevaux et al., 2008).
There are a total of eight functional proteins in the SOCS family (cytokine-inducible SH2- 
containing protein (CIS) and SOCS 1-7). Among these eight SOCS proteins, SOCS1 and 
SOCS3 are the well-studied SOCS proteins in the family. They share a similarity in their
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structural homology with the presence of SH2 domain and a carboxyl-terminal SOCS box 
domain. These SOCS proteins are distinguishable via the length of their amino-terminus and 
the presence of kinase inhibitory region (KIR) domain. SOCS protein utilised its SH2 domain 
to bind to the phosphorylated tyrosine residue on the JAK kinases, resulting in cytokine 
inhibition. The action of SOCS protein on cytokine regulation is SOCS protein specific, as each 
of the SOCS protein members has been shown to act on different cytokine-bound receptors, 
hence delivering distinct SOCS-induced effects (Dalpke et al., 2008). This can be clearly 
illustrated through the study which revealed the reciprocal function of SOCS1 and SOCS3 in 
IL-6 and IFN-y regulation. Mice with SOCS3 deficiency initiated a prolonged IL-6-induced 
STAT1 and STAT3 activation but did not deliver an impact towards IFN-y-induced STAT1 
activation. As opposed to that, mice with SOCS1 deficiency developed a prolonged IFN-y- 
induced STAT1 activation but showed no impact in response to the IL-6 treatment (Croker et 
al., 2003).
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Figure 1.4. SOCS protein functions. Each domain of SOCS protein initiates different 
interaction and functions. All SOCS proteins share a similar N-terminal domain consists of an 
extended SH2 subdomain (ESS) and a SOCS box whereas the KIR domain only present at the 
N-terminal of SOCS 1 and SOCS3. The complex of SOCS box interaction provides a diversity 
of functional consequences, for instance, regulation of SOCS protein stability, the receptor 
interaction and the elimination of targeted protein.
* Redrawn from Piessevaux, et al., 2008.
22 | P a g e
I
1.3.1 Structural and functional o f  SOCS
As previously stated, all SOCS proteins share a similar N-terminal domain that consists 
of an extended SH2 subdomain (ESS) and a SOCS box whereas the KIR domain is only 
present at the N-terminal of SOCS1 and SOCS3 (Dalpke et al., 2008; Piessevaux et al., 
2008).
Protein expression of SOCS protein is regulated through SOCS box, a conserved domain 
which is located at the C-terminal of SOCS protein (Piessevaux et al., 2008). This region 
comprises of a total of 40 amino acids which forms three alpha-helices that binds to the 
E3 ubiquitin ligase complex. Such ligase complex consists of Elongin B/C, a ring-finger 
protein Rbxl and a scaffolding protein, Cullin 5 proteins (Croker et al., 2008). Several 
studies suggested that Elongin C bound to the SOCS protein, thus provided stabilization 
to the SOCS protein expression and the disruption of such interaction resulted in 
proteasome-mediated SOCS destruction (Haan et al., 2003; Zhang et al., 1999). 
Additionally, the SOCS box is also involved in protein degradation by linking the 
targeted protein towards proteasomal machinery (Figure 1.4) (Piessevaux et al., 2008).
As for the SH2 domain, both N-terminal (N-ESS) and C-terminal (C-ESS) of SOCS3- 
SH2 domains are important for the binding of phosphorylated tyrosine residues. N-ESS 
consists of a 15-residue alpha helix and plays the role in determining the structure 
orientation of N-ESS bound phosphotyrosine-binding loop(Croker et al., 2008). Mutation 
of Val34 and Leu41 which interacted directly with the phosphotyrosine binding loop 
consequently affected SOCS3 ability to inhibit STAT activation (Sasaki et al., 1999). 
Hence, this indicated the role of the SH2 domain in completing for the binding site with 
STAT protein. On the contrary, C-ESS possesses a 35-residue of unstructured PEST 
motif that is rich in proline, glutamate, serine and threonine (Croker et al., 2008). The
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loss of PEST motif did not impact on the interaction of the SH2 domain with the 
phosphorylated-tyrosine residue. Interestingly, the removal of the PEST motif induced a 
greater effect on SOCS3 protein stability, as compared to the loss of the SOCS box. This 
suggested that the PEST motif also has a role in maintaining SOCS3 protein stability 
(Babon et al., 2006). Various studies indicated the involvement o f PEST motif in SOCS3 
degradation. However, there is still a controversy as to whether the PEST motif is 
modulated through the proteasomal-degradation pathway (Babon et al., 2006; Garcia- 
Alai et al., 2006; Rechsteiner and Rogers, 1996).
Next, the KIR domain, which is present in both the N-terminal domain of SOCS1 and 
SOCS3 proteins, is shown to act as the pseudo-substrate to inhibit JAK kinases in the 
JAK-STAT signalling cascade (Kershaw et al., 2013; Piessevaux et al., 2008; Sasaki et 
al., 1999). The KIR domain of SOCS3 possesses a higher binding affinity to JAK2, as 
compared to the KIR domain of SOCS1 (Sasaki et al., 1999).
1.3.2 SOCS3 in inflammatory regulation
SOCS3 is the key regulator for IL-6 and IL-10 cytokines production in response to TLR 
activation (Yoshimura et al., 2007). TLR is involved in the initiation of innate immune 
response in response to pathogen invasion. IL-6 is a pro-inflammatory cytokine which is 
up-regulated in many inflammatory diseases (rheumatoid arthritis, Crohn’s disease, 
ulcerative colitis) (Mudter and Neurath, 2007), whereas IL-10 is an anti-inflammatory 
cytokine which can inhibit the TLR signalling activation. It is interesting that SOCS3 is 
induced by both of these cytokines which deliver an absolute opposite effect in response 
to inflammation. However, interestingly, IL-6 induces an anti-inflammatory response in 
the absence of SOCS3 and this was demonstrated through the study where both IL-6 and
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IL-10 suppressed LPS-induced TNF-a production in SOCS3 deficient macrophages 
(Yasukawa et al., 2003). Also, despite the fact that SOCS3 is induced by both IL-6 and 
IL-10, SOCS3 only acts on IL-6 receptor but not on IL-10 receptor and initiates a 
negative feedback inhibition on IL-6 signaling. With that, this suggests that SOCS3 is 
the central negative regulator for IL-6 signaling (Yasukawa et al., 2003).
1.3.3 SOCS3 action in IBD
It has been reported that SOCS3 is up-regulated in both animal and human intestinal 
inflammation (Suzuki et al., 2001). SOCS3 (both mRNA and protein) was shown to be 
up-regulated in colon samples from UC and CD patients compared with healthy controls. 
SOCS3 also limits proliferation of epithelial cells in the damaged crypt, but contrary to 
in vitro investigations, up-regulation of SOCS3 in inflamed intestines, does not appear to 
sufficiently limit STAT3 and NF-KB inflammatory pathways (Rigby et al., 2007).
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1.4 Autophagy
Autophagy is a cellular mechanism utilised to adapt to the cellular environmental changes by 
promoting proteolytic degradation of the cytosolic compartments at the lysosomes (Chang et 
al., 2009; Glick et al., 2010; Klionsky and Emr, 2000; Singh and Cuervo, 2011). Autophagy 
can be characterized into three categories: chaperon-mediated autophagy (CMA), 
microautophagy, and macroautophagy (Glick et al., 2010; Mizushima, 2007). In CMA, the 
misfolded proteins are bound to the chaperone proteins and delivered to the lysosome through 
the lysosomal membrane receptor, the lysosomal-associated membrane protein 2A (LAMP-2A) 
(Glick et al., 2010). In contrast, for microautophagy, the cytoplasmic cargo is engulfed directly 
into lysosomes through the lysosomal membrane, whereas in macroautophagy, the cytosolic 
compartment is degraded via the autophago-lysosomal degradation pathway. The cytosolic 
compartments are taken up into autophagosome, a double membrane vesicle, which resulted in 
the fusion with lysosome to form autolysosome where the cytosolic compartment is degraded 
(Mizushima et al., 2008). Macroautophagy is the major type of autophagy process and it is the 
main autophagy process investigated in this project, therefore, the term of “autophagy” will be 
used in the following texts as the synonym for “macroautophagy”.
1.4.1 Overview in autophagy process
Although the autophagy process is well-recognized in the mammalian system, the vast 
majority of the breakthroughs associated with the understanding of the autophagy process 
and its regulation are discovered in yeast (Saccharomyces cerevisiae) (Glick et al., 2010). 
To date, 32 autophagy-related genes (ATGs) have been discovered through the genetic 
screening experiment performed in the yeast model system (Glick et al., 2010; 
Nakatogawa et al., 2009). The importance of ATG is emphasized as most of the ATG 
genes are well-conserved in yeast, mammals, flies and even plants (Glick et al., 2010).
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The complexity of the autophagy process can be summarized into three key stages: (i) 
autophagy initiation, (ii) autophagolysosome formation, and lastly, (iii) autophagic 
degradation (Figure 1.5).
(I) Initiation (II) A utophagosom e form ation
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Figure 1.5. Molecular event in autophagy. Autophagy is regulated by a set of autophagy 
related proteins (ATGs). The complexity of the autophagy process can be categorized 
into three key stages: (I) autophagy initiation, (II) autophagosome formation, and lastly, 
(III) autophagic degradation.
* Modified and redrawn from Levine and Deretic, 2007.
i. Autophagy initiation
The autophagy process begins with phagophore, an isolation membrane (Glick et al., 
2010). There is controversy regarding the origin of phagophore. Studies suggest that 
phagophore may originate from various cellular compartments such as the plasma 
membrane, endoplasmic reticulum (ER), golgi and mitochondria (Axe et al., 2008; Glick 
et al., 2010; Moreau and Rubinsztein, 2012; Simonsen and Tooze, 2009). An autophagy 
protein complex which consists of ATG1-ATG13-ATG17 is required for phagophore
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formation and it is thought that ATG9 may facilitate lipid recruitment to expand the 
phagophore structure. These activities are regulated through the energy-sensing TOR 
kinase as the TOR kinase will phosphorylate ATG13, hence inhibiting the interaction of 
ATG 13 on ATGl(Diaz-Troya et al., 2008). Rapamycin-induced inactivation of 
mammalian target of Rapamycin (mTOR) or the lack of nutrient availability in a cell will 
increase autophagy induction by rapid dephosphorylating ATG13, resulting in increased 
binding affinity of ATG13 to ATG 1, thus enhancing ATG1 activity and proceeding 
towards autophagosome formation (Diaz-Troya et al., 2008; Kamada et al., 2000). 
ATG17, on the other, is likely to be involved in the maintenance of the ATG protein 
complex stability (Diaz-Troya et al., 2008).
Additionally, PI3Kinases (PI3K)-Class III, notably Vps34 (vesicular protein sorting 34), 
is also required in phagophore formation. PI3K-Class III protein binds to another protein 
complex that consists of ATG6-Beclinl (Figure 1.5) (Levine and Deretic, 2007). PI3K- 
Class III uses phosphatidylinositol (PI) as its substrate to produce phosphatidyl inositol 
triphosphate (PI3P), which is required for phagophore elongation and recruitment of the 
ATG6-Beclinl protein complex to the phagophore (Glick et al., 2010). The beclin-1 
activity in autophagy induction on the other hand, is regulated through the apoptosis 
regulator, B-cell lymphoma 2 (Bcl-2). Interaction of bcl-2 to beclin-1 disturbs the 
interaction between PI3K-Class III and beclin-1 (Pattingre et al., 2005). During 
starvation, bcl-2 inhibits beclin-1 associated autophagy activity by binding to the BH3 
domain on beclin-1, resulting in the disruption of bcl-2 apoptotic action and the activation 
of the autophagy process in response to starvation (Glick et al., 2010; Pattingre et al., 
2005).
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ii. Autophagosome formation
Two ubiquitin-like systems are required for autophagosome formation: the conjugation 
of ATG 12 and ATG5 and the processing of the microtubule-associated protein light chain 
3 (LC3B) (Figure 1.5).
Once the membrane is isolated by ATG6-Beclinl protein complex, ATG7, the El-like 
ubiquitin-activating enzyme, binds to the carboxy-terminal glycine residue of ATG 12 
and activates the enzyme activity of ATG12. This subsequently leads to the transferring 
o f ATG12 to ATG10, where ATG10 acts as an E2-like ubiquitin carrier protein to 
facilitate the interaction of ATG 12 to the lysine 130 residue on ATG5 (Glick et al., 2010; 
Klionsky and Emr, 2000). This is then followed by the association of ATG16L to the 
conjugated ATG5-ATG12 protein complex, resulting in the formation of a multimeric 
protein complex (Glick et al., 2010). Initiation of ATG5-ATG12 conjugation is not 
dependent on the activation of autophagy (Barth et al., 2010) but the conjugation of 
ATG12-1TG5 is crucial for the elongation of the phagophore membrane as the study 
showed that the loss of the ATG5 gene led to a defect in autophagosome formation in the 
mouse embryonic stem (ES) cells (Mizushima et al., 2001; Yoshimori, 2004). ATG5 
protein complex binds to the back of the isolation membrane and only dissociates from 
the phagophore membrane prior to the closure of the membrane, resulting in 
autophagosome formation (Yoshimori, 2004). In addition to the role of ATG5-ATG12- 
ATG16L1 protein complex in facilitating isolation membrane elongation, such protein 
complex also appears to be required for targeting LC3 to the isolation membrane as the 
study showed that the loss of ATG5 gene in mouse ES cells consequently disrupted the 
recruitment of LC3 to autophagic membrane (Mizushima et al., 2001).
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The newly synthesized LC3 (22 amino acid) is cleaved at its c-terminal by ATG4 
protease to form LC3-I. This subsequently leads to a series of ubiquitin-like reactions 
with the involvement of ATG7 and ATG3, resulting in the conversion of LC3-I (18KDa) 
to LC3-II (16KDa). Upon the conversion, LC3-I is distributed in the cytoplasm whereas 
LC3-II is bound to the autophagosome (Glick et al., 2010; Mizushima, 2007; Patel and 
Stappenbeck, 2013; Yoshimori, 2004). A phosphatidylethanolamine (PE) group is 
attached to the LC3-II where this protein promotes the integration of LC3-II into the lipid 
membrane of autophagosome (Barth et al., 2010; Patel and Stappenbeck, 2013). It is 
worth noted that LC3-II is the only discovered protein that is specifically localised to the 
autophagic structure (starting from phagophore membrane to lysosomal degradation) and 
the amount of LC3-II correlates well to the number of autophagosome (Yoshimori, 2004). 
Taken together, this has made LC3-II a hallmark feature in studying the autophagic 
process.
iii. Autophagic degradation
In the final stage, the autophagosome maturation stage, the completed autophagosome 
will fuse with lysosome to form autophagolysosome for degradation (Glick et al., 2010; 
Klionsky and Emr, 2000; Patel and Stappenbeck, 2013).
1.4.2 Autophagy in the cellular energetic balance
The autophagic process can be triggered by various occasions and one of the best 
characterized stimuli is starvation. The removal of nutrient source such as nitrogen and 
carbon and the lack of amino acid are the contributors towards autophagy induction 
(Deretic and Levine, 2009; Kuma and Mizushima, 2010; Mizushima, 2007; Singh and 
Cuervo, 2011). The autophagic activity in response to nutrient status is regulated by the
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mTOR (Diaz-Troya et al., 2008; Singh and Cuervo, 2011). Under normal nutritional 
status, mTOR phosphorylates ATG13 and inhibits its interaction with ATG1, which 
subsequently prevents the formation autophagosome. In contrast, during starvation, the 
activation of a second cellular energy sensor protein, 5’ adenosine monophosphate- 
activated protein kinase (AMPK) will inhibit mTOR activity by phosphorylating ATG1, 
which promotes the release of ATG1 from mTOR, resulting in the autophagy induction 
(Singh and Cuervo, 2011).
In addition to the role of autophagy in response to nutritional status, the autophagic 
process is also involved in protein aggregates turnover or degradation (Komatsu et al., 
2005; Singh and Cuervo, 2011). This role of autophagy is clearly demonstrated in the 
liver where autophagy is responsible for breaking down 1.5% to 5% of the total proteome 
per hour, under normal nutritional condition or starvation, respectively (Deter et al., 
1967). Amino acids which result from protein breakdown may be used to maintain 
protein synthesis, as well as for the replenishment of the intracellular pool of amino acid 
(Onodera and Ohsumi, 2005; Singh and Cuervo, 2011). However, the mechanism 
involved in the regulation of the intracellular pool of amino acid and autophagy process 
is still unclear. Despite that, it is certain that defect in autophagy often relates to the 
formation of protein aggregates and study suggested that this may contribute to the 
developing of protein conformation diseases such as Alzheimer’s disease (Komatsu et 
al., 2006; Singh and Cuervo, 2011).
1.4.3 A utoph agy regulation in gastrointestinal (GI) tract
The GI tract is composed from a single layer of intestinal epithelial cells. This cellular 
structure is responsible for facilitating the GI tract in nutrient absorption and digestion.
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Nonetheless, it also serves as the intestinal barrier against microbial invasion, as well as 
antigens passing through the intestinal lumen (Patel and Stappenbeck, 2013). In addition 
to hosting innate and adaptive defence mechanisms, various autophagy proteins are 
shown to be required for the cellular intestinal function in response to inflammatory 
threat. Autophagy proteins were demonstrated to be involved in: (i) cytokine secretion 
by monocyte-derived cells, (ii) bacteria handling in dendritic cells, (iii) antimicrobial 
peptide secretion by Paneth cells, and lastly, (iv) xenophagy induction.
i. Autophagy mediated cytokine secretion bv macrophages
Autophagy suppresses intestinal inflammation by mediating macrophage-induced 
cytokine secretion. A study showed that LPS-treated ATG16L1-deficient macrophages 
induced a high level of pro-inflammatory cytokines, IL-1P and IL-18 (Saitoh et al., 2008). 
The loss of the ATG16L1 gene in mice impacts on the recruitment o f ATG12-ATG5 
conjugate to the isolation membrane, which subsequently affects autophagosome 
formation, as well as degradation of lone-lived proteins (Saitoh et al., 2008). Additionally, 
another study revealed that the LPS-induced effect in ATG16L1 -deficient macrophages 
was mediated through the TRIF (TIR-domain-containing-adaptor inducing interferon-p), 
the key adaptor protein for TLR3 and TLR4 signalling (Hardy et al., 2004). This was 
concluded based on the finding where ATG16L1-deficient macrophages did not respond 
to both TLR2 and TLR5 ligand but induced an increase in IL-lp production in response 
to LPS treatment, a TLR4 ligand (Saitoh et al., 2008). As the production and secretion of 
IL-ip and IL-18 are both mediated via the activation of inflammasome (Petrilli et al., 
2005), this suggests that ATG16L1 is responsible for regulating endotoxin-mediated 
inflammasome activation via a TRIF-dependent manner.
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ii. Autophagy in bacteria handling in dendritic cells
Activation of the autophagy process is also required for bacteria-handling in dendritic 
cells (DCs) (Cooney et al., 2010; Patel and Stappenbeck, 2013). These cells have been 
implicated to protect the intestine from microbial invasion by sampling luminal bacteria 
through the formation of tight junction-like structure with intestinal epithelial cells (IEC), 
allowing the projection of dendritics into the lumen to capture the invasive bacteria 
(Coombes and Powrie, 2008). Study showed that nucleotide-binding 
oligomerizationdomain-containing-2 (NOD2), the bacteria sensor in DC, induces 
autophagy activation in response to bacteria ligand treatment (Cooney et al., 2010). Such 
effect is mediated by autophagy proteins ATG5, ATG7, as well as ATG16L1 and 
receptor-interacting serine-threonine kinase-2 (RIPK-2) protein. The NOD2-mediated 
autophagy process is crucial in bacteria-handling and the importance of the role of NOD2 
in IEC is further emphasized in CD where mutation in the NOD2 gene disrupts autophagy 
induction, as well as bacteria-trafficking in IEC (Cooney et al., 2010).
iii. Autophagy in antimicrobial peptide secretion in Paneth cells
Paneth cells are located at the base of the intestinal crypt villus structure. These cells are 
responsible for secreting anti-microbial proteins which are present in the lumen of the 
gut (Klionsky, 2009; Radtke and Clevers, 2005). Interestingly, studies showed that there 
seems to be a cross-talk between Paneth cells and the intestinal bacteria. Paneth cells 
alter the composition of microbes in the gut lumen and the microbes influence the gene 
expression and function of Paneth cells (Cadwell et al., 2008; Stappenbeck, 2010).
Autophagy is shown to be actively involved in Paneth cells as the loss of function for the 
ATG16L1 gene leads to the disruption of the secretory function of Paneth cells
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(Stappenbeck, 2010). Moreover, the complete loss of autophagy function in Paneth cells 
impacts on the packaging of antimicrobial proteins into granules and thus disrupts the 
exportation of these anti-inflammatory components into gut lumen (Cadwell et al., 2008). 
Taken together, this emphasizes the importance of autophagy in Paneth cells in targeting 
antimicrobial proteins to limit the expression of inflammatory cytokines in the intestinal 
epithelium.
iv. Xenophagy induction
Xenophagy is the term for the process where autophagy is used as a tool to destroy 
intracellular bacterial pathogens in a selective manner (Patel and Stappenbeck, 2013). 
Intracellular bacteria pathogens are generally engulfed by autophagosome and killed in 
the acidic environment through the lysosomal degradation pathway. However, some of 
the invasive pathogens are capable of avoiding the conventional autophagy degradation 
pathway by possessing a phagosome-like structure. Upon infection, Salmonella, for 
instance, evades the destructive pathway through its Salmonella-containing vacuoles 
(SCV) and some of these invasive pathogens will escape from SCV to proliferate in the 
cytosol. To stop further pathogen invasion, these pathogens will be rapidly ubiquitylated, 
resulting in the recruitment of autophagy adaptor proteins, p62 and several autophagic 
receptors such as NDP52, TANK-binding kinase 1(TBK1), and optineurin (OPTN) 
(Galluzzi et al., 2011). NDP52 binds to the ubiquitin-coated pathogen, as well as LC3 
and delivers the targeted pathogen into autophagosome. Cells with NDP52 deficiency 
will fail to restrict pathogen proliferation and invasion (von Muhlinen et al., 2010). TBK1, 
on the other hand, responses to LPS activated TLR4 by binding to NDP52 receptor. This 
indirectly limits the replication of cytosolic Salmonella (Galluzzi et al., 2011). As for 
the OPTN autophagy receptor, the study showed that the OPTN-contained LIR domain
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regulates the interaction between OPTN and LC3 via its N-terminal, which subsequently 
leads the ubiquitylated-pathogen to nascent autophagosome, hence initiating xenophagy 
clearance (Galluzzi et al., 2011).
1.4.4 A  utophagy in Crohn’s Disease (CD)
As previously stated, not only is autophagy responsible for maintaining cellular and 
energetic balance, such a process is also crucial in regulating the immunity and cellular 
defence mechanism in intestinal epithelium (Kirkegaard et al., 2004; Levine et al., 2011; 
Mihalache and Simon, 2012; Patel and Stappenbeck, 2013). Thus, it is not surprising to 
discover that a number of autophagy-associated genes, such as ATG16L1 and NOD2, 
are linked to the pathogenesis of CD (Henderson and Stevens, 2012; Patel and 
Stappenbeck, 2013).
A single nucleotide polymorphism (T300A) in the ATG16L1 is often associated with 
pathogenesis of CD in the Caucasian population (Henderson and Stevens, 2012). As 
previously stated in section 4.1, ATG16L1 forms a multimeric protein complex with 
ATG5 and ATG12, and this protein complex is involved in LC3 lipidation during 
autophagosome formation (Mizushima et al., 2001). Henderson and Stevens (2012) 
revealed that it is vital to correctly localise ATG16L1 to sites of LC3 lipidation, as correct 
localization of the gene is required for appropriate autophagosome formation . Low 
expressing ATG16L1 in hypomorphic mice demonstrated that the autophagy inducer, 
rapamycin, could no longer induce p62 and LC3-II degradation, and such effects could 
be reversed by restoring ATG16L1 into the system (Cadwell et al., 2008). Furthermore, 
ATG16L1 is also involved in Paneth cells regulation, as these hypomorphic mice 
developed abnormalities in the morphology of these cells in response to a reduced
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ATG16L1 gene in the model system (Cadwell et al., 2008). In agreement with these 
findings, ileocolic resection specimens obtained from CD patients carrying ATG16L1 
risk allele also exhibited morphology changes in Paneth cells (Henderson and Stevens, 
2012), which further demonstrates the role of ATG16L1 in autophagy, as well as Paneth 
cell regulation.
In addition to ATG16L1, NOD2 is also one of the susceptible genes for CD. NOD2 was 
first discovered through the fine mapping of IBD1 locus on chromosome 16, where it 
was discovered that the leucine-rich repeats (LRR) at the C-terminal of NOD2 are 
susceptible to CD (Hugot et al., 2001). As previously stated in section 4.3, NOD2- 
mediated autophagy is crucial in bacteria-handling and mutation in the NOD2 gene 
disrupts autophagy induction, as well as bacteria-trafficking in the intestinal epithelium 
(Cooney et al., 2010). Kersse et al. (2011) also proposed that NOD2 may be involved in 
the recognition of danger-associated molecular patterns (DAMPs), a signal which is 
released in response to the cellular membrane damage and the presence of pathogenic 
infection. Taken together with a recent study by Philpott, et al. (2013) which 
demonstrated the localisation of NOD2 on the plasma membrane, these data suggest that 
NOD2 may engage directly with the pathogens, resulting in the activation of 
inflammatory and antimicrobial response during microbial invasion.
Possible action of both ATG16L1 and NOD2 in pathogen recognition is further assessed 
in a study where both NOD2 and ATG16L1 were found to surround the invading 
pathogens at the entry foci, an activity not observed with mutant NOD2 proteins. 
Additionally, in the same study, muramyl dipeptide (MDP), aNOD2 ligand, was shown 
to activate autophagy process, resulting in an increase of Salmonella eradication in the
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IEC, such events were facilitated by CD-associated NOD2 mutation (Homer et al., 2010). 
An abnormal capture of internalised Salmonella has also been observed in the 
autophagosome of epithelial cells which carry the polymorphism T300A in ATG16L1 
(Kuballa et al., 2008). Again, these findings demonstrate the functional consequences of 
autophagy-associated genes in CD and the importance of autophagy as a pathogenic 
mechanism in CD.
1.4.5 Cannabinoid action in autophagy process
To date, cannabinoids (A9-THC or CBD) have been shown to exhibit therapeutic 
potential in inducing autophagy process in breast cancer cell lines, as well as human 
glioma cell (Donadelli et al., 2011; Shrivastava et al., 2011). CBD induced autophagy- 
mediated cell-death in human breast cancer cell lines and this effect was not mediated 
through the cannabinoid receptors (CNR1 and CNR2) or vallinoid receptor (TRPV1). 
This study suggested that CBD-mediated autophagy cell-death by inducing endoplasmic 
reticulum (ER) stress, which subsequently inhibits both AKT and mTOR signalling 
pathways (Shrivastava et al., 2011). The action of cannabinoid-mediated autophagy via 
the activation of ER stress was also demonstrated in A9-THC-mediated autophagy cell 
death in human glioma cell. Also, unlike the CBD action on breast cancer cells, the A9- 
THC-induced effect may be mediated through CNR1 receptor (Salazar et al., 2009).
In addition to CBD and A9-THC action in breast cancer cells and human glioma cells, a 
recent study demonstrated the use of cannabinoid ligands (ACPA, synthetic agonist of 
CNR1; SR141716, CNR1 antagonist; GW405833, CNR2 agonist) in combination with 
the chemotherapy drug Gemcitabine (GEM) on pancreatic adenocarcinoma cells 
(Donadelli et al., 2011). GEM is currently used to treat advanced pancreatic
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adenocarcinoma but this drug only delivers a response rate of <20%, therefore the study 
was conducted with the purpose of improving the drug efficiency by having the 
cannabinoid ligands as the combination treatment. The study showed that combined 
treatment of cannabinoids and GEM successfully inhibited pancreatic adenocarcinoma 
cell growth through ROS-dependent autophagic cell-death (Donadelli et al., 2011), 
suggesting that the combined treatment of GEM and cannabinoids may be a new 
therapeutic strategy in treating pancreatic cancer.
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1.5. Summary
As previously stated, the autophagy process not only responsible for the maintenance of 
cellular energetic balance, this is also crucial in the regulation of the immunity and cellular 
defence mechanisms in the intestinal epithelium. The polymorphism of autophagy-associated 
genes (ATG16L1, NOD2) has been correlated to the pathogenesis of CD (Hugot et al., 2001; 
Henderson and Stevens, 2012), emphasizing the importance of this cellular mechanism in 
disease regulation.
Both ECS and SOCS3 are thought to have a role in IBD, as the production o f both 
endocannabinoids and SOCS3 are evident in inflamed intestines (Izzo et al., 2001; Suzuki et 
al., 2001; Di Marzo and Izzo, 2006). CBD is an attractive therapeutic entity due to its non­
psychoactive effect and its beneficial pharmacological effects in various diseases. To date, both 
A9-THC and CBD-mediated autophagy cell-death have only been demonstrated in cancer cell 
models (breast cancer, glioma cells, pancreatic adenocarcinoma), but not in any non-cancer 
cell model system (Donadelli et al., 2011; Shrivastava et al., 2011). The autophagy process is 
a particularly valuable therapeutic target in CD, as this cellular mechanism is involved in 
pathogen clearance, along with the polymorphism of autophagy genes, which contributes to 
the pathogenesis of CD (Henderson and Stevens, 2012), suggesting that the autophagic process 
is disrupted in CD, thereby promoting the penetration of pathogens across the epithelial carrier 
and exploiting the mucosal host defence.
CBD, but not A9-THC, was shown to reduce NF-kB activity, up-regulate the activation of 
STAT3 and decrease the mRNA expression level of SOCS3 (Kozela et al., 2010b). Both 
mRNA and protein expression of SOCS3 was up-regulated in colon samples obtained from CD 
patients, as compared to healthy controls (Suzuki et al., 2001). Furthermore, in vivo SOCS3
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limits proliferation of the inflammatory epithelial cells in damage crypts, which leads to the 
reduction of TNF-a mediated NF-kB activation (Rigby et al., 2007). However, it is noted that 
cellular SOCS3 expression level is constantly oscillating, and there are no current data that 
identify how cyclic SOCS3 is regulated beyond the transcriptional level (Yoshiura et al., 2007; 
Li et al., 2012).
Based on the emerging data, the onset of intestinal inflammation is associated with an impaired 
autophagy, increased activity in the ECS and up-regulation of SOCS3 protein expression. In 
this project, I explored the impact of cannabinoids administration (synthetic, endo-, and phyto- 
cannabinoid) on the autophagy process in the intestinal epithelial cell model. I hypothesized 
that cannabinoid administration would increase autophagic activity in my intestinal epithelial 
CaCo2 cell model. Furthermore, I also explored whether these actions were responsible for 
cyclic SOCS3 protein levels. This project may possibly offer a new functional role of 
cannabinoid in intestinal regulation, as well as a possible role of autophagy as a homeostatic 
regulator for cyclic proteins, such as SOCS3.
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2.1. MATERIALS
Table 2.1 Chemicals used; supplier and supplier address.
*These chemicals were used in all experiment except for the [35S]GTPyS binding assay.
Chemical Supplier Supplier address
1 -bromo-3-chloro-propane Sigma-Aldrich Poole, UK
2-Mercapoethanol Sigma-Aldrich Poole, UK
2-Propanol Sigma-Aldrich Poole, UK
2% Bis Solution BioRad Laboratories Herts, UK
40% Acrylamide Solution BioRad Laboratories Herts, UK
Albumin, from bovine serum Sigma-Aldrich Poole, UK
Agarose powder Sigma-Aldrich Poole, UK
Ammonium Persulfate Sigma-Aldrich Poole, UK
Bradford Reagent Sigma-Aldrich Poole, UK
Cannabinoid-receptor 1 primer Qiagen Manchester, UK
Cannabinoid-receptor 2 primer Qiagen Manchester, UK
Clarity Western ECL Substrate BioRad Laboratories Herts, UK
Cyto-ID® autophagy detection kit Enzo Life Science Exeter, UK
Dansylacadaverine (MDC) Sigma-Aldrich Poole, UK
Dried Skimmed milk Marvel -
Dulbecco’s Phosphate Buffered saline Sigma-Aldrich Poole, UK
Dulbecco’s Phosphate Buffered saline, 
Gibco
Life Technologies Paisley, UK
Dyna Beads Protein G Life Technologies Paisley, UK
Ethanol Thermo Fisher Scientific Loughborough, UK
Fetal Bovine Serum (FBS) 
Lot No: 07F4314K
Life Technologies Paisley, UK
Glycine Sigma-Aldrich Poole, UK
HMBS pre-validated primer Qiagen Manchester, UK
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Chemical Supplier Supplier address
HuSH 29mer shRNA 




Hydrochloric Acid (36.5-38%) Sigma-Aldrich Poole, UK
iBlot® Gel Transfer Stacks, 
Nitrocellulose Life Technologies Paisley, UK
iScript One-Step RT-PCR kit with 
Syber Green BioRad Laboratories Herts, UK
IGEPAL CA-630 Sigma-Aldrich Poole, UK
Laemmli sample buffer BioRad Laboratories Herts, UK
Minimum Essential Medium (MEM), 
Gibco Life Technologies Paisley, UK
N,N,N,N,-
Tetramethylethylenedramine Sigma-Aldrich Poole, UK
Non-Essential Amino Acid (NEAA) Life Technologies Paisley, UK
NuPAGE, LDS Sample buffer (4X) Life Technologies Paisley, UK
O2/CO2 gas BOC Gases -
Paraformaldehyde powder BDH Poole, UK
Phosphotase Inhibitor Cocktail 2 Sigma-Aldrich Poole, UK
Precision Plus Protein Dual Colour 
Standard BioRad Laboratories Herts, UK
PrestoBlue® Cell Viability Reagent Life Technologies Paisley, UK
Protease Inhibitor Cocktail Sigma-Aldrich Poole, UK
RPLPO Pre-validated primer Qiagen Manchester, UK
SOCS3 pre-validated primer Qiagen Manchester, UK
Sodium dodecyl sulphate (SDS), 10% Sigma-Aldrich Poole, UK
Sodium deoxycholate Sigma-Aldrich Poole, UK
Sodium chloride Melford Ipswich, Suffolk, UK
SuperBlock blocking buffer Thermo Fisher Scientific Loughborough, UK
Tris(hydroxymethylaminomethane) Melford Ipswich, Suffolk, UK
TRI reagent® Sigma-Aldrich Poole, UK
Tween-20 Sigma-Aldrich Poole, UK
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As the work for [35S]GTPyS binding assay was performed in Professor Ruth Ross’s laboratory 
in University of Aberdeen (UK), an additional list of chemicals used for [35S]GTPyS binding 
assay was shown in Table 2.2.
Table 2.2 Chemicals used; supplier and supplier address.
Chemical Supplier Supplier address
[35S]GTPyS Perkin Elmer Massachusetts, USA
BioRad Dc Protein Assay BioRad Laboratories Herts, UK
Dithiothreitol Sigma-Aldrich Poole, UK
EDTA BDH Poole, UK
Fatty acid free BSA Thermo Fisher Scientific Loughborough, UK
GDP Sigma-Aldrich Poole, UK
GF/B filters Semat Hertfordshire, UK
HEPES Sigma-Aldrich Poole, UK
Magnesium chloride Sigma-Aldrich Poole, UK
Sodium chloride Melford Ipswich, Suffolk, UK
Trizma base Sigma-Aldrich Poole, UK
Trizma hydrochloride acid Sigma-Aldrich Poole, UK
Ultima Gold scintillation fluid Perkin Elmer Massachusetts, USA
45 | P a g e
Table 2.3. Drugs used; supplier and supplier address.
Drugs Supplier Supplier address
(-)-Cannabidiol R&D System Europe Ltd. Abingdon, UK
3-Methyladenine R&D System Europe Ltd. Abingdon, UK
ACEA R&D System Europe Ltd. Abingdon, UK
AEA R&D System Europe Ltd. Abingdon, UK
AM251 PeproTech EC Ltd London, UK
Bafilomycin Al R&D System Europe Ltd. Abingdon, UK
IFN-y PeproTech EC Ltd London, UK
IL-1P PeproTech EC Ltd London, UK
Leptin PeproTech EC Ltd London, UK
LPS PeproTech EC Ltd London, UK
MG 132 PeproTech EC Ltd London, UK
TNF-a PeproTech EC Ltd London, UK
Table 2.4. Antibodies used for western blotting; supplier and supplier address.
Primary Antibodies Supplier Supplier address
p-actin New England Biolab Herts, UK
Cannabinoid receptor 1 
(Caymen Bioscience) Cambridge BioScience
Cambridge, UK
phospho-mTOR New England Biolab Herts, UK
phospho-STAT3 (Tyr705) New England Biolab Herts, UK
phospho-STAT3 (Ser727) Insight Biotechnology Ltd. Middlesex, UK
SOCS3 (Anti-rabbit) New England Biolab Herts, UK
SOCS3 (Anti-mouse) abeam® Cambridge, UK
Total-STAT3 New England Biolab Herts, UK
Ubiquitin-1 (used for IP) abeam® Cambridge, UK
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2.2. METHODS
2.2.1 Cell Culture
Human colonic epithelial cell line, CaCo2, is extensively used in studies associated 
with drug permeability, transport mechanism, and gene regulation of transporters and 
enzymes (Sun et al., 2008). To date, CaCo2 cells are currently the best characterised 
gut epithelial monolayer system available for in vitro study. CaCo2 cells exhibit 
similar characteristics as enterocytes residing in the human small intestinal epithelium. 
These cells differentiate to reach confluency where a monolayer of polarised cells that 
functionally and structurally resembled the small intestinal epithelial are formed 
(Bailey et al., 1996). Fully differentiated CaCo2 address the intact intestinal epithelial 
cell barrier where both luminal and basolateral compartments are present in the model 
system (Hidalgo et al., 1989; Hilgers et al., 1990). Interestingly, there were reviews 
stating differences in the finding with the use of CaCo2 cells in different laboratories 
and they have suggested this may due to several reasons, for instance, the source of 
the cells, the culturing conditions and maintenance and the associated passage numbers 
(Bailey et al., 1996). Taken that, CaCo2 cell differentiation from day 0 to day 21 was 
monitored via cell staining for a brush border enzyme alkaline phosphatase (ALP). 
This set of experiment was performed by Tara Macpherson (Karen Wright’s PhD 
student). ALP is a common marker of enterocyte differentiation and it has been shown 
to be highly expressed in differentiated CaCo2 cells (Ferruzza et al., 2012; Matsumoto 
et al., 1990). In agreement with previous findings, Tara’s result showed that ALP is 
highly expressed in the CaCo2 cells when they were grown for 14 to 21 days, as 
compared to the third day of culturing, confirming that the CaCo2 cells exhibit 
differentiated phenotype from day 14 onwards.
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In this study, CaCo2 was cultured routinely in T75 culture flasks with roughly 12mL 
of Minimum Essential Medium-MEM. Media were supplemented with 8% (vol/vol) 
fetal bovine serum (FBS) and 1% of MEM Non-Essential Amino Acid (NEAA). This 
would be referred as “complete medium”. The cells were cultured in the humidified 
incubator that was maintained at 37°C in the 5% CO2 atmospheric condition. The 
culture medium was changed in every 2 to 3 days. When the growing cells reached 
70% confluency, they would either be passaged into new T75 culture flask for further 
culture or into Petri dishes or 6/12-well plates for experimental use (Figure 2.1).
P ro life ra tin g
ce lls
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H u m id ified  in c u b a to r
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Figure 2.1. Schematic diagram for culturing human colonic epithelial cell line, CaCo2. 
CaCo2 cells were cultured in a humidified 37°C, 5% CO2 incubator. Growing cells 
reached with -70% confluency would either be passaged into new T75 culture flask 
or onto culture dishes for experimental use. Only CaC02 cells that were actively 
proliferating would continue the passaging process as these cells display changed 
phenotypes from proliferating to post-confluent stage. Differentiated post-confluence 
CaCo2 cells that were developed into a polarized monolayer of cells would be used in 
this project.
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2.2.2. Treatments
Unsynchronized differentiated CaCo2 cells were used for all experiments, unless 
otherwise stated. 1 hour prior to treatment induction, culturing medium for the treated 
cells would change from MEM medium with 8% serum into MEM medium with 1% 
serum. The rational for this additional step was to ensure the treated cells were in 
stress-free condition before treatments were added.
2.2.3. RNA Extraction
RNAs from the treated CaCo2 cells were extracted by using TRI reagent®. To minimize 
genomic DNA contamination during tissue preparation, 1 -bromo-3-chloro-propane was 
added to each of the RNA sample. Samples were centrifuged at 10,000rpm, 15min at 
4°C. Total RNA from the aqueous phase was further purified via isopropanol 
precipitation, washed twice with 75% (v/v) ethanol and resuspended in 20pL to 30pL 
of RNase-free water. The final concentration of total RNA for each sample was between 
1.5-4.5pg/pL. Purity of RNA was accessed by a ratio of absorbance at 260nm and 
280nm through NanoDrop 2000c Spectrophotometer (Thermo Scientific). A ratio of 
-2 .0  is accepted as “pure” for RNA. Lastly, to verify the integrity of total RNA, RNA 
samples were run on a 2% denaturing agarose gel and stained with ethidium bromide. 
Two sharp, non-smearing 28S and 18S rRNA bands would indicate the non-degrading 
condition of the RNA samples. Extracted RNA was then stored at -80°C for later use.
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2.2.4 Quantitative Real Time PCR (qR T-PCR)
i. Primer set and Evaluation
Validated primer sets for cannabinoid receptor (CNR)-l, suppressor of cytokine 
signaling (SOCS)-3, human large ribosomal protein (RPLPO), hydroxymethylbilane 
synthase (HMBS) were purchased from Qiagen. RPLPO and HMBS were used as the 
reference genes in the PCR reaction. Prior to the analysis of cytokines or drug-treated 
CaCo2 samples, each primer set was evaluated. In order to generate standard curve, 
each validated primer set was used to amplify from different dilution of cDNA (Table 
2.5). Ct values obtained were plotted against log2 of the dilution factor against the Ct 
value for these five reactions to generate standard curve for each set of primers. 
Equation of linear regression line along with the R2 value could be used to evaluate 
optimization of the qRT-PCR assay. Only primer set with R2 value > 0.90 would be 
used for further QRT-PCR analysis on the treated CaCo2 cell samples. Efficiency 
obtained from the equation was incorporated into the final calculation using the Pfaffl 
method (Pfaffl, 2001).
Table 2.5. CDNA dilution used for testing primer efficiency.
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ii. Primer Evaluation
Validated primer designed for cannabinoid receptor (CNR)-l and suppressor of 
cytokine signalling (SOCS)-3 were used for qRT-PCR analysis. qRT-PCR data were 
analysed using Pfaffl Method. The relative mRNA expression ratio or the fold changes 
were analysed based on the efficiency of the associated primers and the ACt deviation 
of the test sample versus a control. Results were standardised by comparison to the 
expression of reference genes (Figure. 2.2). RPLPO and HMBS were integrated in the 
qRT-PCR analysis.
RatlO =  (E f c j g g ,  ) ACT(‘est> (“ ntrol-sample)
/  U  \  ACT(ref) (control-sample)
\r^  reference/
Figure 2.2. Mathematical model used in Pfaffl method for qRT-PCR analysis (Pfaffl, 
2001).
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iii. Reliability of real-time PCR detection
Overall, due to the fact that these purchased primers were pre-validated primers from 
Qiagen, reliability for these primers should not be an issue in this context. However, 
the calculations of the efficiency for each primer were performed, as results were 
required to integrate into the qRT-PCR analysis that been shown in Table 2.6. Primer 
efficiency was determined as the correlation coefficient from standard curve where 
ACt values for cDNA dilution were plotted against the concentration for each primer.
Table 2.6. Primer efficiency and R2 value of the pre-validated primers for Cannabinoid 
receptor (CNR)-l, CNR2, Suppressor of cytokine signalling (SOCS)-3, Human Large 
Ribosomal protein (RPLPO) and hydroxymethylbilane synthase (HMBS).
Gene Product Code Prim er Efficiency (%) R2 value
CNR1 QT00203287 95.5 0.9996
CNR2 QT00012376 94 0.9632
SOCS3 QT00244580 87 0.9521
RPLPO QT00075012 82.93 0.7207
HMBS QTO1002176 82 0.9474
Primer efficiency was the correlation coefficient from the standard curve where ACt 
values for cNDA dilution were plotted against the concentration of each primer. For 
100% efficiency, there would be a doubling of the amount of cNDA at each cycle and 
as a result, the factor was 2.0 for each cycle. R2 value was also obtained from the 
standard curve.
*Pre-validatedrprimers were purchased from Qiagen
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2.2.5. Western Immunoblot
i. Cell Lvsing
Treated cells were washed with cold PBS and lysed in cold RIPA buffer supplemented 
with phosphatase inhibitor cocktail 2 and protease inhibitor cocktail. Lysing procedure 
required to be performed on ice to avoid degradation of the protein samples. Insoluble 
cell debris was removed by centrifugation at 12,000 rpm for 3min. Lysed protein was 
then stored at -20°C for later use.
ii. Quantifying protein concentration
Protein concentrations across samples were quantified with the use of Bradford 
Reagent. Performing a Bradford assay is to ensure equivalent protein loading in the 
SDS-PAGE gel, which will be performed in later stage. Such assay involves the 
formation o f a complex between the dye, Brilliant Blue G, and the proteins in solution. 
Absorption of the dye towards the present proteins can be detected by measuring the 
dye absorbance at 595nm; a microplate reader was used for further analyse.
To determine protein samples with unknown concentration, a standard curve was 
prepared by using protein standards which were made up from BSA with known 
concentration ranging from 0 to 20pg/mL. 450pL of Bradford Reagent was added into 
50pL o f the protein standards. Samples were incubated at room temperature for 5-10 
minutes. Absorbance for the protein standards were measured at 595nm. Absorbance 
readings obtained were plotted against protein standard concentration to generate a 
standard curve. After obtaining the standard curve, the whole procedure was repeated 
with protein samples obtained from treated cells. Protein concentrations for treated 
samples were determined by comparing the absorbance values against the generated 
standard curve.
53  | P a g e
iii. Preparation of SDS-PAGE gel
Molecular weight of the protein of interest determined the percentage of the SDS- 
PAGE gel to be used (Table 2.7). AWAW-Tetramethylethylenedramine (TEMED) 
was the last reagent to be added into the mixed solution as the use of TEMED leads to 
the polymerization of the gel matrix.





Range of molecular 
weight (kD) 16-70 14-60 12-45
40% Acrylamide 480 pL 2.43 mL 2.92 mL 3.40 mL
2% Bis 260 pL 1.34 mL 1.61 mL 1.88 mL
0.5M ofTris HCL 
pH6.8 1.26 mL
- - -
1.5M ofTris HCL 
pH8.8
- 2.5 mL 2.5 mL 2.5 mL
10% SDS 50 pL 100 pL 100 pL 100 pL
10% Ammonium 
persulfate 25 pL 75 pL 75 pL 75 pL
TEMED 10 pL 10 pL 10 pL 10 pL
Water 2.92 mL 3.58 mL 2.83L 2.03L
iv. SDS-Page
Prepared protein samples were mixed with 4X NuPAGE LDS sample buffer 
supplemented with 5% of 2-mercapoethanol, boiled at 95°C for 2min. 20—30pg 
aliquots resolved on SDS PAGE gels. 5-7pL of BioRad precision plus protein 
standards were loaded along with the protein samples for molecular weight referencing. 
The precision plus protein standards are a mixture of ten recombinant proteins which 
have the molecular weight ranging from 10-250kD. The gel was run at 50-60V for 
lOmin to ensure all protein samples were evenly stacked through the stacking gel
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before increasing the running voltage to 160V. Proteins from the gel were transferred 
onto a nitrocellulose membrane by using a Trans-Blot Turbo Transfer System 
(BioRad). The electrophoretic transfer of proteins was performed at 1.3A, 25 V for 7 
min.
v. Antibody Staining
To prevent non-specific bindings between the nitrocellulose membrane and the primary 
antibody used for detecting the target protein, the nitrocellulose membrane was 
incubated with blocking solution for a minimum of 2 hour. After the blocking step, 
membrane was incubated with primary antibody which has been diluted with 
SuperBlock Blocking buffer. Incubation was performed overnight in a cold room. 
Followed by the incubation, membrane was washed with IX TBS supplemented with
0.1% (vol/vol) Tween-20 for 3 times, lOmin each. This was followed by incubation 
with the appropriate anti-mouse monoclonal antibody (1:10,000) or anti-rabbit 
monoclonal antibody (1:10,000) for 1 hour in room temperature. Washing steps were 
repeated after the incubation, followed by blot developing with Clarity western ECL. 
Image was taken via BioRad ChemiDox™ XRS+ System. Densitometry was performed 
via Image Lab™ software to quantify the expression of the protein of interest.
*Primary antibodies used to detect the protein o f  interest with their corresponding 
secondary antibodies and their preference in SDS-PAGE gel percentage and the type 
o f blocking solution to be used were listed in Table 2.8.
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2.2.6. Immunoprecipitation (IP)
Protein concentrations were normalized across the samples tested. 1 pg of anti-SOCS3 
antibody was added into a total of 1 mL protein lysate, followed by 1 h incubation on ice. 
After the incubation, 50pL of DynaBeads Protein G suspension with the concentration 
of 1.5mg was added into each sample, followed by lh incubation in cold temperature. 
During incubation, samples were constantly mixed by placing on a rotating machine. 
After incubation, samples were placed in the Magnet DynaMag rack (Life Technologies, 
Paisley, UK) to separate out the magnetic bound SOCS3 protein, supernatant was 
removed and the magnetic bound SOCS3 proteins were rinsed by PBS. The rinsing 
procedure was repeated three times. The magnetic bound protein samples were 
resuspended with 15pL of PBS and 15pL of lx NuPAGE sample buffer. Samples were 
boiled at 95°C for 2min. The total of 30pL of protein samples would be loaded into the 
SDS-PAGE gel. The SOCS3 protein would then be analysed by immunoblotting with 
ubiquitin-1 specific antibody.
2.2.7 Cell staining and imaging
106cells/well of CaCo2 cells were seeded on sterilised cover slips that were inserted 
into a 12-well culturing plate. Cells were grown until a cell monolayer was formed 
before proceeding to experimental use. Two different autophagic dyes (MDC and 
Cyto-ID® autophagy Green Detection reagent) were optimized and used in this project.
i. Dansvlcadaverine (MDC) dye
Treated cells were stained with MDC dye at the concentration of 0.05mM for lOmin, 
at 37°C in MEM medium. After the incubation, cells were carefully rinsed with PBS 
and fixed with 2% paraformaldehyde for lOmin at room temperature. Images were
56  | P a g e
captured with Delta Vision microscopy with the excitation wavelength of 360nm and 
emission wavelength of 525nm.
ii. Cvto-ID® autophagy detection kit
Treated cells were stained with Cyto-ID® autophagy detection kit. The kit consists of 
Cyto-ID® Green Detection reagent, Hoechst 33342 nuclear stain reagent, and associated 
10X assay buffer. Microscopy Dual Detection Reagent was prepared by diluting 2pL 
of Cyto-ID® Green Detection reagent and lpL of Hoechst 33342 nuclear stain reagent 
into lmL of IX Assay Buffer (Enzo Life Science, Exeter, UK) supplemented with 1% 
FBS. Treated cells were carefully rinsed with IX Assay Buffer to remove any dead cells 
in the well, followed by incubating treated cells with 300pL of Microscopy Dual 
Detection Reagent per well for 30min at 37°C. After the incubation, cells were carefully 
rinsed with IX Assay Buffer and fixed with freshly made 4% paraformaldehyde for 20 
min at room temperature. Paraformaldehyde was rinsed off by Assay Buffer before 
imaging with confocal microscopy. Images were captured with a Zeiss confocal 
microscope by using FITCS and DAPI filter sets and analysed with LSM Image 
software.
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3.1 Introduction
This chapter comprises a series of experiments performed for the understanding o f the CaCo2 
cell model system and the generation of the optimized CaCo2-autophagy model system to be 
used to investigate the correlation between autophagy, SOCS3 and ECS in human intestinal 
epithelium. Although CaCo2 cell line is the best characterised gut epithelial monolayer system 
available for in vitro study, there is an inconsistency among the results generated with its use 
in different laboratories. For example, Ligresti, et al. (2003) reported that CNR2 was absent 
in their CaCo2 cell model system, whereas Wright, et al. (2005) showed the presence of both 
functional CNR1 and CNR2 receptors in their CaCo2 cell line. Such controversy makes it 
vital for us to understand my CaCo2 cell line by clarifying the presence of the genes of interest 
(CNR1, CNR2) in my model system and exploring the differences of my CaCo2 cell model 
system as compared to the CaCo2 cell lines from other laboratories.
Additionally, CaCo2 cells display different characteristic of intestinal epithelium during 
different stages of cell growth, as they lose their tumorigenic phenotype and display 
characteristics of mature enterocytes upon differentiation (Stierum et al., 2003; Sambuy et al., 
2005). A recent proteomics study revealed that such phenotypic change of CaCo2 is associated 
with the change in the expression of tumorigenesis-associated proteins, as well as a variety of 
distinct biochemical pathways which are involved in protein folding, cytoskeleton formation 
and maintenance and nucleotide metabolism (Stierum et al., 2003). SOCS3 has previously 
been shown to act as an anti-proliferative agent in several cancer cell lines, and this includes 
the CaCo2 cell line (Rigby et al., 2007; Barclay et al., 2009). However, given the distinct 
characteristic of the CaCo2 cell line, it is essential to determine the basal expression of SOCS3 
in each of these growth stages and its regulatory pattern across the 21 days of culture period.
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Furthermore, both proliferating and confluence CaCo2 cells have commonly been utilised in 
various studies as the autophagy model system to investigate the cellular autophagy activity 
in human colorectal cancer (Comes et al., 2007; Kuballa et al., 2008; Xie et al., 2011), but, to 
date, no study has demonstrated the use of differentiated CaCo2 cells to study cellular 
autophagy activity in human intestinal epithelium systems. Considering that autophagy is a 
cellular mechanism utilised to adapt to the cellular environment changes (Klionsky and Emr, 
2000), it is necessary to maintain cellular stress at a minimal level in order to avoid false 
positive findings resulting from cannabinoid treatment. Thus, the generation of the optimised 
CaCo2-autophagy model system is reviewed in this chapter.
3.2 Aim
Determine presence of the gene of interests (CNR1 and CNR2) in 
CaCo2 cell model
Explore changes of basal expression of CNR1 and SOCS3 in three 
growth stages of CaCo2 cells: Proliferating, Confluent and 
Differentiated
Establish an ideal experimental model that was closer to the cell 
system in the GI tract to study autophagosome formation
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3.3 Cannabinoid receptors in CaCo2 cells
To determine whether transcript for CNR1 and CNR2 were present in CaCo2 cells, one step 
quantitative real time PCR (qRT-PCR) was performed with pre-validated primers for CNR1 
(Qiagen, QT00203287), CNR2 (Qiagen, QT00012376) and RPLPO (human large ribosomal 
protein; Qiagen, QT00075012) on RNAs obtained from pooled cytokines-treated CaCo2 
samples. RPLPO, a house keeping gene, was selected as the positive control in this study.
I  300
95
Figure 3.1 Melt curves obtained from quantitative real time PCR (qRT-PCR) with (A) CNR1, 
(B) CNR2 and (C) RPLPO primers. lOng/pl of pooled RNAs from cytokines-treated 
differentiated CaCo2 cells were used as the templates. Non-template control was integrated 
as the negative control for this study. qRT-PCR performed with the use of one-step QuantiTect 
Qiagen primer assay kit.
DNA melt curve indicates the total number of products generated from the amplification of 
the gene of interest (Pfaffl, 2001). Following qRT-PCR, only sample amplification against 
CNR2 primer showed more than one DNA melting curve (Figure 3.IB). The outliners 
presented in both CNR1 (Figure 3.1A) and RPLPO (human large ribosomal protein) (Figure 
3.1C) were the gene amplification obtained from the negative control sample (negative control 
sample = presence of associated primers for the gene of interest without RNA template).
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The experiment was repeated twice to ensure that the multiple melting curves obtained were 
not related to the degradation of RNA samples or the degradation of CNR2 receptor primer, 
as well as the insensitivity of QuantiTect primer assay kit used. Considering that experiments 
were performed by using the same RNA template with the same primer assay kit, this leave 
us to question the quality of CNR2 primer used in this study. Furthermore, I also speculate 
that the number of copy for CNR2 gene is too low in my CaCo2 cell line, resulting in the 
difficulty for qRT-PCR to detect the presence of the gene.
Therefore, to further verify the status of CNR2 in this cell line, I performed Polymerase Chain 
Reaction (PCR) with the CNR2 primer on cDNA generated from the same cytokines-treated 
CaCo2 samples used in previous qRT-PCR experiment. Experiment was conducted by using 
CaCo2 cell, as well as the immortalized T lymphocyte (Jurkats) cell line. The use o f Jurkats 
cells in this study provided us with a positive control for my experiments, as the expression 
of CNR2 has previously been reported in this cell line (Ghosh et al., 2006). DNA for both 
CNR2 and RPLPO were amplified with pre-validated CNR2 and RPLPO primers. RPLPO is 
the house keeping gene and used as the second positive control in this study.
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CaCo2 cells Jurkats cells
Figure 3.2. Expressions of cannabinoid receptor (CNR)-2 at transcriptional level in CaCo2 
and immortalized T lymphocyte cell line (Jurkats cells). Polyacrylamide gel electrophoresis 
(PAGE) was performed on RNAs obtained from cytokines-treated CaCo2 and Jurkats cells. 
RNAs (2pg) were amplified against CNR2 and human large ribosomal protein (RPLPO) pre­
validated primers with the annealing temperature of 53°C. RPLPO with 141 base pair (bp) was 
observed in both CaCo2 and Jurkats cell lines whereas CNR2 receptor with 116bp only 
present in Jurkats cell line.
Result showed that RPLPO band with 141 base pair (bp) was observed in both CaCo2 and 
Jurkats cell lines whereas CNR2 band with 116bp only present in Jurkats cell line (Figure 
3.2), indicating the absence of CNR2 receptor in my CaCo2 cell model. There has been a 
controversy regarding to the presence of functional CNR1 and CNR2 receptors in CaCo2 cells 
(Ligresti et al., 2003; Wright et al., 2005). In agreement to my finding, Ligresti and group also 
reported that CNR2 was absence in their CaCo2 cell model system (Ligresti et al., 2003). The 
absence of CNR2 simplifies the cell model system and provides us with the advantage in 
experiment setting as I can entirely rule out the possible involvement of CNR2 in response to 
cannabinoid treatment and only concentrate on CNR1 action in the system.
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3.4 SOCS3 expression in CaCo2 cells
Due to the cancerous nature of CaCo2 cells, qRT-PCR was performed to determine the 
changes of basal SOCS3 mRNA expression level throughout the growth of CaCo2 cells and 
determine whether this cell line is an appropriate model.
a 12_o ‘K 








Figure 3.3. Basal SOCS3 mRNA expression in CaCo2 cells. 106 cells/dish of CaCo2 cells 
were seeded in petri dishes. RNAs of the seeded cells was extracted and collected from day 1 
where cells are proliferating to day 22 where cells are fully differentiated. All data were 
analysed in relative fold change against day 0 (the day cells were seeded). Data were given as 
fold change with error bars representing standard error of the mean (n<2).
Level of SOCS3 mRNA expression was shown to be gradually increasing from day 1 to day 
22 (Figure 3.3). CaCo2 cells reached its confluency around day 7 and achieved fully 
differentiated cell monolayer around day 14 (Sambuy et al., 2005). Quantitative RT-PCR 
detected relatively low SOCS3 expression in proliferating cells and high SOCS3 expression 
in fully differentiated cells (Figure 3.3). SOCS3 has previously been shown to exert a modest 
anti-proliferative effect in CaCo2 cells and this may explain the absence of SOCS3 mRNA 
expression in proliferating CaCo2 cells (Rigby et al., 2007).
Relative SOCS3 mRNA
i i i i i i i i r
0  1 2 4  7 10  12 15  19 22
Growth of CaCo2 cells (days)
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3.5 CNR1 and SOCS3 expression in cytokine-treated CaCo2 cells: Proliferate, 
Confluent, Differentiated
Different growth stages of CaCo2 ostensibly reflect different characteristic of intestinal
epithelium (Sambuy et al., 2005). Proliferating CaCo2 cells were exposed to treatments from
both apical and luminal surfaces as tight junction have not yet been formed. Confluent CaCo2
cells, on the other hand, represent a model of confluent monolayer of epithelium that is not
fully differentiated. Differentiated CaCo2 cells provide a recognised model of a polarized
epithelial cell monolayer that creates a barrier to the passage of ions and molecules.
Considering that the basal expression of SOCS3 is significantly different throughout the
growth of CaCo2 cells (Figure 3.3), therefore, both CNR1 and SOCS3 expression in
proliferating, confluent and differentiated CaCo2 cells in response to cytokine treatment was
evaluated.
Proliferating, confluent, and differentiated CaCo2 cells were cultured for 2 days, 7 days and 
17 days, respectively. Treated CaCo2 cells had not been starved overnight. TNF-a, IFN-y, 
CBD, Leptin and LPS were the main five treatments applied in the experiments. Leptin, TNF- 
a and IFN-y were selected to be the main factors/treatments because studies have illustrated 
their role as the pro-inflammatory cytokines and these cytokines are highly involved in IBD. 
LPS, on the other hand, is a cell wall component of Gram-negative bacteria and this TLR4 
ligand has been shown to contribute to the occurrence of inflammation in GI tract. Lastly, 
CBD was selected because it was one of the main cannabinoid of interest in this project.
Result showed that in proliferating CaCo2 cells, CNR1 mRNA expression was up-regulated 
in response to LPS treatment (Figure 3.4). Both IFN-y and CBD treatments significantly 
reduced CNR1 mRNA expression, as compared with no treatment control (Figure 3.4).
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Interestingly, as the same experiment was repeated on confluent CaCo2 cells, result showed 
that CNR1 mRNA expression did not respond to any of the treatments, compared to no 
treatment control (Figure 3.6).
Conversely, SOCS3 mRNA expression was up-regulated in response to IFN-y and LPS 
treatments in proliferating CaCo2 cells, as compared with no treatment control (Figure 3.5). 
TNF-a treatment increased SOCS3 mRNA expression in confluent CaCo2 cells and this was 
the only treatment induced a response in confluent cells (Figure 3.7). Again, as the same 
experiment was repeated on differentiated CaCo2 cells, result showed that SOCS3 mRNA 
expression did not respond to any of the treatments compared with non-differentiated CaCo2 
(Figure 3.8).
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i. Proliferating CaCo2 cells
Relative CNR1 mRNA
***
CONTROL TNF IFN CBD
T re a tm en ts
LEP LPS
Figure 3.4. Effect of treatments on CNR1 mRNA expression in proliferating CaCo2 
cells. Cells were treated for 4 hour. Data were given as fold change with error bars 
representing standard error of the mean (n=3, *P<0.05, ***P<0.001, compared to no 
treatment control, ANOVA).
Relative SOCS3 mRNA
C ontrol TNF IFN CBD
T re a tm en ts
LEP LPS
Figure 3.5. Effect of treatments on SOCS3 mRNA expression in proliferating CaCo2 
cells. Cells were treated for 4 hour. Data are given as fold change with error bars 
representing standard error of the mean 0= 3 , **P<0.01, compared to control with no 
treatment, ANOVA).
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ii. Confluent CaCo2 cells
Relative CNR1 mRNA
C ontrol TNF IFN CBD LEP LPS
T re a tm e n ts
Figure 3.6. Effect of treatments on CNR1 mRNA expression in confluent CaCo2 cells. 
Cells were treated for 4 hour. Data are given as fold change with error bars representing 
standard error of the mean 0= 3 , data were analysed versus no treatment control, 
ANOVA).
Relative SOCS3 mRNA
Control TNF IFN CBD LEP LPS
Treatm ents
Figure 3.7. Effect of treatments on S0CS3 mRNA expression in confluent CaCo2 
cells. Cells were treated for 4 hour. Data are given as fold change with error bars 
representing standard error of the mean 0= 3 , **P<0.01, compared to no treatment 
control, ANOVA).
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iii. Differentiated CaCo2 cells
Relative SOCS3 mRNA
1.8 -  
!  1-6 -
'111111
C ontrol TNF IFN CBD LEP LPS
T re a tm e n ts
Figure 3.8. Effect of treatments on SOCS3 mRNA expression in differentiated CaCo2 
cells. Cells were treated for 4 hour. Data are given as fold change with error bars 
representing standard error of the mean 0= 3 , data were analysed versus no treatment 
control, ANOVA).
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3.6 Effect of the integration of fetal bovine serum (FBS) in treatm ents
i. CNR1 and SOCS3 mRNA expression
In light of previous analysis, it is possible that FBS may interfere with treatment- 
induced effect on both CNR1 and SOCS3 mRNA expression. Therefore, another 
experiment was conducted to investigate serum effect on CNR1 and SOCS3 mRNA 
expression in differentiated CaCo2 cells. The experiment was performed by comparing 
two different culturing protocols as stated in Figure 3.9. Considering that the baseline 
expression for no treatment control in both of the experiments were different, data has 
also been re-analysed in relation to the no treatment control based on the ‘serum 
containing’ protocol (Figure 3.9, Protocol A). Significance of the results was 
obtained through Dunnett statistical test with 95% confident interval.
B
Cells seeded — — Cells differentiated —
Day -1 Day 16 Day 17
Treatment
i i i j
♦  — >
Indication:
CaCo2 cells cultured in MEM with 8% FBS 
CaCo2 cells cultured in MEM with no serum
Figure 3.9. Schematic diagram of two experimental protocols: ‘serum
containing’/Protocol A and ‘serum starved’/Protocol B. Colour variation indicated the 
type culture medium used during culturing process.
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Following 1 hour treatment, CNR1 mRNA expression was up-regulated with both 
leptin and LPS treatments (Figure 3.10). On the contrary, CNR1 mRNA expression 
was reduced in IFN-y treated cells (Figure 3.10). SOCS3, on the other hand, its mRNA 
expression was significantly up-regulated in response to TNF-a treatment in 
differentiated CaCo2 cells.
As stated previously, considering that the baseline expression for no treatment control 
in both of the experiments were different, data were re-analysed in relation to the no 
treatment control from “serum containing” protocol. Based on that analysis, previously 
found IFN-y-induced CNR1 mRNA reduction was no longer statistically significant 
(Figure 3.11). Interestingly, increased CNR1 mRNA in response to CBD-treated 
“serum starved” cells appeared to be statistically significant (Figure 3.11). The leptin 
and LPS induced effect on CNR1 mRNA expression were still statistically significant 
despite the way the data was analysed (Figure 3.10 & 3.11). As for the SOCS3 mRNA 
expression, re-analysing the data did not affect the significance of TNF-a increased 
SOCS3 mRNA expression in “serum starved” cells (Figure 3.12 & 3.13).




C ontrol TNF IFN CBD LEP LPS
T rea tm en ts
Figure 3.10. Effect of treatments on CNR1 mRNA expression in serum starved CaCo2 
cells. Treatments were applied for 1 hour. Data are given as fold change with error 
bars representing standard error of the mean (n=3, **P<0.01, ***P<0.001, compared 
to no treatment control, ANOVA).
Relative CNR1 mRNA
Control TNF IFN CBD LEP LPS Control TNF IFN CBD LEP LPS
Serum  C ontain ing Serum  starved
T re a tm e n ts
Figure 3.11. Effect of treatments on CNR1 mRNA expression in both serum 
containing and serum starved CaCo2 cells. Treatments were applied for 1 hour. Data 
are given as fold change with error bars representing standard error of the mean (n=3, 
*P<0.05, ***P<0.001, compared to no treatment control from ‘serum containing’ 
protocol, ANOVA).
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Figure 3.12. Effect of treatments on SOCS3 mRNA expression in serum starved 
CaCo2 cells. Treatments were applied for 1 hour. Data are given as fold change with 
error bars representing standard error of the mean (n=3, *P<0.05, ***JP<0.001, 
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Figure 3.13. Effect of treatments on SOCS3 mRNA expression in both serum 
containing and serum starved CaCo2 cells. Treatments were applied for 1 hour. Data 
are given as fold change with error bars representing standard error of the mean (n=3, 
*P<0.05, compared to no treatment control from ‘serum containing’ protocol, 
ANOVA).
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ii. mTOR and JAK-STAT signalling pathway
Previous studies suggested FBS did interfere with CNR1 mRNA expression but not 
SOCS3 mRNA expression. Therefore, experiments were performed to further evaluate 
the serum effect for SOCS3 and the JAK-STAT3 signalling pathway at the 
translational level. Activation of STAT3 via phosphorylation will initiate the 
transcription of SOCS3 and other target genes (Piessevaux et al., 2008). In addition to 
STAT3 and SOCS3, the mTOR protein was also included in the study. TOR signalling 
is known to be involved in the regulation of cellular stress response. Previous finding 
showed that TOR signalling was inhibited in response to starvation-induced stress in 
Drosophila fat body (Scott et al., 2004), therefore the activation of mTOR protein was 
selected as a positive control for this study.
The treated cells were cultured in the presence or absence of FBS overnight prior to 
cytokine or cannabinoid treatment for additional 30 minutes. As previous finding 
suggested that FBS did not affect the SOCS3 mRNA expression in response to 1 hour 
cytokine treatment and since STAT3 is located on the upstream signalling of SOCS3, 
30 minutes was selected as the treatment time for this experiment.
ACEA and IL-ip were the main treatments applied in this set of experiment. ACEA 
was chosen to be the treatment for this study because ACEA is a CNR1 agonist and 
for my project, I am interested in investigating the cannabinoid effect on autophagy 
process, therefore it was crucial to determine whether serum status has an impact on 
cannabinoid-induced effect on both p-MTOR and JAK-STAT signalling pathways in 
my model system. As for IL-lp, studies showed an increase of IL-ip production in 
inflamed gut mucosa in IBD patients (Reimund et al., 1996; Reinecker et al., 1993).
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IL-ip, a pro-inflammatory cytokines, is released by immune cells to the site of injury 
during inflammation (Harris et al., 2011). Taken together, it was interesting to explore 
whether serum status has an impact on IL-ip induced effects in this context. Overall, 
this data would offer us further understanding of my model system and the importance 
of serum availability to both cannabinoid-induced effects, as well as the IL-1P induced 
inflammatory setting.
Result showed that the basal protein expression for p- mTOR was up-regulated in the 
presence of FBS (Figure 3.14). ACEA-induced effect was not affected in p-mTOR 
protein expression, albeit the serum status. However, IL-1 P-induced effect on p-mTOR 
protein expression was dependent on the serum status in the treated cells (Figure 3.15).
In agreement to my previous finding (Figure 3.13), the presence of FBS did not impact 
on the basal expression of SOCS3 (Figure 3.14). Consistent with the SOCS3 respond, 
the basal protein expression of p-STAT3 was not affected by the addition of FBS 
(Figure 3.14). Interestingly, both IL-1 P and ACEA reduced SOCS3 protein expression 
in “serum-starved” cells but such effects were not observed in “serum containing” cells 
(Figure 3.15). As for p-STAT3, both IL-ip and ACEA did not affect p-STAT3 protein 
expression, albeit the serum status (Figure 3.15).






FBS 8% (vol/vol) - - - -  + + +  +
ACEA (1 OOnM) - + .  + _ + . +
IL-1 P (1 Ong/mL) - + + - - + +
H 0.5V
(+)FBS (-)FBS (+) FBS (-)F B S  (+) FBS (-)F B S
Figure 3.14. Effect of Fetal Bovine Serum (FBS) on p-mTOR, p-STAT3 and SOCS3 
basal protein expressions in fully differentiated CaCo2 cells. Data are given as fold 
change compared to cells that were pre-starved overnight prior to protein lysing for 
western blotting; n=l.
(Molecular weight fo r p-MTOR:289KDa; p-STAT3:91KDa; t-STAT3:79KDa; SOCS3:27KDa; 
P-Actin: 4 5 KDa)
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Figure 3.15. Effect of treatments on p-mTOR, p-STAT3 and SOCS3 protein 
expressions in both serum containing and serum starved CaCo2 cells. Cells were 
starved overnight prior to treatment application for additional 30minute. Data are 
given as fold change with error bars representing standard deviation (n>2), compared 
to their corresponded no treatment control.
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3.7 Establishing autophagy model system
Autophagy is a cellular mechanism utilised to adapt to the cellular environmental changes by 
promoting proteolytic degradation of the cytosolic compartments at the lysosomes (Chang et 
al., 2009; Glick et al., 2010; Klionsky and Emr, 2000; Singh and Cuervo, 2011). The 
autophagic process can be triggered by various occasions and one of the best characterized 
stimuli is starvation. The removal of nutrient source such as nitrogen and carbon and the lack 
of amino acid are the contributors towards autophagy induction (Deretic and Levine, 2009; 
Kuma and Mizushima, 2010; Mizushima, 2007; Singh and Cuervo, 2011). Considering that 
autophagy is highly involved in cellular regulation of catabolic processes, the chances of 
obtaining a false positive result is relatively high if the experimental model system is not 
properly designed.
As noted from previous findings, cells were less responsive to applied treatment when they 
were treated with 8% FBS. Equally, a complete absence of serum in culture media may not 
be physiologically relevant as well as it will be unrealistic for nutrients to be inaccessible to 
epithelial cells in GI. Taken together, a new experimental protocol was designed to 
compromise both settings by reducing the serum concentration from 8% to 1%. Therefore, in 
this section, experiments were performed to evaluate the impact of FBS concentration (8% or 
1% FBS) on p-mTOR and LC3-II protein expression. LC3-II is the hallmark feature in 
autophagy process. The formation of autophagosome was monitored through the conversion 
of LC3 from LC3-I to LC3-II (Kabeya et al., 2000).
Experiments were performed only in “serum containing” differentiated CaCo2 cells. Based 
on previous experiments, the rational for pre-starving treated cells was to synchronize cells 
into Go position in cell cycle. However, a recent study by Mehran and group demonstrated 
that CaCo2 cells that were cultured for 20 days were mostly in the Gi phase of the cell cycle.
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Around 18% of the cells were found in the proliferating state which included the S, G2 and M 
phase of the cell cycle (Mehran et al., 1995), suggesting that by synchronizing the cell cycles 
back to Go position may interfere with the physiological setting as not all the epithelial cells 
in GI tract were in the Go position. Furthermore, in light of previous finding, phosphorylation 
of mTOR protein was greatly reduced in pre-starved cells (Figure 3.14), suggesting that the 
cells may experience starvation-induced cellular stress, which may subsequently impact on 
treatment-induced LC3-II expression in later stage. Therefore, taken together, the pre-starved 
protocol was aborted and experiments were proceeded only with “serum-containing” cells.
Result showed that the basal p-mTOR and LC3-II protein expression were unaffected by 
changes of serum concentration in treated cells (Figure 3.17). As mTOR signalling is known 
to be involved in the regulation of cellular stress response (Jung et al., 2010), the result 
suggested that the reduction of serum from 8% to 1% did not induce unnecessary cellular 
stress in treated cells. Furthermore, the result showed that IL-lp increased p-MTOR protein 
expression only in 1% serum-treated cells (Figure 3.18). This finding was consistent with 
previous finding which suggested that IL-ip-induced effects on p-mTOR protein expression 
were serum dependent. In contrast, IL-lp increased LC3-II protein expression in 1% serum 
treated cells but not in 8% serum treated cells (Figure 3.18), suggesting that similar to the 
mTOR expression, the IL-lp-induced effect on LC3-II protein expression was also serum 
dependent. This finding is in agreement with previous study which showed that the IL-ip- 
induced autophagy effect in rat annulus fibrosis cells was serum dependent (Shen et al., 2011).
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Indication:
CaCo2 cells cultured in MEM with 8% FBS
CaCo2 cells cultured in MEM with 1% FBS
Figure 3.16. Schematic diagram of two different experimental protocols applied in the 
experiment. Colour variation indicated the differences of serum concentration in the culture 
medium.
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Figure 3.17. Effect o f  fetal bovine serum (FBS) on basal protein expression o f  p-mTOR and 
LC3-II in differentiated CaCo2 cells. Data are given the as fold change normalised to 8% 
FBS-treated cells with error bars representing standard deviation; n=2. Further detail for the 
experimental set up was presented on the schematic diagram on Figure 3.16.
(Molecular weight for p-MTOR:289KDa; LC3-I & II: 14&16KDa; p-Actin:45KDa)
1.5 -i 2.5
Control ControlControlControl
Figure 3.18. Effect o f  fetal bovine serum (FBS) on p-mTOR and LC3-II protein expression 
in IL-ip-treated CaCo2 cells. Data are given as fold change associated untreated control 
within the same experimental protocol with error bars representing standard deviation; n=2. 
Further detail for the experimental set up was presented on the schematic diagram on Figure 
3.16.
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3.8 Discussion
CaCo2 cells are derived from the human epithelial colorectal adenocarcinoma cells. This cell 
line was chosen as the inflammatory cell model system based on their ability to mimic primary 
intestinal epithelium after differentiation in culture (Bailey et al., 1996). The inter-laboratory 
variation in the morphology and permeability of CaCo2 cells has been addressed in previous 
publications (Hayeshi et al., 2008; Sambuy et al., 2005). Despite of the variation in CaCo2 
cells, this cell model is still the best characterised gut epithelial monolayer system available 
for in vitro study. CaCo2 cells mimic the characteristics of enterocytes residing in human 
small intestinal epithelium (Bailey et al., 1996).
Due to the characteristic of CaCo2 cells as stated above, there has been a controversy 
regarding the presence of functional CNR1 and CNR2 receptors in CaCo2 cells (Ligresti et 
al., 2003; Wright et al., 2005). Therefore, experiments were performed to verify the presence 
of CNR1 and CNR2 in my model system. Interestingly, in my CaCo2 cell model system, only 
CNR1 is being expressed in the cells. With that, the absence of CNR2 can be beneficial to my 
cell model system as it not only simplifies the cellular regulatory system but also provides us 
with the advantage of excluding possible involvement of CNR2 in response to cannabinoid 
treatment in the regulatory system.
Even though characteristic of CaCo2 had been previously reported, it is essential that the cell 
culture system employed is carefully characterized and thus experimentally controlled. 
Therefore, the CNR1 and SOCS3 mRNA were explored in proliferating, confluent and 
differentiated CaCo2 cells. In general, treatments-induced CNR1 and SOCS3 expressions 
were less significant as the cells started to form confluent, differentiated monolayer. Decline 
responses of CaCo2 cells to exogenous stimulation upon reaching confluency may be the
consequence results from the formation of tight junctions in the cells. Presence of tight
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junctions will limit the absorption of treatments applied to the cells as treatments will only be 
exposed to the apical or luminal surface on the cell monolayer whereas the treatments 
approach the proliferating cells on both the basal and apical cell surfaces. Apart from a 
possible consequences from the tight junction formation, stationary growth stage of the cells’ 
progress may also contribute to the decline response of both confluent and differentiated 
CaCo2 cells to exogenous stimulation. During the phase of stationary growth, cells will stop 
proliferating (Watanabe and Okada, 1967) and considering that these cells were well- 
maintained with sufficient growth nutrients in culture dishes, the rate of response for these 
cells may slowly decline, hence explains the decline responses of CaCo2 cells to exogenous 
stimulation upon reaching confluency.
Proliferating CaCo2 cells showed a significant increase of CNR1 mRNA expression in 
response to LPS treatment (Figure 3.4). This may indicate the involvement of TLR4 signalling 
pathway on CNR1 expression. TLR4 signalling pathway is required for pathogen recognition 
activation of innate immunity and so, presence of bacteria ligands will stimulate the activation 
of TLR4 receptor (Fukata et al., 2005). Interestingly, in proliferating CaCo2 cells, SOCS3 
mRNA illustrated an increase expression in response to LPS and IFN-y treatments as well 
(Figure 3.5,). This phenomenon only occurred in proliferating cells and not in confluent and 
differentiated cells. This is a new observation as it has not been shown in previous studies. 
Based on this result, I suggest that the increase of SOCS3 mRNA may be due to the initiation 
of the negative feedback loop of SOCS3 in reducing inflammatory cytokines induced 
activities. In contrast to proliferating CaCo2 cells, result showed that in confluence cells, 
SOCS3 expression was increased in response to TNF-a treatment, but not LPS and IFN-y 
treatments (Figure 3.7). Again, this may due to stationary growth stage of the cells’ progress, 
as well as the formation of tight junctions in confluent cells and the tight junctions act as a 
barrier to penetration of inflammatory treatments.
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On the whole, I have a better understanding of the implication of using cells at different growth 
stages in my model system based on the results I have obtained. Even though differentiated 
CaCo2 cells were less responsive to applied treatments, these cells were most likely to be the 
closest model system to the physiological setting in intestinal epithelium. Therefore, I have 
decided to perform all the following experiments in differentiated CaCo2 cells.
Next, experiments were performed to explore the serum effect on CNR1 and SOCS3 
expression in both serum containing and serum starved differentiated CaCo2 cells. The 
rational of pre-starving the treated cells prior to cytokine treatment was to normalize the cell 
cycle by returning all the cells to Go position. As a result, this should provide more significant 
fold changes for both CNR1 and SOCS3 expression in the treated CaCo2 cells. My result 
showed that FBS may interfere with CNR1 mRNA expression and this was demonstrated 
through the CBD treatment. This finding was in agreement with previous findings from 
Jacobsson and groups where they demonstrated that FBS did affect CBD expression in human 
glioblastoma cells. However, the mechanism behind this finding is still unknown (Jacobsson 
et al., 2000). Additionally, considering that leptin is involved in nutrient sensing regulatory 
pathway (Wang et al., 1998), it was interesting to notice that leptin increased CNR1 mRNA 
expression regardless of the serum availability in the treated cells.
In contrast to serum-induced effect on CNR1 mRNA expression, SOCS3 was not affected by 
the presence of serum at both transcriptional and translational level. Consistent with the 
SOCS3 finding, FBS did not cause an impact on p-STAT3 protein expression level, 
suggesting that the JAK-STAT3-SOCS3 signalling pathway was unaffected by the change of 
nutritional status in the model system. Interestingly, both ACEA and IL-ip induced SOCS3 
protein expressions were serum dependent, as opposed to their induced effect on p-STAT3
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expression. This implied that even though the basal expression of SOCS3 was unaffected 
regardless of the serum status in treated cells, cytokine or cannabinoid treatment may act 
differently according to the serum availability in the treated cells, hence indirectly impact on 
the SOCS3 expression.
In my model system, the basal p-mTOR protein expression was reduced in pre-starved cells, 
as compared to cells treated with full serum (8%), suggesting that that the starvation step may 
deliver unnecessary cellular stress into the cellular system. Additionally, the starvation step 
may also interfere with the physiological setting as not all the epithelial cells in the GI tract 
were in Go position. Taken together, the “serum starving” protocol was later being excluded 
from the experimental setting. It has been reported that starvation-induced stress may inhibit 
TOR activation in Drosophila fat body (Scott et al., 2004). Inhibition of p-mTOR may act as 
a rescue mechanism for the cell to initiate autophagy activation, a cellular process that 
maintains the cellular energetic homeostasis in the cells (Diaz-Troya et al., 2008). Considering 
that autophagy pathway was the main readout for this project and autophagy pathway is tightly 
regulated by the nutritional status in the model system, the exclusion of this additional 
starvation protocol may also reduce the probability of attaining false positive result for 
cytokine or cannabinoid-induced effect on autophagy process in treated cells.
Apart from the impact of starvation-induced onto the treated cells, I also noticed that the 
differentiated CaCo2 cells were less responsive to applied treatments in the presence of 8% 
serum, suggesting that the use of 8% serum may dominate over cytokines or cannabinoids 
treatments in the cells and a higher concentration of cytokines/cannabinoids may be required 
to obtain a significant induced-response in this experimental set up. Consequently, increased 
dosage of the cytokines and cannabinoids treatment may increase the cytotoxicity in the
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treated cells, subsequently affect the experimental outcome. Therefore, experiments were 
performed to explore the use of reduced serum concentration (1% serum) in the experimental 
protocol. My results showed that the changes of serum concentration from 8% to 1% did not 
affect the basal p-mTOR protein expression, suggesting that the cellular homeostasis in treated 
cells was not disturbed by the serum reduction. Taken together, this finding implied that 1% 
serum culturing protocol may be more appropriate to study autophagy induction in my cell 
model.
Overall, differentiated CaCo2 cells were selected as my in vitro model system to study 
cannabinoid-induced effect on autophagy process in the intestinal epithelial cells. Treated 
CaCo2 cells would not be pre-starved and treatment would be applied along with MEM 
supplemented with 1% serum.
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Chapter 4
Cannabinoid receptor (CNR)-1 
knockdown CaCo2 cell model
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4.1 Introduction
Cannabinoid receptor (CNR)-l is one of the most well studied examples of cannabinoid 
receptors. CNR1 was the first to be discovered and studies have shown that the expression level 
of CNR1 is high in brain regions that associate with cannabinoids and low in regions where 
cannabinoids are not normally produced such as the respiratory center of medulla (Herkenham 
et al., 1991). CNR1 is classified under G-coupled protein receptor (GPCR) superfamily, where 
CNR1 couples and activates the Gj/G0 subunits in G-proteins (Glass and Northup, 1999).
To date, studies have reported several beneficial effects of cannabinoid administration to the 
gut (Izzo and Sharkey, 2010; Wright et al., 2005). Association of CNR1 to cannabinoid 
treatments have previously been reported and studies have suggested that the role of CNR1 in 
cannabinoid-induced effect is functionally dependent. For instance, administration of CBD, a 
non-psychoactive phytocannabinoid, induced a concentration-dependent inhibition of the 
migration of glioma cells and this effect was not mediated by CNRl(Vaccani et al., 2005). 
Interestingly, in other study, CBD was shown to inhibit inflammatory hypermotility and such 
effect was mediated by CNR1 despite the fact that CBD does not bind to cannabinoid receptors 
with high affinity (Capasso et al., 2008). However, the association of CNR1 in cannabinoid- 
induced autophagosome formation was unknown. The use of antagonists to the CNR1 receptor 
has been an important tool in the dissection of receptor-mediated signalling and function, but 
a novel way to study the functional consequence of CNR1 loss is through reduced gene 
expression in the cell system, thus by shRNA-induced knockdown of CNR1 gene, a new cell 
model was generated. The methods applied in developing this new cell model system are 
reviewed in this chapter.
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4.2 Aims
To generate cannabinoid receptor (CNR)-l knockdown 
CaCo2 cell model (CaCo2_CNRl KD).
To determine the optimal puromycin concentration to be 
used as a selectable marker for in CaCo2_CNRlKD cells.
To verify the percentage of knockdown for CNR1 gene in 
CaCo2 CNR1KD cell model.
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4.3 Generation of CNR1 knockdown CaCo2 cell model
In this project, CNR1 gene knockdown CaCo2 cell model (CaCo2-CNRlKD) was generated 
by introducing CNR1-specific HuSH short-hairpin RNA (shRNA) (CNR1 Gene ID = 1268) 
into the wild type CaCo2 cells through direct transfection. Introduction of shRNA allows the 
generation of stable and long-term knockdown of CNR1 gene in CaCo2 cell model. During 
transfection, pRetroSuper (pRS) retroviral vector was selected by OriGene to deliver the 
inserted CNR1- shRNA expression cassettes into the CaCo2 cell. pRS vectors with CNR1 
shRNA inserts were purchased from OriGene (product code, TR316500).
4.3.1 pRetroSuper (pRS) retroviral vector
i. Retroviruses
Retroviruses are enveloped viruses which consist of a linear, single-stranded RNA as the 
genome (Zhang and Godbey, 2006). Retroviruses integrate into the host genome by 
initiating fusion between the viral envelopes and the host cell membranes, resulting in 
the release of viral components into the cell cytoplasm. The viral RNA will be utilised as 
a template by the viral reverse transcriptase to generate a double stranded cDNA and 
incorporate into the host genome. With the use of the host machinery, cDNA will be 
transcribed into mRNA and subsequently translated into a viral protein (Zhang and 
Godbey, 2006). Such replication system employed by the retroviruses was targeted and 
engineered into retroviral vector, which has become a valuable approach in introducing 
a foreign gene of interest into a target cell.
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ii. OriGene engineered pRetroSuper (pRS'l vector
A pRS retroviral vector contains the retroviral long terminal repeats (LTRs) from the 
murine moloney leukemia virus, a puromycin resistance gene, an ampicillin resistance 
gene, a SV40 promoter and a U6 small nuclear RNA gene promoter (Figure 4.1). LTRs 
are the main gene expression regulator for the retrovirus by ensuring the integration 
between the pRS vector and the host cell. The U6 promoter, which is designated straight 
upstream from the shRNA construct, drives the expression of the inserted shRNA 
expression cassettes. The presence of the selectable markers is crucial in determine the 
efficacy of transformation/transfection. The bacterial selection maker for this pRS vector 
is ampicillin whereas the mammalian selection marker is puromycin. The first is 
expressed by the LTR promoter whereas the latter is expressed by SV40, an internal and 
heterologous promoter (Figure 4.1). Based on the selection system, cells that were 
successfully transfected with CNR1-shRNA contained pRS vector, which would have 
the puromycin resistance gene integrated into the genome. Consequently, the puromycin 
antibiotic treatment would have no impact on the transfected cells, and vice versa.
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Features for pRS vector:
Start End Description
t 5 EooRl




413 681 SV40 promoter
743 1342 PuromydrvN-ace-tyl transferase sequence
1441 2034 3* LTR
2381 3010 p6R322 ORI
3172 4032 Beta4actamase for amp*tffen resistance
4168 4638 5' LTR
Loop
Target Sequence Target Sequence RC




Figure 4.1. pRS shRNA expression vector. Please see appendix for the complete DNA 
sequence of the pRS vector without shRNA expression cassette.
Figure adapted from OriGene HUSH shRNA plasmids (29-mer) application guide.
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4.3.2 Short hairpin RNA (shRNA) expression cassette
i. shRNA
RNA interference (RNAi) is a post-transcriptional cellular machinery which involves in 
the sequence-specific gene silencing process (Sandy et al., 2005). RNAi has become a 
powerful research tool, both in vivo and in vitro (Hausmann et al., 2011; Ikonomou et al., 
2012; Szymanska, 2007). Such technique is broadly used to study gene regulation in 
disease states and subsequently, their associated proteins function in the interactive 
pathway. RNAi acts on the targeted gene through the delivery of short hairpin RNA 
(shRNA) or small interfering RNA (siRNA) with sequence complementary to the 
targeted gene to the host cell (Moore et al., 2010). shRNA is produced as a single 
stranded molecules with the length of 50 to 70 nucleotides (Sandy et al., 2005). Once 
shRNA is integrated into the host genome, it will be constitutively transcribed by RNA 
polymerase III and transported into cytosol. The stem-loop structure of shRNA will be 
removed by Dicer, resulting in the formation of siRNA. Such siRNA will be encountered 
by a RNA-induced silencing protein complex (RISC) and subsequently unwound the 
double stranded siRNA. Consequently, the antisense strand of the siRNA will bind to the 
activated RISC and use as a template strand to target mRNA with identical sequence. 
This results in the degradation of the targeted mRNA in the cell, hence impacts on the 
expression of the targeted gene in the cells (Sliva and Schnierle, 2010).
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ii. OriGene HuSH shRNA plasmid (29-MER1
HuSH-29 hairpin shRNA construct consists of a longer nucleotide sequence compared 
to the conventional 19-21mer shRNA construct. The increase length in shRNA sequences 
results in an increase in the efficacy of the shRNA in inhibiting the targeted gene (Siolas 
et al., 2005). The gene-specific shRNA construct was inserted downstream of U6 
promoter in the pRS expression vector (Figure 4.1.). Each shRNA constructs was 
designed based on the structure sequence as stated in Figure 4.2. In this project, four 
different CNR1-specific shRNA constructs were directly transfected into the wild type 
CaCo2 proliferating cells, resulting in four versions of CaCo2_CNRlKD cells. The 
sequences for each of the shRNA constructs were stated in Table 4.1.
U6 promoter — G ATCG -- 29 nt sense —TCAAGAG -  29 nt reverse
complement --TTTTTT (termination) - G A A G C T
Figure 4.2. Structure sequence for OriGene designed gene-specific short-hairpin RNA 
(shRNA). The nucleotide sequences highlighted in bold were the BamHI/Hind III 
cloning sites to be found in the pRS expressing vector. “29 nt sense” represented 29 
nucleotide gene-specific sequences inserted in plus (+) orientation; the nucleotide 
sequences for TCAAGAG formed a 7 nucleotide loop in the shRNA.
Table 4.1. 29-nucleotides sequences for CNR1-specific short hairpin RNA (shRNA) 
constructs. Nucleotide sequences were listed in plus (+) orientation.





TI363211 TACTGCTTCTGTT C ATCGT GT ATGCGT AC
TI363212 GTGTCCACAGACACGTCTGCCGAGGCTCT
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4.3.3 Puromycin kill curve
To determine the optimal concentration of puromycin to be used as the selectable marker 
for eliminating the non-transfected cells, a puromycin kill curve was performed by using 
wild type proliferating CaCo2 cells. Proliferating CaCo2 cells were seeded at the cell 
density of 50,000 cells per well in a 96 well plate. Puromycin with the concentration 
ranging from 0.05|ig/mL to 100pg/mL was applied to the cells and incubated for 72hours. 
A cell viability assay was performed to evaluate the viability of treated cells in response 
to puromycin treatment. 20pL of PrestoBlue™ Cell Viability Reagent was added to a 
total of 180pL culture media with treated puromycin CaCo2 cells, followed by 10 
minutes incubation at 37°C. Such reagent acts as a cell viability indicator by using the 
reducing environment maintained by the living cells to quantitatively measure the 
proliferation of cells. Addition of such reagent to the cells induces a fluorescent colour 
change from blue to red, which can then be detected via fluorescence measurement. 
Fluorescence readouts were obtained at the excitation wavelength of535nm and emission 
wavelength of 615nm. A graph was plotted with the percentage of cell viability against 
the puromycin concentration applied to the CaCo2 cells (Figure 4.3).





s  50 -
> 40 -
Puromycin Concentration (pg/mL)
Figure 4.3. Viability of CaCo2 cells in response to puromycin treatment. Proliferating 
CaCo2 cells were treated with puromycin concentration ranging from 0.05pg/mL to 
50pg/mL. Cell viability assay was performed by using PrestoBlue™ Cell Viability 
Reagent. Readings were obtained at the excitation wavelength of 535nm and emission 
wavelength of 615nm (n=3).
As fluorescence readouts reflect the metabolic activity in the cells, result suggested that 
the treatment of puromycin concentration ranging from roughly 0.5pg/mL to 5pg/mL 
was lethal to the proliferating CaCo2 cells. Such response was consequence from the 
puromycin-induced inhibition in the translational process during protein synthesis 
(Azzam and Algranati, 1973). Taken that, puromycin at 0.6pg/mL was chosen to apply 
as the selectable marker for the knockdown cells. Cells which have been successfully 
transfected with shRNA-expressed vector will be resistant to puromycin treatment, or 
vice versa. Treatment with puromycin at the concentration of 0.6pg/mL will therefore 
allow cells to differentiate and eliminate the non-transfected CaCo2 cells, hence 
maintaining the culture under selection process.
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4.3.4 Experimental Procedures
TurboFectin 8.0, as recommended by OriGene, was chosen as the transfection reagent to 
achieve optimal delivery of nucleic acid into the CaCo2 cells. Overall, CaCo2 cells were 
transfected with four different CNR1-specific shRNA cassettes, resulting in four 
different CaCo2-CNRlKD cell lines. An additional OriGene provided shRNA construct 
which consisted of pRS vector with non-effective (scrambled) shRNA cassette has also 
been transfected into the CaCo2 cells. The CaCo2 cells that have been transfected with 
scrambled shRNA cassette (CaCo2-Scrambled) were treated as the specific negative 
control for gene down regulation in this procedure.
Wild type CaCo2 cells were seeded at a cell density of 2 x 105 cells per well in a 6 well 
culture plate a day before the transfection. A mixture of different reagents was required 
to be freshly prepared before proceeding towards transfection. The order of reagent to be 
added into the mixture was crucial in order to achieve an optimal transfection. First, 
lOOpL of serum free-MEM culture medium were prepared in a sterile plastic tube. 3pL 
of TurboFectin 8.0 was added directly into the prepared MEM culture medium and mixed 
thoroughly with gentle pipetting, followed by incubation at room temperature for 
5minutes. Next, lpg  of shRNA cassette was added into the TurboFectin-containing 
media and mixed thoroughly with gentle pipetting. The mixture was incubated at room 
temperature for 30minutes. After the incubation, the mixture was carefully added and 
evenly distributed onto the seeded CaCo2 cells and incubated for additional 48hours. 
During the incubation period, cells were observed by light microscopy to ensure the cells 
did not overgrown.
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After 48h incubation, transfected cells were passaged in complete medium supplemented 
with 0.6|ag/mL of puromycin antibiotic reagent. These transfected cells were evenly 
distributed into a 96 well plate for selection process. A large number of cells were killed 
under the puromycin treatment as a result of the lack of puromycin resistance gene in the 
cells. After 4-7 days, some treated cells started to show sign of recovery from the 
selection pressure, indicating that HuSH shRNA cassette has been successfully integrated 
into the CaCo2 cell genome. 3 to 4 clonal populations of cells were selected, passaged 
and transferred into a 6-wells culture plates and gradually into T75 culture flask to 
promote further cell growth. Cells were maintained in complete medium with the 
selection pressure of puromycin.
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4.4 Verifying transfection efficiency
Two experimental methods have been used to verify the transfection efficiencies in each of the 
CaCo2-CNRlKD cell lines: immunoblotting and [35S]GTPyS binding assay. Immunoblotting 
was chosen as the method to study CNR1 protein expression in the knockdown cells. In contrast, 
[35S]GTPyS binding assay, a functional ligand binding assay, was employed to study the 
functional consequences resulting from the binding activity of CNR1 agonist on GPCR, hence 
revealed the status of functional CNR1 in the CNR1 knockdown CaCo2 cells.
4.4.1 Immunoblotting
Protein samples for different clones of CNR1 knockdown CaCo2 cells were run on two 
separate SDS-PAGE gels (Figure 4.4). Protein samples prepared for CNR1 
immunoblotting were heated at 65°C for 2 minutes before loading into the gel. The 
modification of boiling temperature from 95°C to 65°C was based on the immunoblotting 
protocol described by Grimsey et.al. study (Grimsey et al., 2008).















2 3 4 5 6 7 8
Figure 4.4. Immunoblot analysis of the verification of cannabinoid receptor (CNR)-l 
protein expression in CNR1 knockdown CaCo2 cells (CaCo2_CNRlKD). In total, 4 
different CNR1 shRNA -expressed cassettes were used for the transfection with 2 to 3 
clones selected from each shRNA cassettes. Both non-transfected CaCo2 cells and cells 
transfected with shRNA cassette with non-effective (scrambled) sequence insert (CaCo2- 
Scrambled) were treated as the negative controls for the experiment. Samples in Gel A 
were run in a 12% SDS-PAGE gel whereas the samples in gel B was run in a 10% SDS- 
PAGE gel. Samples loading order for gel A: (1-2) Non-transfected CaCo2; (3-4) 
CaCo2_CNRl KD with shRNA cassette ID: TI363209; (5-6) CaCo2_Scrambled; (7-8) 
CaCo2_CNRlKD with shRNA cassette ID: TI363210. Sample loading order for Gel B: 
(1) Non-transfected CaCo2; (2-4) CaCo2 CNR1KD with shRNA cassette ID: TI363211; 
(5-7) CaCo2_CNRl KD with shRNA cassette ID: TI363212.
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CNR1 immunoblots showed that out of all four CNR1-specific shRNA cassettes used, 
only CaCo2 cells that have been transfected with shRNA cassette with the sequence ID 
of TI363209 successfully knockdown the CNR1 gene in CaCo2 cell line. As for the 
remaining CaCo2_CNRlKD cell line, the concentration and purity of the shRNA 
construct may be the factor which influences the successful transfection. Additionally, 
this may also due to experimental error during transfection as every small procedures 
performed during transfection can greatly affect the transfection outcome.
Despite that the manufacture company of CNR1 antibody has suggested a single CNR1 
band to be detected at the molecular weight of approximately 60KDa, a minimum of two 
clear protein bands (75KDa and 50KDa) were obtained in both immunoblots. This may 
due to the characteristic of CNR1 as CNR1 is a receptor with complex architecture and 
actively involves in the post-translational modifications (Bosier et al., 2010; Console- 
Bram et al., 2012). Such modifications can have profound effects on the protein structure 
and consequently affect the molecular weight of the associate protein (Beck-sickinger 
and Mori, 2006). Apart from that, additional protein bands may also due to the lack of 
specificity in CNR1 antibody. Specificity of the commercially available CNR1 antibody 
has been addressed in a recent study by Grimsey, et al. (2008). In agreement to my 
finding, they have encountered similar problem of obtaining multiple protein bands with 
the use of CNR1 antibody via western blotting. Interestingly, there was a significant 
inconsistency in the range of bands detected with the use of different CNR1 antibodies 
purchased from different manufacture companies (Grimsey et al., 2008). Considering the 
difficulty in the use of CNR1 antibody to access CNR1 protein expression, [35S]GTPyS 
binding assay was employed to verify the knockdown efficiency by studying the 
functional consequence of receptor activation followed by the binding of CNR1 agonist.
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4.4.2 [35S] GTPyS Binding Assay
[35S]GTPyS binding assay was the second technique used to determine the CNR1 
knockdown efficiency in CaCo2 cell model. CNR1 is classified under G-coupled protein 
receptor (GPCR) superfamily, where CNR1 couples and activates the Gi/G0 subunits in 
G-proteins (Glass and Northup, 1999). The rational for performing such assay was to 
further evaluate the transfection efficacy as results obtained from western 
immunoblotting were unable to deliver a clear picture for the protein expression of CNR1 
in the cell model system. Difficulty in assessing CNR1 protein expression has been 
addressed previously and this is mainly due to the lack of good commercially available 
antibody for the receptor (Grimsey et al., 2008). Therefore, [35S] GTPyS binding assay 
was a better strategy in verifying CNR1 knockdown efficiency in the cell model system 
as this assay relies on direct CNR1 binding data rather than the reliability of antibody 
specificity.
i. Principle of f35Sl GTPyS Binding Assay
The [35S]GTPyS binding assay measures the level of G-protein activation following 
agonist occupation of the GPCR (Harrison and Traynor, 2003). This functional assay is 
a popular tool to study ligand binding for GPCR as it measures the functional 
consequences resulting from GPCR occupancy. Binding of an agonist to the receptor will 
mediate a guanine nucleotide exchange event on the G-protein Ga subunit. Such 
nucleotide exchange is the first event to be mediated by GPCR activation in the signalling 
cascade (Harrison and Traynor, 2003). This assay provides an accurate measure of the 
ligand binding activity on GPCR by excluding the likelihood of receptor modulation in 
response to other events that may occur further down the signalling cascade.
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GPCR consists of an extracellular N terminus, seven transmembrane spanning domains 
and an intracellular C terminus. The heterotrimeric protein, which couples to the C 
terminus of GPCR, comprises a Ga subunit and a dimer of G(3 and Gy subunits. G|3y 
subunit plays an important role in maintaining the protein structure as it is required for 
the binding of Ga subunit to the receptor and acting as a scaffolding protein to connect 
the G-protein to the cell membrane (Harrison and Traynor, 2003). An inactive G-protein 
has a GDP bound to the Ga and Gpy subunits, presented as Ga(GDP)py. Binding of an 
agonist to the receptor will initiate a conformation change in the receptor, resulting in the 
exchange of GDP to GTP and the release of GPy subunit. Such event activates the G- 
protein and leads to the initiation of the downstream effectors. Intrinsic GTPase activity 
on the Ga subunit hydrolyses the bound GTP, resulting in the re-association of G-protein 
into its heterotrimeric protein structure (Figure 4.5) (Harrison and Traynor, 2003).
In contrast, in the [35S]GTPyS binding assay, [35S]GTPyS replaces the endogenous GTP 
and binds to the Ga subunit, forming Ga-[35S]GTPyS. The y-thiophosphate in 
[35S]GTPyS is resistant to hydrolysis by the GTPase of Ga subunit, hence inhibiting the 
reformation of Ga-[35S]GTPyS back to Ga(GDP)Py. Consequently, this results in an 
accumulation of Ga subunit labelled with [35S]GTPyS (Figure 4.6). Taken that, the level 
of GPCR activation in response to ligand binding can then be measured by quantifying 
the amount of [35S]-labelled GTPyS in the sample (Harrison and Traynor, 2003).
Downstream
effectors
Figure 4.5. Schematic diagram for G-protein mediated signalling cascade. The binding 
of agonist to the receptor initiates the exchange of GDP to GTP in the G-protein Ga 
subunit. Ga-GTP and Gpy subunits will initiate downstream cellular effectors. However, 
Ga-GTP subunit can be re-formed back into Ga(GDP)Py by GTPase activity and return 
the G-protein into an inactive state. Figure adapted from (Harrison and Traynor, 2003).




Figure 4.6. Schematic diagram for the principle of [33S]GTPyS binding assay. 
[35S]GTPyS replaces the endogenous GTP and binds to the Ga subunit. As [35S]GTPyS 
cannot be hydrolysed by the GTPase of the Ga subunit, heterotrimeric reformation step 
cannot occur, resulting in the accumulation of [35S]GTPyS-labelled Ga subunit. Taken 
that, activity of ligand binding to GPCR can be measured by quantifying [35S]-labelled 
GTPyS in the sample. Figure adapted from (Harrison and Traynor, 2003).
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ii. Preparation of cell samples for 135S1 GTPyS Binding Assay
Two CaCo2_CNR 1KD clones with shRNA cassette ID TI363209 were cultured in T150 
culture flask and grown into fully differentiated cell monolayer. Cells were rinsed with 
PBS, scraped with a cell scraper and transferred into a 50mL falcon tube. The sample 
was centrifuged at 10,000rpm for 5minutes to obtain a cell pellet, which was then stored 
at -20°C for later use.
iii. Experimental Procedures
[35S]GTPyS binding assays were performed using previously prepared cell pellet (5pg 
protein per well). Cells were treated with 0.1% vehicle, 30pM of unlabelled GTPyS or 
ACEA in assay buffer (50mM Tris-HCL, 50mM Tris-base, 5mM MgCh, ImM EDTA, 
lOOmM NaCl, ImM dithiothreitol, 50mM HEPES and 0.1% fatty acid free BSA) 
supplemented with 20pM GDP and 0. InM [35S]GTPyS to a total assay volume of 500pL 
(Table 4.2.). This was followed by the incubation step at 30°C for 60 minutes. Binding 
was initiated with the addition of [35S]GTPyS. Non-specific binding was measured by 
using 30pM of unlabelled GTPyS. Binding was terminated by the addition of ice cold 
GTPyS wash buffer (50mM Tris-HCL, 50mM Tris-Base, 0.1% BSA) and rapid vacuum 
filtration by using a 24-well sampling manifold and GF/B glass-fibre filters that has been 
soaked for at least 24 hours at 4°C in the GTPyS wash buffer. Each reaction well was 
washed around 6 times with GTPyS wash buffer. The filters were oven dried for 60 
minutes and placed in 5mL scintillation vials with 4mL scintillation fluid (Ultima Gold). 
Radioactivity was quantified by using liquid scintillation spectrometry. Specific binding 
was defined as the difference between the binding in the presence and absence of 30pM 
GTPyS and varied between 70-90% of the total binding.
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Table 4.2. Plate set up for [35S]GTPyS binding assay.





Al-2 350 30pM GTPyS
A3-4 350 0.1% Vehicle
A5-6 350 InM ACEA
A7-8 350 lOnM ACEA
A9-A10 350 lOOnM ACEA
A ll-12 350 lOOOnM ACEA
Bl-2 350 lOOOOnM ACEA
B3-4 350 InM ACEA
B5-6 350 lOnM ACEA
B7-8 350 lOOnM ACEA
B9-10 350 lOOOnM ACEA
B ll-12 350 lOOOOnM ACEA >y y
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iv. ACEA-induced functional consequences on GPCR activation in CNR1 knockdown 
CaCo2 cells.
Figure 4.7. [35S]GTPyS binding activity in response to ACEA treatment in CNR1 
knockdown CaCo2 cells (CaCo2_CNRlKD). Both non-transfected CaCo2 cells and cells 
transfected with shRNA cassette with non-effective (scrambled) sequence (CaCo2- 
Scrambled) were treated as the negative controls for the CNR1KD cells. Overall, two 
different clones of CaCo2_CNRlKD with shRNA cassette ID TI363209 were tested in 
the assay. Data represents percentage of [35S]GTPyS binding activity ± S.E.M (n=5). 
*C1 corresponded to sample in Figure 4.4/A/LaneS; C2 corresponded to sample in 
Figure 4.4/A/Lane4.0
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Arachidonyl-2-chloroethylamide (ACEA), a cannabinoid agonist for CNR1, was applied 
as a binding ligand for the [35S]GTPyS binding assay in both wild type and CNR1KD 
CaCo2 cells (Hillard et al., 1999). CNR1 is classified under G-coupled protein receptor 
(GPCR) superfamily, where CNR1 couples and activates the Gi/G0 subunits in G-proteins 
(Glass and Northup, 1999). Application of ACEA as the binding ligand in the 
[35S]GTPyS binding assay will provide an indication towards the level of activated CNR1 
present in the cell system.
Result showed that both non-transfected and “scrambled” CaCo2 cells induced an 
approximate 25% increase in [35S]GTPyS binding activity in response to 10'5M of ACEA 
treatment (Figure 4.7). With the use of ACEA, a high affinity CNR1 agonist, one would 
expect to achieve a higher percentage of ACEA-induced [35S]GTPyS binding activity in 
wild type CaC02 cells. Nevertheless, here, ACEA only managed to induce an 
approximate 25% increase in the [35S]GTPyS binding activity. Such relatively low 
binding activity may relate to the basal amount of functional CNR1 present in the wild 
type CaCo2 cells. It is worth noting that most of the [35S]GTPyS binding assays were 
performed on cells which have been manipulated to stably expressed CNR1 gene (Hillard 
et al., 1999). Therefore, it is fairly reasonable to obtain a relatively low percentage of 
ACEA-induced receptor binding in the non-transfected CaCo2 cells. Thus, the result 
obtained from [35S]GTPyS binding assay for non-transfected CaCo2 cells is still reliable 
to be used as the negative control for the CaCo2_CNRlKD cells.
There were two different clones of CaCo2_CNRlKD cells being tested in the assay. The 
first clone of CaCo2_CNRlKD cells (CaCo2_CNRlKD_Cl) showed an approximate 17% 
increase in [35S]GTPyS binding activity. Conversely, for the second clone of 
CaCo2_CNRlKD cells (CaCo2_CNRlKD_2), insignificant [35S]GTPyS binding
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activity was observed in response to the ACEA treatment (Figure 4.7). By comparing to 
the percentage of [35S]GTPyS binding activity obtained in both non-transfected and 
“scrambled” CaCo2 cells, CNR1 gene was successfully knocked down by approximately 
70% in CaCo2-CNRlKD C2 cells.
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4.5 Discussion
As stated previously, CNR1 is reported to be associated with cannabinoid-induced beneficial 
effects in the gut and the role of CNR1 in cannabinoid-induced effect is suggested to be 
functionally dependent (Capasso et al., 2008; Izzo and Sharkey, 2010; Vaccani et al., 2005; 
Wright et al., 2005). Taken that, it is interesting to generate CNR 1-knockdown CaCo2 cells to 
further explore the functional consequence of CNR1 in cannabinoids-induced effect during 
autophagy process.
In this project, shRNA system was selected to generate the CNR 1-knockdown CaCo2 cells in 
this project. Such system was chosen against the conventional siRNA system. The advantage 
of selecting shRNA over siRNA is that shRNA can induce a stable integration of CNR1- 
shRNA sequence into the cell genome, which allows the long term knockdown of CNRlgene. 
siRNA, on the other hand, is introduced into the cytoplasm of the host cells, therefore will only 
be able to induce a transient CNR1 knockdown in CaCo2 cells (Moore et al., 2010; Sandy et 
al., 2005). As the knockdown of a gene can effectively change the fundamental DNA in the 
cells, it is useful to generate a stable cell line to study the corresponded consequences from the 
knockdown of CNR1 gene in the host cell.
Regarding the culture characteristics of the CNR1 knockdown CaCo2 cells, it was noticed that 
adherence of CaCo2 cells was affected by the knockdown of CNR1 gene in the cell system. In 
normal non-transfected wild type CaCo2 cells, cells can be grown and maintained in the culture 
medium up to 21 days. However, for the CNR1KD cells, it was surprisingly difficult to 
maintain the culture up to 21 days as the cell monolayer would lift from the surface around day 
16. This response may be a consequence of CNR1 loss in cell system. In vivo studies have 
reported that mice lacking in CNR1 exhibited an enhanced colitis compared to their wild-type
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control and such effect may be associated with the increased permeability in response to the 
loss of CNR1 gene (Massa et al., 2004). Therefore, it could be speculated that knockdown of 
the CNR1 gene disrupted the cell adhesion such that changes in permeability in the CaCo2 
cells.
In addition, the seeding cell density also greatly affected the growth of CNR 1-knockdown 
CaCo2 cells. In a 12 well plate, these cells have been optimized to be seeded at approximate 
4x104 cells per well. Seeding the knockdown cells above or below the optimized cell density 
will lead to a poor outcome in cell adherence. The importance in seeding the wild type CaCo2 
cells at the right cell density has been addressed previously as the differentiation of CaCo2 
cells only started once the cells were grown to confluence (Sambuy et al., 2005). It has been 
reported that the seeding density of CaCo2 cells greatly affects the monolayer structure and the 
associated carrier-mediated transport (Behrens and Kissel, 2003). Lower cell density may 
impact on the cell permeability as the cells may have encountered irregular growth along with 
a reduction in the intercellular contacts (Sambuy et al., 2005). Therefore, as well as the receptor 
loss, the transfection process may have slightly affected the growth characteristics of the 
CaCo2 cells, resulting in increased difficulty in reaching full maturity.
As for the process in verifying the transfection efficiency in the CNR1 -knockdown CaCo2 cells, 
the lack of specificity in CNR1 antibody led to the difficulty in obtaining an absolute level of 
CNR1 protein expression in the CNR 1-knockdown cells via western blotting. The problem 
encountered was in agreement with previous finding as the study addressed the unreliability of 
data obtained from CNR1 western blotting due to the lack of good commercially available 
CNR1 antibody in the current market (Grimsey et al., 2008). Apart from that, quantitative RT- 
PCR (qRT-PCR) was also performed by using the extracted RNA samples from the CNR1
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knockdown cells. However, the CNRl-knockdwn cells have significant low copies of CNR1 
gene in the cells and this resulted in no single peak for the DNA melt curve in qRT-PCR (see 
appendix). As it is well-known that DNA melting curve represents the total number of product 
generated from the amplification of the gene of interest and based on the golden rules for qRT- 
PCR, it is essential to ensure that analysis was performed based on the amplification of a single 
product (Pfaffl, 2001). As a result, no data was obtained via qRT-PCR but the failure in 
obtaining a single peak in the DNA melt curve indicated a possible knockdown of CNR1 gene 
in the CaCo2 cells since both wild type CaCo2 cells and the CaCo2_Scrambled cells did 
produce a single peak in their DNA melt curve (see appendix).
To resolve the problems encountered via qRT-PCR and western blotting, another method was 
applied to verify the transfection efficiency in CNR1 knockdown CaCo2 cells. Considering 
CNR1 is classified under G-coupled protein receptor (GPCR) superfamily, [35S]GTPyS 
binding assay was selected to verify the level of functional CNR1 in the CNR1 knockdown 
cells (Glass and Northup, 1999). The formal principle for this [35S]GTPyS binding assay is to 
measures the level of G-protein activation following agonist occupation of the GPCR (Harrison 
and Traynor, 2003). Based on that, ACEA, an CNR1 agonist, was applied as the binding ligand 
for GPCR and results showed that second clone of the CaCo2-CNRlKD cells have 
insignificant [35S]GTPyS binding activity as compared to the non-transfected CaCo2 cells and 
the CaCo2_Scrambled cells. Overall, result showed that a high concentration of ACEA was 
required to induce the ligand binding (ie. ACEA at 1 andlOpM induced the binding activity 
but ACEA at lOOnM induced a low, negligible binding activity), indicating only a low level of 
CNR1 receptor present in the wild type CaCo2 (Figure 4.7). Therefore, this explained the 
[35S]GTPyS binding activity of ACEA in wild type CaCo2 cells where this synthetic 
cannabinoid compound only managed to induce an approximate 25% increase in the binding
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activity. As for the knockdown cells, the low binding activity in the CaCo2-CNRlKD cells is 
possible as the CNR1 gene is not being completely knocked out from the cell system; therefore 
it is likely to still have a relatively low copy of CNR1 gene in CaCo2-CNRl KD in the system.
Overall based on the [35S]GTPyS binding assay, the CNR1 gene has been successfully knocked 
down by -70% , hence indicated a CaCo2-CNRlKD cell line was successfully generated.
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Chapter 5 
Cannabinoid action on 
Autophagosome formation
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5.1 Introduction
Autophagy exhibits multiform of physiological roles in the cellular process. Regulation and 
induction of autophagy will correspond to the outcome of the cell: survival or death. In normal 
colonic cells, autophagy process is required for the renewal of colonic epithelium. This is 
demonstrated in the lower part of the crypt in the colonic gland where autophagy occurs at high 
frequency to sustain proliferation of the colonic stem cell populations (Groulx et al., 2012). 
Induction of such cellular mechanism may also act as a key regulator of cellular fate. During 
nutrient or growth factor deprivation, stress-induced autophagy may initiate a catabolic process 
to maintain cellular homoeostasis through the recycling of non-essential cellular compartments 
(Chang et al., 2009; Lum et al., 2005; Sakiyama et al., 2009). Additionally, autophagy has been 
reported to be involved in immunity and cellular defence mechanism. Such mechanism protects 
cytosol from microbial invasion by targeting the invading microbes to the degradation pathway 
(Kirkegaard et al., 2004; Levine et al., 2011; Mihalache and Simon, 2012).
Importance of autophagy regulation has been demonstrated in various pathologies, for instance, 
Crohn’s Disease (CD) (Levine and Kroemer, 2008; Massey and Parkes, 2007). An increase 
susceptibility in Crohn’s Disease (CD) has been reported with polymorphism of autophagy- 
associated genes such as ATG16L1 and IRGM (Massey and Parkes, 2007; Parkes et al., 2007). 
Variation (T300A) of ATG16L1 gene in CD delivered an autophagy-associated defect to 
Paneth cells, which reside in the crypt of Lieberkiihn within the small intestinal epithelium 
(Cadwell et al., 2008; Klionsky, 2009).
During intestinal inflammation, up-regulation of endocannabinoid levels and the increased 
expression of cannabinoid receptor will enhance the action of endocannabinoid system (Di 
Marzo and Izzo, 2006). This is shown by increase cannabinoid receptor (CNR)-l expression in
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the colon of the intrarectal dinitrobenzene sulphonic acid (DNBS) treated mice (Massa et al.,
2004). Interestingly, cannabinoids such as A9-tetrahydrocannabidiol (THC) and Cannabidiol 
(CBD) have been previously shown to induce autophagy in cancer cell lines (Salazar et al., 
2009; Shrivastava et al., 2011). However, to date, no studies have been performed to explore 
the cannabinoid action in the non-cancer cell model system. Therefore, in this chapter, the roles 
of phyto-, synthetic-, and endo-cannabinoid in autophagy induction were investigated in human 
intestinal epithelial cell model.
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Investigate the action of phyto-, synthetic, and endo-cannabinoids 
in autophagy process and possible mechanisms involved by using 
mature human intestinal cells, CaCo2 cell line.
Investigate the possibility that cannabinoid receptor (CN R)-l 
contributes towards the cannabinoid-induced effects in autophagy 
process through the use of synthetic CNR1 antagonist, as well as 
the generated CaCo2-CNRlKD cell model.
5.3 Cannabinoid action on autophagy induction in intestinal epithelium cells
A recent study revealed that CBD exerted a cytotoxic effect on tumor cells, resulting in 
autophagy induction in breast cancer cells (Shrivastava et al., 2011). Interestingly, thus far, no 
studies have explored the association of cannabinoids in autophagy induction in the gut 
epithelium, considering that it has been previously reported that polymorphism of autophagy 
genes did contribute to an increase of susceptibility to CD and endocannabinoid levels were 
up-regulated during intestinal inflammation (Di Marzo and Izzo, 2006; Massey and Parkes, 
2007). Hence, to study the effect of cannabinoids (ACEA, AEA, CBD) in the context of 
autophagy on fully differentiated CaCo2 cells, I examined autophagosome formation by 
monitoring the conversion of microtubule-associated protein light chain 3 (LC3) from LC3-I 
to LC3-II through immunoblot analysis (Kabeya et al., 2000). Modification of LC3 is the 
hallmark for autophagy (Cherra et al., 2010). LC3 protein was first discovered as the 
mammalian autophagosomal homologue of Apg8p protein in yeast. During autophagosome 
formation, LC3 is cleaved into LC3-1, followed by lipidation to form LC3-II. LC3-1 is a 
cytosolic protein whereas LC3-II is a membrane bound protein (Kabeya et al., 2000; Tanida et 
al., 2005). LC3-II protein is localized on autophagosome, therefore accumulation of LC3-II 
provides an indication towards the level of autophagosome formed in the cells (Tanida et al.,
2005). LC3 has three isoforms in mammalian cells, named LC3A, LC3B and LC3C. However, 
only LC3B correlates to the formation of autophagic vesicles, hence only antibody targeted 
towards LC3B isoform is used for the analysis (Barth et al., 2010). LC3-I consists of the 
molecular weight of approximately 16KDa and LC3-II at approximately 14KDa. Interestingly, 
during SDS-PAGE, despite the molecular weight of LC3-II is shown to be higher than LC3-I, 
LC3-II migrates faster than LC3-I and this is due to the hydrophobicity of LC3-II (Mizushima 
and Yoshimori, 2007; Mizushima et al., 2010).
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Dose and time course responses revealed that CBD at lOpM induced LC3-1I formation within 
4 to 6h (Figure 5.1) and that this effect was dose-dependent up from 0.1 pM to 25pM (Figure 
5.2). However, the low dose o f 0.1 pM appeared to inhibit this effect. To further evaluate the 
inhibition o f  LC3-II formation, low dose o f 0.1 pM CBD was applied under low nutrient 
conditions to explore whether the low dose o f  CBD could still reverse the stress-induction 
autophagy. Result showed that CBD was able to inhibit autophagosome formation but this 
effect was not sustained after 8h (Figure 5.3).
p-Actin *mmmm  mmmmm
Control 2 hour 4 hour 6 hour 24 hour
Figure 5.1. Immunoblot analysis o f  LC3-II in fully differentiated CaCo2 cells in response to 
lOpM cannabidiol (CBD) treatment within 24h. Data plotted are relative fold-increase in LC3- 
II protein expression (adjusted to P-actin, mean ± SE). * denotes significant different (p<0.05) 
when compared to untreated control. (n>3, data were analyzed with Dunnett t-test (2-sided))
(Molecular weight for LC3-1 & II: 14&16KDa; fl-Actin: 45KDa)
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P-Actin
Control CBD25|iM CBDlOgM CBDlgM CBDO.lpM
Figure 5.2. Dose response for CBD on LC3-II formation in CaCo2 cells. Cells were treated 
with CBD for 4h. Data plotted are relative fold-increase in LC3-II protein expression (adjusted 
to P-actin, mean ± SE). * denotes significant different (p<0.05) when compared to untreated 
control. (n>3, data were analyzed with Dunnett t-test (2-sided)).
(Molecular weight for LC3-I & II: 14&16KDa; (I-Act in: 45KDa)
8h__________ 4h__
LC3-I <•** 4 |N t  < P P  4***
LC3-II mm •«—
P-actin ■' —    ■
Basal Control +
Starvat ion- induced  - + +
C B D ( O . l j iM )  - - + - +
Figure 5.3. LC3-II formation for 0.1 pM CBD treated starvation-induced CaCo2 cells. Cells 
were pre-starved with MEM supplemented with l%(vol/vol) NEAA for 48h before adding
cannabinoids for additional 4 to 8h.
(Molecular weight for LC3-I & II: 14&l6KDa; /3-Actin: 45KDa)
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Both synthetic cannabinoid (ACEA) and endocannabinoid (AEA) significantly increased LC3-
II formation within 4h time frame (Figure 5.4 and 5.5).
p-Actin
Control ACEA 10 nM ACEA 100 nM
Figure 5.4. Dose response for Arachidonyl-2'-chloroethylamide(ACEA) on LC3-II formation 
in CaCo2 cells. Cells were treated with ACEA for 4h. Data plotted are relative fold-increase in 
LC3-II protein expression (adjusted to P-actin, mean ± SE). * denotes significant different 
(p<0.05) when compared to untreated control. (n>3, data were analysed with Dunnett t-test (2- 
sided)).
(Molecular weight fo r LC3-I & II: I4&16KDa; [3-Actin: 45KDa)
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Control AEA 1 pM AEA 1 OpM
Figure 5.5. Dose response for N-arachidonoylethanolamine (AEA) on LC3-II formation in 
CaCo2 cells. Cells were treated with AEA for 4h. Data plotted are relative fold-increase in 
LC3-II protein expression (adjusted to P-actin, mean ± SE). * denotes significant different 
(p<0.05) when compared to untreated control. (n>3, data were analysed with Dunnett t-test (2- 
sided)).
(Molecular weight fo r LC3-1 II: !4&l6KDa; /3-Actin: 45KDa)
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5.4 M echanism  of action for cannabinoids-induced LC3-II form ation
There are various approaches in exploring autophagosome formation and the route to 
lysosomal degradation. Autophagosome formation can be manipulated and quantified with the 
use of protein inhibitor to target proteins that are involved in different stages of autophagy 
pathway (Figure 5.6). For instance, the use of 3-methyladenine (3-MA) to inhibit 
phosphoinositide 3-kinase (PI3-K) Class III, a protein which is required for phagophore 
fonnation in the early stage of autophagy pathway (Juenemann and Reits, 2012). Another 
frequent tool to study autophagy pathway is through the manipulation of lysosomal pH with 
endosomal acidification inhibitor, Bafilomycin-Al (Baf-Al) (Figure 5.6). Baf-Al neutralizes 
lysosomal pH and impacts on the LC3-II degradation (Klionsky et al., 2008; Yamamoto et al., 
1998). In this section, experiments were conducted to investigate (1) the involvement of PI3K- 
Class III in cannabinoid-induced autophagy (2) the role of cannabinoid in autophagosome 
synthesis and autolysosomal degradation, and (3) the involvement of CNR1 in cannabinoid- 
induced autophagic process.
A tgl2-A tg5-A tgl6L l
•  LC3B
Baf-Al
AUTO LYSOSO M ELYSOSOMAL FUSIONAU TO PHA G O SO M EPH AG O PO R E
3-MA
Figure 5.6. Point of inhibition for 3-methyladenine (3-MA) and bafilomycin-Al (Baf-Al) on 
autophagosome formation and degradation.
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5.4.1 Mechanism o f  Action: Canonical vs Non-canonical autophagy
PI3K-Class III has a significant role in the initiation of autophagy by recruiting 
autophagy-related gene (ATG) complexes to induce membrane phagophore formation 
(Axe et al., 2008). Involvement of PI3K-Class III in autophagy can be assessed through 
the use of the PI3K-Class III inhibitor, 3-methyladenine (3-MA) (Figure 5.6). Studies 
proposed that there are alternative routes that lead to the induction of autophagy and 
3-MA can be used to determine which routes cannabinoids may engage in bringing 
cytoplasmic compartment towards lysosomal degradation (Figure 5.7) (Juenemann and 
Reits, 2012).







Figure 5.7. Alternative routes towards autophagy lysosomal degradation. 4 distinct 
autophagy pathways that lead to the formation of double membrane autophagy 
structures, followed by delivery of the cytoplasmic component towards lysosomal 
degradation. Conventional autophagy involved the recruitment of LC3 which may be 
origin from endoplasmic reticulum (ER) whereas Atg5/Atg7-independent autophagy 
pathway forms Rab9 positive double membrane autophagy structure which may be 
origin from Golgi and late endosome (LE). Both of these autophagy pathways are 3- 
MA dependent. Stress-induced non-canonical autophagy is 3-MA independent but 
requires Atg5 and LC3 for autophagy induction. Peptidase-resistance peptides-induced 
autophagy is independent toAtg5/LC3 and insensitive to 3-MA treatment.
Figure adapted from  Juenemann and Reits, 2012.
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i. Dose and time course response for 3-MA treatment
3-MA is an inhibitor that is widely used to inhibit autophagy as PI3K class III, the 
corresponded target of inhibition, is known to be required for autophagosome formation 
(Simonsen and Tooze, 2009). However, a recent study proposed that 3-MA established 
dual roles in the modulation of autophagy: inhibition or induction. 3-MA has been 
shown to supress autophagy formation in nutrient-deprived condition but promote 
autophagy when treated in nutrient-rich condition for up to 9h. The latter effect was not 
the consequence effect from the inhibition of lysosomal degradation pathway but it was 
shown to be related to the increased autophagy flux resulted from 3-MA treatment (Wu 
et al., 2010). This suggested that 3-MA may act as autophagy inducer or suppressor and 
the response is treatment condition dependent. Therefore, to determine the exact role of 
3-MA under the current experiment setting where low serum condition was applied to 
the treated cells, cells were treated with both high (lOmM) and low (5mM) doses of 3- 
MA at three time frame (lh , 5h and 8h). Again, 3-MA induced effect on autophagosome 
formation was examined by monitoring the conversion of microtubule-associated 
protein light chain 3 (LC3) from LC3-I to LC3-II through immunoblot analysis (Kabeya 
et al., 2000).
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Under the experimental setting where cells were treated with 1% serum, the low 
dosage (5mM) of 3-MA was insufficient to inhibit LC3-II formation. Conversely, the 
increased dosage of 3-MA to lOmM successfully inhibited LC3-II formation within 
5h (Figure 5.8). This indicated in my experimental setting,, 3-MA at lOmM inhibited 
PI3K Class III, consequently led to the inhibition of autophagosome formation within 
5h time frame. Therefore, lOmM of 3-MA with the total of 5h incubation period was 
selected to applied in the following study where experiment was conducted to explore 





8H 5H 8H 5H 1H
LC3-I
LC3-II
Figure 5.8. Dose response for 3-methyladenine (3-MA) on LC3-II formation in 
CaCo2 cells. Fully differentiated CaCo2 cells were treated with low dose (5mM) and 
high dose (lOmM) of 3-MA treatment within 8h time frame.
(Molecular weight for LC3-1 & II: l4&16KDa; p-Act in: 45KDa)
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ii. Cannabinoids differentially impact on the canonical pathway
To study the involvement of PI3K-Class III in ACEA, AEA or CBD-induced LC3-II 
formation, cells were pre-treated with 3-MA (lOmM) for 1 h, followed by cannabinoid 
treatment for an additional 4h.





Figure 5.9. Effect of cannabinoids treatment on LC3-II formation in the presence of 3- 
MA. Fully differentiated CaCo2 cells were pre-treated with 3-MA (lOmM) for lh prior 
to addition of cannabinoids: CBD (lOpM), ACEA (lOOnM), AEA (10pM) for 
additional 4h. Data plotted are relative fold-increase in LC3-II protein expression 
(adjusted to P-actin, mean ± SE). * denotes significant different (p<0.05) when 
compared to untreated control, i denotes significant different (p<0.05) when compared 
to paired treatment control. (n>3, data were analysed with Tukey post hoc test). 
(Molecular weight for LC3-I <£ II: 14&16KDa; /3-Actin: 45KDa)
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iii. Assess cannabinoid action via confocal imaging
Fluorescent imaging is another method to use to measure autophagy process apart from 
the western blotting assay, where processed LC3 can be detected. This additional method 
in measuring autophagy is performed to validate the findings found through LC3 western 
blotting. Therefore, to further verify the significance of these data, cells were stained with 
the Cyto-ID® green autophagy dye which served as the selective marker of 
autophagolysosomes and earlier autophagic compartments (Chan et al., 2012).
Analysis of fluorescence using confocal microscopy indicated an increase of 
autophagolysosomes and earlier autophagic compartments in response to ACEA, AEA 
and CBD treatment, which was inhibited in the presence of 3-MA, (Figure 5.10 & 5.11). 
Both western blot (Figure 5.9) and confocal images (Figure 5.10 &5.11) showed that 
CBD reduced the autophagosome and earlier autophagic compartments but to a lesser 
extent, as compared to both ACEA and AEA treatments.
Figure 5.10. Confocal images analysis for 
cannabinoids and/or 3-MA treated CaCo2 
cells. Bar chart showed the relative fold 
change of fluorescence intensity in relation to 
the untreated control. Data correlated to the 
confocal images presented in Figure 5.11. 
(n>2).
(Molecular weight for LC3-I eft II: 14&16KDa; 
f-Ac tin: 45KDa)
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5.4.2 Autophagosome formation vs Autophagosome degradation
A snapshot of LC3-II by immunoblotting may not accurately reflect the effect the 
cannabinoids on autophagosome formation, as the increased LC3-II may well correlate 
to increased autophagic flux with a reduction in autophagosome degradation 
(Rubinsztein et al., 2009). Therefore, an autophagy modulator, Bafilomycin A1 (Baf- 
Al), was applied to investigate the act of cannabinoid in autophagy induction by 
inhibiting the formation of autolysosome, hence disrupting the lysosomal degradation 
pathway (Figure 5.12).
PHAGOPORE AUTOPHAGOSOME LYSOSOMAL FUSION AUTOLYSOSOME
Figure 5.12. Point of inhibition for bafilomycin-Ai (Baf-Al) in autophagy process.
Baf-Al
i
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i. Time course response for Bafilomvcin Al
Baf-Al neutralizes lysosomal pH and impacts on the LC3-II degradation (Klionsky et al., 
2008; Yamamoto et al., 1998). A review by Klionsky etal. in 2008 discussed the possible 
impact of Baf-Al treatment time on LC3-II formation in treated cells as there was a 
controversy over the Baf-Al data obtained from different labs (Klionsky et al., 2008). At 
short incubation time, Baf-Al acts by slowing the degradation of LC3-II within the 
existing autophagolysosome whereas at prolonged incubation time, Baf-Al acts by 
inhibiting the fusion between autophagosome and lysosome (Klionsky et al., 2008). 
Therefore, Baf-Al induced effect on LC3-II formation was examined at two different 
time points; cells were pre-treated with Baf-Al (1 OOnM) for prolonged (20h) or short (lh) 
treatment time prior to cannabinoid treatment.
Treatment between Baf-Al alone and Baf-Al with CBD showed no differences at both 
time frames. Prolonged Baf-Al treatment resulted in an accumulation of LC3-II 
formation, as compared to the shorter treatment time (Figure 5.13). However, despite the 
similarity in Baf-Al induced effect at both time frames, interpretation for the outcome is 
different as the target of inhibition for Baf-Al varies in according to the treatment time 
(as stated above). Additionally, study showed that short incubation for Baf-Al only 
inhibits the lysosomal acidification but did not impact on the autophagy flux into the 
lysosomal compartment (Mousavi et al., 2001), suggesting that the BAF-A1-induced 
LC3-II increase in my treated cells may be the indirect result of the acidification defect. 
With that, prolonged incubation period (24h) of Baf-Al has been selected to apply on the 
treated cells to investigate the corresponded effect of cannabinoid induced 
autophagosome in response to the blockage of lysosomal degradation pathway.




Vehicle Control + - -  - + - - -
CBD( l OgM)  + - + - + - +
Baf-Al (lOOnM) + +
Figure 5.13. Immunoblotting showed the effect of Bafilomycin Al (Baf-Al) on LC3-II 
protein expression within 24 hour time course. Fully differentiated CaCo2 cells were pre­
treated with Baf-Al (lOOnM) for two different time course: (A)20h (#)lh prior to CBD 
treatment for additional 4h.
(Molecular weight for LC3-I & II: !4&l6KDa; p-Actin: 45KDa)
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ii. Cannabinoids inhibit autophagosome degradation
To further evaluate the impact o f  ACEA, AEA and CBD on autophagosome synthesis, a 
‘autophagy flux assay’ was performed by treating the cells with B af-A l. Result showed 
that ACEA, AEA, CBD and Baf-Ai alone significantly increase LC3-II formation under 
this experimental setting (Figure 5.14/A) but the cannabinoids did not further enhance 
Baf-Al-induced LC3-II formation (Figure 5.14/B).
A  LC3-1 
LC3-II 
P-A ctin
Figure 5.14. Immunoblotting showed the effect o f  cannabinoids treatment on LC3-1I 
protein expression in the presence o f Bafilomycin A l (Baf-A l). Fully differentiated 
CaCo2 cells were pre-treated with Baf-Al (lOOnM) for 20h prior to addition o f  
cannabinoids: CBD (lOpM), ACEA (lOOnM), AEA (lOpM) for additional 4h. Due to 
non-linearity o f  enhanced chemi luminescence (ECL) with the use o f Baf-Ai, Baf-Ai data 
is presented in two forms: ( A )  overexposed and (B ) normal exposure. Data plotted are 
relative fold-increase in LC3-I1 protein expression (adjusted to [3-actin, mean ± SE). * 
denotes significant different (p<0.05) when compared to untreated control. + denotes 
significant different (p<0.05) when compared to paired treatment control. (n>3, data were
analysed with Tukey post hoc test).
(Molecular weight fo r LC3-I & II: 14&I6KDa; (3-Actin: 45KDa)
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5.4.3 Cannabinoids differentially engage CNR1
Association of CNR1 to cannabinoid treatments have previously been reported and 
studies suggested that the role of CNR1 in cannabinoid-induced effect is functionally 
dependent. For instance, administration of CBD, a non-psychoactive phytocannabinoid, 
induced a concentration-dependent inhibition of the migration of glioma cells and this 
effect was not mediated by CNR1 (Vaccani et al., 2005). Interestingly, in other study, 
CBD was shown to inhibit inflammatory hypermotility and such effect was mediated by 
CNR1 despite the fact that CBD does not bind to cannabinoid receptors with high affinity 
(Capasso et al., 2008). As for both AEA and ACEA, despite the dissimilarity in their 
binding affinity to CNR1, previous findings demonstrated that both of these cannabinoid 
treatments induced similar level of autophagy process in the intestinal epithelial cell 
model system. Taken together, it is interesting to explore the role of CNR1 in 
cannabinoid-induced autophagy as no data was available to indicate the association of 
CNR1 in such context.
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i. Assess CNR1 via pharmacologically-induced CNR1 inhibition
To determine whether ACEA, AEA and CBD-induced LC3-II formation was CNR1 
mediated, CaCo2 cells were pre-treated with CNR1 antagonist, AM251.
Despite AM251-induced blockage of CNR1 in CaCo2 cells, CBD at lOpM was able to 
increase LC3-II conversion. In contrast, both ACEA and AEA required the CNR1 
activation (Figure 5.15).
LC3-I
















Figure 5.15. Immunoblotting showed the effect of cannabinoids treatment on LC3-II 
protein expression in the presence of AM251. Fully differentiated CaCo2 cells were 
pre-treated with AM251 (lOOnM) for lOmin prior to cannabinoid treatments: 
CBD(lOpM), ACEA(lOOnM), AEA (lOpM) for additional 4h.
(Molecular weight for LC3-I & II: I4&16KDa; f-Act in: 45KDa)
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ii. Assess CNR1 via CaCo2-CNRlKD cell model
As previously mentioned in chapter 4, even though the use of antagonists to the CNR1 
receptor has been an important tool in the dissection of receptor-mediated signalling 
and function, but a novel way to study the functional consequence of CNR1 loss is by 
the use of CNR1 knockdown cell model system. Therefore, to further verify the role of 
CNR1 in cannabinoid-induced autophagy, ACEA, AEA and CBD were treated on both 
CaCo2-CNRlKD and CaCo2-Scrambled cells.
CBD increased LC3-II formation in both CaCo2-CNRlKD and CaCo2-Scrambled cell 
lines, whereas both ACEA and AEA show an increased LC3-II formation in CaCo2- 
Scrambled cells but not in CaCo2-CNRlKD cells (Figure 5.16)
CaCo2-Scrambled CaCo2-CNRlKD
LC3-I mp«— m m  ■
p-Actin ' ““
ACEA - + +
AEA - + +
CBD - + +
Figure 5.16. Effect of cannabinoid treatments on LC3-I1 protein expression in both 
CaCo2-Scrambled and CaCo2-CNRlKD cell lines. Cells were treated with 
cannabinoids: CBD(lOpM), ACEA(lOOnM), AEA (lOpM) for 4h prior to lysing.
(Molecular weight for LC3-I & II: I4&l6KDa; f-Act in: 45KDa)
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5.5 Discussion
The endocannabinoid, A-arachidonoyl-ethanolamine (Anandamide, AEA), is synthesized 
through the endocannabinoid system (ECS). Elevated level of AEA has been reported in the 
2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced inflamed mice colon samples, as well as 
the biopsies samples from ulcerative colitis (UC) patient (Argenio et al., 2006). Such findings 
suggested the role of AEA as an anti-inflammatory agent during inflammation. Here, result 
showed that AEA has significantly enhanced LC3-II formation in a dose-dependent manner 
and this may indicate that autophagy induction could be a possible mechanism mediated by 
AEA to limit inflammatory responses. Similarly, application of arachidonyl-2'- 
chloroethylamide (ACEA), the synthetic cannabinoid, also enhanced the LC3-II formation. 
ACEA is a synthesized analog of AEA. AEA binds and activates both cannabinoid receptor 
(CNR)-l and CNR2 whereas ACEA is the modified compound of AEA to induce a greater 
binding affinity towards CNR1 but not CNR2 (Hillard et al., 1999). Taken together, despite 
the dissimilarity in the receptor binding affinity on CNR1, results demonstrated that both AEA 
and ACEA treatments induced a 2-3 fold increase in LC3-II formation in the intestinal 
epithelial cell model system, hence, suggesting the involvement of CNR1 in this context.
Apart from the endo- and synthesis cannabinoids, the phytocannabinoid, cannabidiol (CBD), 
also enhanced LC3-II formation and such effect was sustained up to 24 hours. CBD has been 
shown to be cytotoxic in a number of cell lines, in particular breast cancer cells (Shrivastava et 
al., 2011). CBD was shown to decrease viability of breast cancer cell line in dose dependent 
manner but maintained higher survival rate with normal cells (Shrivastava et al., 2011). It is 
important to note that fully differentiated CaCo2 cells are thought to be more like normal 
enterocytes and application of CBD treatment did not affect viability of fully differentiated 
CaCo2 cells (Macpherson, et al., 2014). Study showed induced autophagy-mediated-cell death
in breast cancer cell line whereas here, result shows that CBD induces autophagy but this does 
not lead to cell death. This suggests a cell type dependent effect, in which CBD has differential 
impact on both cancer and “normal” cells. Administration of low concentration of CBD (0.1 pM) 
lead to an inhibition of LC3-II formation but this effect was transient. To date, there is no data 
showing the exact dose of cannabinoid delivered to the GI tract and absorbed by the 
gastrointestinal cells after CBD administration. Consequently, the finding of CBD induced- 
autophagy to be dose dependent could be an important finding for the therapeutic use in disease 
with disordered autophagy, for instance, CD.
Activation of PI3K Class III is required for the recruitment of ATG protein complex, leading 
to the induction and expanding of phagophore membrane (Lindmo and Stenmark, 2006). PI3K 
Class III activation is obligatory for the occurrence of the canonical formation of 
autophagosomes (Juenemann and Reits, 2012). Here, results showed that by blocking PI3KCIII 
activation, ACEA and AEA-induced effects were inhibited but not the CBD-induced 
autophagy effect, which was only partially inhibited. This suggests that CBD may, in part, 
induce the non-canonical autophagy pathway as opposed to ACEA and AEA. Genome-wide 
association studies (GWAS) revealed single nucleotide polymorphisms (SNPs) in ATG16L1 
gene in CD patients (Prescott et al., 2007). ATG16L1 localized ATG5/12/16L1 protein 
complex to the isolation membrane, followed by the formation of autophagosome double 
membrane vesicle (Fujita et al., 2008; Henderson and Stevens, 2012). PI3KCIII activity is 
required for the recruitment of ATG16L1 protein complex (Nishimura et al., 2013), suggesting 
that CBD may still be able to induce autophagy process when ATG16L1 autophagy gene is 
impaired in the system and therefore, promoting the therapeutic potential of CBD in treating 
CD.
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Another methodology to study the role of cannabinoids in autophagic process is through the 
use of the lysosomal inhibitor, Baf-Al. With prolonged Baf-Al treatment, Baf-Al alone 
induces a significant increase in the LC3-II formation, as the result from an accumulation of 
LC3-II, corresponding to the blocking of the autophagolysosomal degradation step. 
Cannabinoids do not further enhance or inhibit the Baf-Al induced accumulation of LC3-11, 
which suggests that the cannabinoid effect on autophagy may be related to reduce 
autophagosome degradation as opposed to increased autophagosome synthesis. In fact, since 
cannabinoids induced 2-3 fold increases in LC3-II formation and Baf-Al induced 4-5 fold 
increases, it is perhaps not surprising that no further enhancement of Baf-Al effect is observed. 
The sensitivity of the method does not allow us to confirm or refute that cannabinoids induce 
autophagosome synthesis, but rather indicates an inhibitory role in late autophagy.
As stated previously, despite both ACEA and AEA exert different binding affinities on CNR1 
receptor, both cannabinoids were able to induce LC3-II to the same extend, I am interested to 
explore the role of CNR1 in this context. AEA binds and activates both cannabinoid receptors 
CNR1 and CNR2. Additionally, AEA is also found to be a ligand for the vanilloid receptor, 
TRPV1 receptor as AEA shares a structural similarity with capsaicin, an exogenous TRPV1 
receptor activator (Melck et al., 1999). In contrast, ACEA, the synthetic modified compound 
of AEA, only induces a greater binding affinity towards CNR1 (Hillard et al., 1999). 
Interestingly, despite both ACEA and AEA displayed different binding affinity on CNR1, these 
cannabinoid-induced effects were shown to be CNR1 mediated. Unlike other G-coupled 
protein receptor (GPCRs), CNR1 can be intracellularly activated by endogenous cannabinoids 
(Rozenfeld, 2011). Remarkably, study showed localization of CNR1 at lysosomal 
compartments (Rozenfeld and Devi, 2008). Intracellular injection of AEA activated functional 
CNR1 and the subsequent mobilization of intracellular calcium concentration was reduced by
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the administration of Baf-Al (Brailoiu et al., 2011). The results illustrated the involvement of 
CNR1 in lysosomal degradation. Taken together, data obtained supports the ACEA and AEA- 
induced effect on late degradation. In contrast to ACEA and AEA-induced effects, CBD- 
induced effect was not mediated by CNR1. A9-THC has previously been shown to induce 
autophagy in human astrocytoma cells and that study showed that the A9-THC-induced effect 
was CNR1 mediated (Salazar et al., 2009). Despite both studies being performed in different 
cell lines, these results suggest that A9-THC and CBD may act through distinct mechanisms 
during autophagy.
5.6 Comments on methodologies used
In this study, autophagosome formation was monitored by measuring the conversion of LC3 
from LC3-I to LC3-II through immunoblot analysis (Kabeya et al., 2000). LC3 is the hallmark 
for autophagy and LC3-probed western blotting has been one of the most reliable techniques 
to Assess autophagy formation. As LC3-I and LC3-II are both involved in autophagy induction; 
it has been a controversy over the application of the most appropriate methodology to analyse 
the LC3 probed immunblot: either the ratio of LC3-II /LC3-I or the ratio of LC3-II/ a house 
keeping gene (Mizushima and Yoshimori, 2007). The latter was applied in this study as the 
anti-LC3 antibody has a higher sensitivity of detection towards LC3-I, as compared to LC3-II. 
Therefore, it may not be appropriate to analyse the data by measuring the ratio of LC3-II/LC3- 
I. Also, it should be noted that endogenous LC3-II is degraded by lysosomal hydrolases after 
the formation o f autolysosome (Tanida et al., 2005). Therefore, the relative fold change of LC3- 
II conversion may not represent the true level of cannabinoid induced LC3-II formation in the 
cell system as some of the cannabinoid induced LC3-II formation may have already been 
degraded during cannabinoid treatment. In order to resolve this problem, autophagy inhibitors 
such as 3-MA and Baf-Al were applied to cannabinoids treated cells. These inhibitors disrupt 
different stages o f autophagy process, thus providing a clearer picture on cannabinoid action 
on autophagy induction.
Despite the specificity of the use of anti-LC3 antibody, as well as the sensitivity provided via 
western blotting, such technique is very delicate and prone to errors, consequently leads to a 
false positive finding and increases the difficulty in replicating and analyzing the results 
obtained. The limitation of performing such technique has been clearly demonstrated through 
the experiment where experiments were conducted to investigate cannabinoid-induced 
autophagy effects in response to Baf-Al treatment (section 3.4.2). Baf-Al induced an
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extraordinary increase in LC3-II formation in the treated cells, resulting in the difficulty to 
compare the LC3-II protein expression between the non-treated and Baf-Al treated samples on 
the same blot with the same exposure intensity. The problem encountered was in agreement 
with previous finding as the study addressed the difficulty in analysing the Baf-Al treated cells 
in LC3-II probed immunoblot due to the non-linearity of the enhanced chemiluminescence 
substrates, which have been applied during blot developing (Rubinsztein et al., 2009). Hence, 
in this study, cells treated with or without Baf-Al were all loaded in a single SDS-PAGE but 
analysed under two different exposure intensities to ensure that the increased LC3-II expression 
is not resulting from the accumulation of chemiluminescence signal on the sample (Figure 
5.14).
Apart from western blotting, fluorescent imaging has also been performed to measure 
cannabinoid induced autophagy process. Confocal microscopy was used to image fully 
differentiated CaCo2 cells which have been stained with Cyto-ID® Green autophagy dye. The 
use of confocal microscopy provided the opportunity to detect cannabinoid-induced effect on 
the treated cell from three dimensional visualization imaging. There are four autophagy 
associated dyes available in the market: the monodasylcadaverine dye (MDC), the Acridine 
Orange dye, the LysoTracker® Red dye from Life Technologies and finally, the Cyto-ID® 
Green autophagy dye from Enzo Life Science. MDC fluorescent dye was first selected as the 
lysomotrophic dye to be tested in this study (see appendix). MDC was applied to label the 
autophagic vacuoles in cannabinoid treated cells (Biederbick et al., 1995). However, the use of 
MDC generated a high background signal with weak fluorescent signal, resulting in the need 
to increase the laser power during imaging, which consequently damaged the treated cells. 
Therefore, it was decided that the MDC may not be an appropriate autophagy dye to be used 
in this study. Next to MDC dye, Cyto-ID® Green autophagy dye was selected as the fluorescent
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maker to label autolysosomes and earlier autophagic compartments in cannabinoids-treated 
cells (Manual, 2011). The difference between Cyto-ID® Green autophagy dye and the Acridine 
Orange dye, as well as the LysoTracker® Red dye is the former weakly stains lysosomes 
whereas the latter primarily detect only lysosome (Manual, 2011). With that, Cyto-ID® Green 
autophagy dye was selected to apply on the treated cells as the detection of lysosome does not 
necessary correlated to the occurrence of autophagic process. Also, it is informative to detect 
the earlier autophagic compartments, as well as the autolysosome in the treated cells as 
autophagy is a sequential process and by staining both of these compartments will provided a 
clear picture of the total cannabinoid induced autophagic activity in the cells.
As previously stated, differentiated CaCo2 cells were stained with Cyto-ID® Green autophagy 
dye for confocal imaging. It is noteworthy that CaCo2 cells which were used for imaging have 
not been cultured up to 17 days, the length of cell growth which has been applied to all previous 
experiments. It is noted that cells cultured to 17 days were no longer formed a single monolayer 
of cell, in fact, cells have grown to overlap the first monolayer of cells, resulting in the difficulty 
to focus on the cells during confocal imaging. Therefore, by compromising to such issue, the 
length of cell growth for the treated cells has been reduced to 10 days. Previous study showed 
that the CaCo2 cells reached a growth plateau after day 10. The extended culture days up to 
day 17 would form a regular tight junction network but an irregular and fairy complete tight 
junction network has already been developed at day 2 (Rothen-Rutishauser et al., 2000). Hence, 
even by reducing the culture period for the treated cells in order to compromise the issue 
encountered during confocal imaging, the results generated from confocal imaging are reliable 
for further analysis.
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Additionally, despite that the developed cell model system is more physiologically relevant to 
the gut epithelium, the use of non-synchronized treated cells did increase the difficulty in 
replicating the experiments. As previously stated in chapter 3, the rational for not synchronizing 
the cell cycles back to Go position was thought that such act would interfere with the 
physiological setting of the GI tract as not all the epithelial cells in GI tract were in the Go 
position. Despite that it was time consuming to generate statistical significance data for the 
experiments, all the findings generated from the experimental setting were definitely more 
physiological relevant and this increases the possibility for the findings to be translated into 
clinical development.
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5.7 Limitations of the in vitro system
As previously stated, CaCo2 cells are currently the best characterised gut epithelial monolayer 
system available for in vitro study, as they exhibit display similar characteristics to enterocytes 
residing in human small intestinal epithelium (Bailey et al., 1996). In this study, CaCo2 cells 
were grown and cultured on a flat culture dish for 17 days prior to treatments. The 2- 
dimensional (2D) CaCo2 culture model approach was employed in this study because I 
wanted to explore the molecular basis for proposed beneficial cannabinoids effects on the 
autophagy process, and a 2D culture model was sufficient to provide reliable data. Such 2D 
culture models have been commonly used in studies to explore cellular homeostasis in the 
intestinal epithelium (Wang et al., 2000; Ruemmele et al., 2003; Lenaerts et al., 2005) and 
they are known to be more cost efficient, as compared to the filtered-grown CaCo2 cells on a 
trans-well insert (3D CaCo2 culture model). However, there are limitations with the use of 
such a 2D culture model, and this needs to be implicated in the data interpretation. The 2D 
culture model may lack physiological relevance as it fails to capture the 3D microenvironment 
present on the intestinal villi, which may affect the correlation between drug-induced effects 
in vitro and in vivo. Furthermore, a recent study showed that CaCo2 cells, which are grown 
on the 3D scaffolds, display a variation in their cell differentiation where cells are more 
polarized and columnar at the top and less differentiated near the villous base (Yu et al., 2012), 
suggesting different culture approaches may result in cell phenotype variation. As I have 
previously demonstrated in Chapter 3 that there was a variation in the cells’ response towards 
exogenous stimulations in different growth stages (proliferating, confluent, and differentiated) 
in my 2D CaCo2 cell model, this finding suggests that the culture approach may affect the 
cell response towards cannabinoid treatments, which subsequently impacts on the 
cannabinoids-induced-effects on the autophagic process.
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Aside from the use of the 2D CaCo2 culture model, the culturing condition may also affect 
the significant findings in this study. In this project, cells were cultured under atmospheric 
conditions (oxygen range -21%), because, not only does this method provide an easy access 
to the cultured cells, which greatly benefits the cell maintenance process, but it also eliminates 
further complications involved during data interpretation. However, this range of oxygen level 
(~21%) is known to be physiologically irrelevant as compared to the hypoxia condition found 
in human colon. A recent study showed that CaCo2 cells which are cultured in a hypoxia 
condition (5%) are more sensitive towards cannabinoid treatment and that there is an increase 
in oxygen reactive species (ROS) in intact mitochondria in cannabinoid-treated cells 
(Macpherson et al., 2014). ROS are small, high reactive molecules which are known to serve 
as signalling molecules in a variety of cellular processes, including growth, differentiation, as 
well as autophagy (Scherz-Shouval and Elazar, 2007; 2011; Sumandea and Steinberg, 2011). 
Accumulation of ROS, which results from induced cellular oxidative stress, leads to the onset 
of the autophagic process (Scherz-Shouval and Elazar, 2007), suggesting a possible impact of 
ROS on the cannabinoid-induced autophagy process if the experiments are performed under 
hypoxia conditions. Despite this, my findings are important preliminary data, which can be 
used to study the cannabinoid-induced autophagy effect under hypoxia conditions and the 
possible role of ROS in this context.
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Chapter 6 
Autophagy mediates cannabinoid 
induced SOCS3 reduction
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6.1 Introduction
SOCS3 acts as an inducible negative feedback regulator in cytokine-induced signaling (Dalpke 
et al., 2008). Binding of cytokines triggers the activation of JAK kinases. This leads to the 
phosphorylation of tyrosine residue on JAK kinases and recruitment of STAT3 via the 
phosphotyrosine-binding SH2 domain. Activated STAT3 will form STAT3 dimers with other 
phorphorylated STAT3 residue and translocated into cell nucleus. Subsequently, accumulation 
of activated STAT3 dimers will initiate the transcription of SOCS3 and other target genes 
(Bjorbaek et al., 1999). Activation of SOCS3 will limit transcription factor activation and its 
translocation in response to the stimulation from inflammatory cytokines (Rigby et al., 2007). 
The SOCS3 protein consists of a SH2 domain, a KIR domain and a SOCS-box located at the 
C-terminus of the protein (Dalpke et al., 2008). SH2 domain is responsible for the binding of 
phosphorylated tyrosine whilst SOCS box is mainly responsible for the recruitment of 
ubiquitin-transferase system, a mechanism which involves in the post translational degradation 
of the proteins (Yoshimura et al., 2005).
It has been reported that SOCS3 is up-regulated in both animal and human intestinal 
inflammation (Suzuki et al., 2001). SOCS3 (both mRNA and protein) was shown to be up- 
regulated in colon samples from UC and CD patients compared with healthy controls. SOCS3 
also limits proliferation of epithelial cells in the damaged crypt, but contrary to in vitro 
investigations, up-regulation of SOCS3 in inflamed intestine, does not appear to sufficiently 
limit STAT3 and NF-KB inflammatory pathways (Rigby et al., 2007). Contrary to several 
publications showing that SOCS3 expression is silenced in many cancers (He et al., 2003; 
Rigby et al., 2007). Caco2 cells express high levels of SOCS3 compared with other cell lines 
(Rigby, personal communication). Therefore the contrasting role of SOCS3 in cancer and 
inflammation is highlighted in my model. Thus, I wish to explore the possible action of
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cannabinoids on SOCS3 protein expression as a mediator o f CBD therapeutic potential
6.2 Aims
To investigate the action of pliyto-, synthetic, and endoannabinoids 
on SOCS3 protein expression using the CaCo2 cell line.
To determine whether the actions of CBD on SOCS3 are mediated 
through the cannabinoid receptor (CNR)-l.
154  | P a g e
6.3 Cannabinoid action on SOCS3 expression in intestinal epithelial cells
Cannabinoids are known to exert significant anti-inflammatory properties in various 
experimental models (Cluny et al., 2012; Kozela et al., 2010b; Ribeiro et al., 2012). 
Cannabinoids reduce lipopolysaccharide-induced STAT3 phosphorylation (Kozela et al., 
2010a), but it is not clear how CBD mediates effects on this anti-inflammatory pathway . To 
date, there is no current study looking into the association of SOCS3 in autophagic process. 
Therefore, it is interesting to explore the role of SOCS3 as a novel inflammatory mediator in 
relation to cannabinoid-induced autophagic process in the gut epithelial cell model. My 
previous experiments demonstrated that 4h cannabinoid treatment appeared to be the optimal 
time for LC3-II formation in my model. Therefore, experiments were conducted to investigate 
cannabinoid-induced SOCS3 protein expression levels at the same time point. These sets of 
experiments provide the first insight into the impact of cannabinoids on SOCS3 protein 
expression in my CaCo2 cell model system.
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To investigate the effects of CBD on SOCS3 protein expression in my model, a time course 
experiment was performed. The result showed that CBD-treatment induced the biggest 
reduction in SOCS3 protein expression at 4h (Figure 6.1), the same time frame that 1 observed 
the biggest induction of LC3-1I. The SOCS3 protein was expressed in an oscillatory manner 
(i.e. not at a stable level) over a 24h period as expected (Yoshiura et al., 2007).
Control
CBD lOfiM
Figure 6.1. Immunoblot analysis of SOCS3 in fully differentiated CaCo2 cells in response to 
lOpM cannabidiol (CBD) treatment within 24h. Data plotted are relative fold-increase in
SOCS3 protein expression (n=l).
(Molecular weight fo r SOCS3: 27KDa; ft-Act in: 45KDa)
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I then performed a dose-response experiment to explore whether CBD-reduced SOCS3 protein 
expression was dose dependant. Dose response revealed that CBD reduced SOCS3 protein 
expression within 4h and this effect was dose-dependent up from 1 pM to the highest 
concentration tested (25pM) (Figure 6.2).
(3-Actin
Control 0.1 nM ljiM  10[rM 25|.iM
Figure 6.2. Dose response for CBD in relation to SOCS3 formation. CaCo2 cells were treated 
with CBD for 4h. Data plotted are relative fold-increase in SOCS3 protein expression (adjusted 
to p-actin, mean ± SE). * denotes significant different (p<0.05) when compared to untreated 
control. (n>3, data were analyzed with Dunnett t-test (2-sided)).
(Molecular weight for SOCS3: 27KDa; f-Actin: 45KDa)
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ACEA and AEA dose-response experiment was conducted to investigate the effects of these 
cannabinoids on SOCS3 protein expression. Result showed that both ACEA and AEA reduced 










Figure 6.3. Dose response for ACEA in relation to SOCS3 formation. CaCo2 cells were treated 
with ACEA for 4h. Data plotted are relative fold-increase in SOCS3 protein expression 
(adjusted to p-actin, mean ± SE). * denotes significant different (p<0.05) when compared to 
untreated control. (n>3, data were analyzed with Dunnett t-test (2-sided)).
(Molecular weight fo r  SOCS3: 27KDa; P-Actin: 45KDa)
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S0CS3
p-A ctin
Control 1 pM 1 OpM
Figure 6.4. Dose response for N-arachidonoylethanolamine (AEA) in relation to SOCS3 
formation. CaCo2 cells were treated with AEA for 4h. Data plotted are relative fold-increase 
in SOCS3 protein expression (adjusted to P-actin, mean ± SE). * denotes significant different 
(p<0.05) when compared to untreated control. (n>3, data were analysed with Dunnett t-test (2- 
sided)).
(Molecular weight fo r  SOCS3: 27KDa; (3-Actin: 45KDa)
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6.4 Mechanism of action for cannabinoid-induced SOCS3 reduction
As previously stated, SOCS3 protein consists of a SH2 domain, a KIR domain and a SOCS- 
box (Dalpke et al., 2008). Each domain of SOCS protein mediates different interaction and 
functions. One of the ways in which SOCS regulate protein expression is through the SOCS 
box, a conserved domain located at the C-terminal (Piessevaux et al., 2008). This region was 
shown to interact with the E3 ubiquitin ligase complex and studies have suggested that such 
interaction provides SOCS with protein stability (Haan et al., 2003; Zhang et al., 1999). 
Additionally, SOCS box is also involved in protein degradation by linking the targeted protein 
towards proteasomal machinery (Piessevaux et al., 2008). The SH2 domain, on the other hand, 
is important for the binding of phosphorylated tyrosine residues (Croker et al., 2008). This 
domain may have a role in competing for the STAT protein binding site as mutation of Val34 
and Leu41 in the domain region consequently affected SOCS3 ability to inhibit STAT 
activation (Sasaki et al., 1999). Furthermore, the SH2 domain also possesses a PEST motif, 
which is involved in SOCS3 protein degradation. However, there is a controversy over the 
mechanism of action for such outcome and study has proposed that the PEST motif may be 
modulated through the proteasomal-degradation pathway (Babon et al., 2006; Garcia-Alai et 
al., 2006; Rechsteiner and Rogers, 1996). Taken together, these findings suggested that there 
is more than one route to drive the turnover of SOCS3 protein. Therefore, experiments were 
conducted to investigate the cannabinoid-induced SOCS3 protein reduction in relation to: (1) 
JAK-STAT3 signalling pathway (2) ubiquitin-proteasome proteolytic pathway and (3) 
autophagy process (Figure 6.5).
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(1) Limits the 
JAK-STAT pathway?
(3) Drives autophagy 
degradation?
(2) Drives ubiquitin- 
proteasome proteolytic 
pathway?
Figure 6.5. Possible mechanism of action that is responsible for Cannabidiol (CBD) or 
cannabinoids induced SOCS3 reduction.
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6.4.1 Involvement o f the JAK-STAT3 signalling pathway in SOCS3 protein reduction
SOCS protein acts as the negative feedback inhibitor of the JAK-STAT pathway. The 
binding of cytokines to the associated receptor initiates a conformational change on the 
receptor itself, resulting in the auto-phosphorylation of the tyrosine residues on Janus 
kinases (JAK). Consequently, the activated JAK kinases will recruit signal transducer 
and activator of transcription factors (STAT). The activated STAT3 will form STAT3 
dimers with other phosphorylated STAT3 residue and the accumulation of activated 
STAT dimers in cell nucleus will eventually initiate the transcription of SOCS3 gene 
(Dalpke et al., 2008; Piessevaux et al., 2008). SOCS3 is capable in binding to JAK2 and 
STAT3, resulting in the initiation of feedback inhibition loop for STAT3 signaling 
pathway (Figure 6.6) (Babon et al., 2012). Taken together, it is comprehensive to 
speculate that cannabinoid treatment may increase the phosphorylation of STAT3, which 
consequently leads to the SOCS3 reduction due to SOCS3 induced negative feedback 
inhibition loop on the STAT3 protein.








S e r7 2 7  P P
DNA transcription of 
S0CS3 & other genesNucleus
Figure 6.6. Schematic diagram shows the JAK-STAT signaling pathway and the 
negative feedback inhibition of SOCS3. Phosphorylation of STAT3 at Tyr705 induced 
the JAK-STAT pathway whereas the phosphorylation of STAT3 at Ser727 induced the 
DNA transcription of SOCS3 and other genes.
i. Cannabinoids induced p-STAT3(Ser727) protein expression
The activated JAK kinases phosphorylate the tyrosine residue (Tyr705) on STAT protein 
and this initiates STAT dimerization, which will translocate into the nucleus, leading to 
the binding of STAT to DNA and initiating the transcription of several genes, such as 
SOCS3 (Figure 6.6). Phosphorylation of the serine residue (Ser727) resides at the -  
COOH terminus of the transactivation domain of STAT3 protein is required for STAT3 
mediated transcriptional activation (Wen and Darnell, 1997). The removal of the C- 
terminal domain in STAT3 resulted in the generation of transcriptionally inactive 
proteins (Decker and Kovarik, 2000). Therefore, cannabinoid-induced effect on the
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serine residue (Ser727) o f p-STAT3 protein was investigated in treated cells.
CBD was the only cannabinoid increased the phosphorylation of STAT3(Ser727) in 
treated cells (Figure 6.7), suggesting that CBD treatment increased the DNA transcription 
of SOCS3. Also, based on the negative impact of ACEA and AEA on p-STAT3 
regulation, the cannabinoid-induced SOCS3 effect may be mediated through a non CNR1 
associated signaling pathway.
phospho-STAT3(Ser727) — m-r <mmmm
total-STAT3 mmmm mmmm mmmm mmmm
Control ACEA AEA CBD
Figure 6.7. Cannabinoid induced phospho-STAT3(Ser727) protein expression. CaCo2 
cells were treated with cannabinoids for 4h. Data plotted are relative fold-increase in p- 
STAT3 protein expression (adjusted to total-STAT3, mean ± SE). * denotes significant 
different (p<0.05) when compared to untreated control, (n—4, data were analysed with 
Dunnett t-test (2-sided)).
(Molecular weight for p-STAT3: 91KDa; t-STAT3: 79KDa)
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ii- Cannabinoid-induced p-STAT3(Ser727) protein expression in autophagy inhibitor 
treated cells
Based on previous findings, cannabinoids increased the autophagic induction (chapter 5) 
but reduced SOCS3protein expression in treated cells. Also, CBD, but not ACEA and 
AEA, has been shown to increase the phosphorylation of p-STAT3 (Ser727) in treated 
cells. Therefore, it is interesting to further explore cannabinoid-induced effects on p- 
STAT3 expression under the circumstances where the autophagolysosomal degradation 
pathway is inhibited by the autophagy inhibitor, Baf-Al. In this study, cells were pre­
treated Baf-Al for 20h prior to the cannabinoid treatment for additional 4h.
The result showed that blocking the autophagy process with Baf-Al did not impact on 
the phosphorylation of STAT3(Ser727) in cannabinoids treated cells (Figure 6.8). This 
implied that SOCS3 reduction was not mediated through the JAK-STAT signaling 
pathway. As the treatment of CBD has been shown to increase autophagy induction 
(Chapter 5), this data further supported the proposal that SOCS3 reduction was regulated 
through SOCS3 protein degradation and not through the change in the rate of SOCS3 
protein synthesis.
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Figure 6.8. Cannabinoid induced phospho-STAT3(Ser727) protein expression in the 
presence of Bafilomycin-Al (Baf-Al). CaCo2 cells were treated with cannabinoids for 
4h. Data plotted are relative fold-increase in p-STAT3 protein expression normalized 
against Baf-Al treatment (adjusted to total-STAT3, mean ± SD; n=2).
(Molecular weight fo r p-STAT3: 9lKDa; 1-STAT3: 79KDa)
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6.4.2 Involvement o f  ubiquitin-proteasome proteolytic pathway in SOCS3 protein 
reduction
The ubiquitin-proteasome proteolytic pathway is a common mechanism involved in the 
protein degradation. Ubiquitylation is formed through the binding between the lysine 
residue at the targeted protein and the C-terminus of ubiquitin protein (Welchman et al., 
2005). As previously stated, the SOCS box, as well as the PEST motif in the SH2 domain 
of SOCS protein has been shown to be involved in protein degradation and the SOCS 
box-induced protein degradation has been shown to be mediated via proteasomal- 
degradation pathway (Babon et al., 2006; Garcia-Alai et al., 2006; Piessevaux et al., 2008; 
Rechsteiner and Rogers, 1996). Based on these findings, an experiment was conducted 
to investigate cannabinoid-induced SOCS3 protein reduction in relation to ubiquitin- 
proteasome proteolytic pathway. The SOCS3 protein was immunoprecipitated from 
CBD-treated cells and analysed by immunoblotting with the Ubiquitin-1 specific 
antibody. The molecular weight for Ubiquitin-1 protein is 8.5KDa and together with the 
molecular weight of SOCS3 protein of 27KDa, the expected molecular weight for the 
protein complex is around 35.5KDa.
A time-course experiment was conducted on CBD treated CaCo2 cells. SOCS3 protein
was immunoprecipitated from CBD-treated cells and analysed by immunoblotting with
Ubiquitin-1 specific antibody. The rational for performing such experiment was to
determine the protein expression of Ubiquitin-1 which would have bound to the SOCS3
protein in the CBD treated cells and to explore whether ubiquitin-1 was correlated to the
reduction of SOCS3 protein in CBD treated cells. In this study, CBD was the only
cannabinoid to be used as the treating compound and this was due to the promising
finding obtained in previous chapter (Chapter 5) where my results suggested that CBD
may have a therapeutic potential in disease with impaired autophagy. Therefore, it is
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interesting to explore the mechanism of action involved in CBD-induced SOCS3 protein 
reduction in the treated cells.
The formation of polyubiquitylation involves the binding of a number of ubiquitin 
proteins to a single lysine residue on the targeted protein, resulting in the formation of a 
single chain of ubiquitin protein (Welchman et al., 2005). This explained the presence of 
a collection of ubiquitin-1 proteins at the molecular weight between 200KDa to 1 OOKDa 
(Figure 6.9). Result showed that the Ubiquitin-1 protein expression was correlated to the 
reduction of SOCS3 protein in response to CBD treatment (Figure 6.9). However, 
because the reduction in ubiquitin is likely to be due to the reduction in SOCS3 available 
(i.e. less immunoprecipitated) I cannot conclusively state that ubiquitin is targeting 
SOCS3 for proteasomal degradation from this experiment.
Figure 6.9. Ubiquitin-1 interacted with SOCS3 protein in CBD treated CaCo2 cells. 
Cells were treated with lOpM CBD for 2h and 4h respectively. SOCS3 protein was 
immunoprecipitated from CBD-treated cells and analysed by immunoblotting with 
Ubiquitin-1 specific antibody; (n=l).
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As the previous experiment suggested that there was a correlation between ubiquitin-1 to 
the reduction of SOCS3 protein expression, an experiment was conducted to further 
explore the association of ubiquitin-mediated degradation pathway in SOCS3 reduction. 
A cell permeable proteasome inhibitor, MG 132 (Guo and Peng, 2013), was applied to 
CBD-treated cells to inhibit ubiquitin-conjugated protein from degradation. CaCo2 cells 
were pre-treated with MG132for 2h, prior to CBD treatment for additional 4 hour.
The result showed that CBD, as well as MG 132, reduced ubiquitin-1 protein expression 
in treated cells (Figure 6.10). Interestingly, blockage of the ubiquitin-conjugated SOCS3 
protein from degrading did not affect the ubiquitin-1 protein expression level in CBD 
treated cells (Figure 6.10). Even though this experiment has only been performed once 
but the result provided an indication that the ubiquitin-proteasome proteolytic pathway 
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Figure 6.10. Effect of MG132 treatment on ubiquitin-1 co-precipitated SOCS3 protein 
in CBD treated CaCo2 cells. Cells were pre-treated with 15pM MG 132 for 2h prior to 
lOpM CBD treatment for additional 4h. SOCS3 protein was immunoprecipitated from 
CBD-treated cells and analysed by immunoblotting with Ubiquitin-1 specific antibody, 
(n=l).
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6.4.3 Involvement o f  autophagy process in S0CS3 protein reduction
As previous experiments indicated that neither the JAK-STAT pathway nor the ubiquitin- 
proteasome proteolytic pathway were responsible for cannabinoid-induced effect on 
SOCS3 protein reduction in treated cells, the involvement of autophagy mediated 
lysosomal degradation pathway was investigated in this context.
To investigate whether the autophagy degradation pathway was responsible for 
cannabinoid-induced SOCS3 protein reduction, cells were treated with autophagy 
inhibitors: 3-MA and Baf-Al. 3-MA inhibits autophagy process by targeting on the 
phagophore formation whereas Baf-Al inhibits autophagy process by targeting on the 
autophagolysosomal formation (Klionsky et al., 2008; Simonsen and Tooze, 2009).
The results showed that by blocking the early stage of autophagy with 3-MA reversed 
AEA and CBD induced SOCS3 protein reduction (Figure 6.11) whereas blocking the late 
stage of autophagy with Baf-Al reversed only the ACEA-induced effect (Figure 6.12).
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SOCS3
p-Actin
Figure 6.11. Immunoblotting showed the effect of cannabinoids treatment on S0CS3 
protein expression in the presence of 3-MA. Fully differentiated CaCo2 cells were pre­
treated with 3-MA (lOmM) for lh prior to addition of cannabinoids: CBD (lOpM), 
ACEA (lOOnM), and AEA (lOpM) for additional 4h. Data plotted are relative fold- 
increase in S0CS3 protein expression (adjusted to p-actin, mean ± SE).
* denotes significant different (p<0.05) when compared to untreated control.
+ denotes significant different (p<0.05) when compared to paired treatment control.
(n>3, data were analysed with Tukey post hoc test).
(Molecular weight fo r SOCS 3: 27KDa; (3-Actin: 45KDa)
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Figure 6.12. Immunoblotting showed the effect of cannabinoids treatment on SOCS3 
protein expression in the presence of Baf-Al. Fully differentiated CaCo2 cells were pre­
treated with Baf-Al (lOOnM) for 20h prior to addition of cannabinoids: CBD (lOpM), 
ACEA (lOOnM), and AEA (lOpM) for additional 4h. Data plotted are relative fold- 
increase in SOCS3 protein expression (adjusted to P-actin, mean ± SE). * denotes 
significant different (p<0.05) when compared to untreated control. =1 denotes significant 
different (p<0.05) when compared to paired treatment control. (n>3, data were analysed 
with Tukey post hoc test).
(Molecular weight for SOCS3: 27KDa; ft-Act in: 45KDa)
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6.5 Possible correlation of CNR1 receptor in cannabinoid-induced SOCS3 reduction
Thus far, experiments have revealed that cannabinoids increased autophagy induction and the 
autophagy process was responsible for cannabinoid-induced SOCS protein reduction in treated 
cells. Also, the ACEA and AEA-induced effect in autophagy induction have been shown to be 
CNR1 mediated; it is therefore interesting to investigate the association of CNR1 in SOCS3 
protein reduction. To determine whether ACEA, AEA and CBD-induced SOCS3 protein 
reduction was CNR1 mediated, CaCo2 cells were pre-treated with CNR1 antagonist, AM251.
The result showed that AM251-induced blockage of CNR1 in CaCo2 cells may reverse 
cannabinoids-induced SOCS3 effects in treated cells (Figure 6.13).
Figure 6.13. Immunoblotting showed the 
effect of cannabinoids treatment on SOCS3 
protein expression in the presence of AM251. 
Fully differentiated CaCo2 cells were pre­
treated with AM251 (lOOnM) for lOmin prior
to addition of cannabinoids: CBD (lOpM), 
ACEA (lOOnM), AEA (10pM) for additional 
4h. Data plotted are relative fold-increase in 
SOCS3 protein expression (adjusted to p-actin, 
mean ± SD, n=2).
(Molecular weight for SOCS3: 27KDa; (i-Actin: 
45KDa)
As previously mentioned in chapter 5, even though the use of antagonists to the CNR1 leceptor 
has been an important tool in the dissection of receptor-mediated signalling and function, but 
a novel way to study the functional consequence of CNR1 loss is by the use of CNR1
knockdown cell model system. Therefore, to further verify the role of CNR 1 in cannabinoid-
S0CS3
P-Actin
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induced S0CS3 piotein ieduction, ACEA, AEA and CBD were treated on both CaCo2- 
CNR1KD and CaCo2-Scrambled cells.
The result showed that cannabinoid reduced SOCS3 protein expression in treated CaCo2- 
Scrambled cells. However, by knocking down the CNR1 gene in CaCo2 cells, the cannabinoid- 
induced effects on SOCS3 protein were reversed (Figure 6.14). This finding is in agreement 
with a previous experiment where cannabinoid-induced effect on SOCS3 protein was disrupted 




kcv■jS s N o v  xr^  ^
Figure 6.14. Effect of cannabinoid treatments on SOCS3 protein expression in both CaCo2- 
Scrambled and CaCo2-CNRlKD cell lines. Cells were treated with cannabinoids: CBD 
(lOpM), ACEA (lOOnM), and AEA (lOpM) for 4h prior to lysing. Data plotted are relative 
fold-increase in SOCS3 protein expression (adjusted to P-actin, mean ± SD, n-2).
(Molecular weight fo r  SOCS3: 27KDa; [3-Act in: 45KDa)
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6.6 Discussion
The phyto-, synthetic and endo-cannabinoids reduced S0CS3 protein expression within 4h. 
This finding supported a previous study where CBD reduced SOCS3 mRNA in microglial cells 
(Juknat et al., 2013). Results demonstrated that CBD induced SOCS3 reduction was dose 
dependent. Interestingly, despite ACEA being a ‘high potency’ analog of AEA, ACEA (Hillard 
et al., 1999) requires a ‘high’ concentration to induce a reduction of SOCS3 protein. The 
reduction in SOCS3 protein may be due to either increased protein degradation, or reduced 
protein synthesis. Caco2 cells express high levels of SOCS3 at both the protein and mRNA 
level (Chapter 3 and Rigby, personal communication), therefore I investigated the mechanism 
of SOCS3 reduction.
At 4h following CBD treatment, there seems to be a reciprocal effect of cannabinoid action on 
autophagic formation and SOCS3 protein expression. Cannabinoid treatment increases 
autophagic induction, but leads to a reduction in SOCS3 protein expression. Therefore, it could 
be assumed that the mechanisms involved in cannabinoid-induced SOCS3 protein reduction 
may be linked to the autophagic process and so I wished to determine whether such 
cannabinoid-induced effect was associated with enhancement of autophagy induction. My 
overall results revealed that the cannabinoid-induced SOCS3 reduction was in fact regulated 
through the autophagy pathway. This finding suggested that apart from previously known 
SOCS protein regulatory pathways, such as the ubiquitin-proteasome proteolytic pathway and 
the JAK-STAT pathway, autophagy induction may be a new mechanism in regulating the 
SOCS proteins (Babon et al., 2012; Babon et al., 2006; Welchman et al., 2005).
Additionally, my result also showed that ubiquitin-1 protein expression was shown to be 
correlated to the reduction of SOCS3 protein in response to CBD treatment but the ubiquinated-
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S0CS3 protein did not go through degradation via the ubiquitin-proteasome proteolytic 
pathway. As previously stated, the SOCS box in SOCS3 consists of a binding site for E3 
ubiquitin ligase complex and such complex is required to facilitate the conjugation of ubiquitin 
to the lysine residue of the targeting protein, therefore explained the binding of ubiquitin-1 to 
the SOCS3 protein (Kuang et al., 2013; Piessevaux et al., 2008). This finding was in agreement 
with previous study which demonstrated the ubiquitylation in SOCS3 (Sasaki et a l, 2003).
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Chapter 7 
Conclusion & Future Work
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These studies demonstrated cannabinoid action in autophagy regulation in a human intestinal 
epithelial cell model system. The key findings of cannabinoid actions are summarized in 
Figure 7.1.
>  Induced canonical autophagy 
(possibly by acting on au tophagosom e 
degradation)
>  Both ACEA and AEA induced effects a re  
CNR-1 m ediated
>  Induced partial non-canonical 
autophagy
(possibly by acting on au tophagosom e 
degradation)







Figure 7.1. Cannabinoid action in autophagy process demonstrated in human intestinal 
epithelial cell model.
A recent review published by Juenemann and Reits highlighted other alternative autophagy 
pathways which do not require the involvement of autophagy key players (Atg5 or lipidation 
of LC3 or PI3K-Class III/Beclin-1) to induce lysosomal degradation (Juenemann and Reits, 
2012), suggesting that autophagy can still be induced despite the absence or impairment of 
these autophagy key players in the regulatory system. I was particularly interested in the LCa 
lipidation dependent canonical/non-canonical route of autophagy regulation (Juenemann and 
Reits, 2012) as my results demonstrated the formation of LC3-II in cannabinoid treated cells, 
suggesting that LC3-I lipidation process was required for autophagy induction. Recent studies 
revealed the induction of non-canonical autophagy by therapeutic potential di ugs such as 
Resveratrol (breast cancer) and Dizocilpine/MK801 (neuronal disease) (Grishchuk et al., 2011,
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Juenemann and Reits, 2012, Scarlatti et al., 2008), suggesting that CBD, which has been a 
potential therapeutic target for various disease (cardiovascular disease, diabetes, Huntington’s 
disease), may also act on the non-canonical autophagy pathway.
In this study, CBD induced autophagy, but canonical autophagy was only part of the signal; 
therefore, CBD may also induce a non-canonical autophagy as opposed to ACEA and AEA. 
Genome-wide association studies (GWAS) revealed SNPs in ATG16L1 gene in CD patients 
(Prescott et al., 2007). ATG16L1 localized ATG5/12/16L1 protein complex to the isolation 
membrane, followed by the formation of autophagosome double membrane vesicle (Fujita et 
al., 2008; Henderson and Stevens, 2012). PI3KCIII activity is required for the recruitment of 
ATG16L1 protein complex (Nishimura et al., 2013). Therefore, the finding of CBD to induce 
a non-canonical autophagy suggests that CBD may have potential therapeutic application in 
CD where autophagy is compromised (Figure 7.2).
Despite AEA and ACEA binding and activating CNR1 with different binding affinities (Hillard 
et al., 1999), both ACEA and AEA induced effects were shown to be CNR1 mediated. Unlike 
other G-coupled protein receptor (GPCRs), CNR1 can be intracellularly activated by 
endogenous cannabinoids (Rozenfeld, 2011). My findings that CBD have effects on autophagy 
are perhaps not that surprising because of localization of CNR1 at lysosomal compartments 
(Rozenfeld and Devi, 2008). Intracellular injection of AEA activated functional CNR1 and the 
subsequent mobilization of intracellular calcium concentration was reduced by the 
administration of Baf-Al (Brailoiu et al., 2011). The results illustrated the involvement of 
CNR1 in lysosomal degradation. Taken together, data obtained supports the ACEA and AEA- 
induced effect on late degradation. In contrast to previous findings, the CBD-induced effect in 
my studies was not mediated by CNR1. A9-THC has previously been shown to induce
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autophagy in human astrocytoma cells and that study showed that the A9-THC-induced effect 
was CNR1 mediated (Salazar et ah, 2009). Despite both studies being performed in different 













Cytoplasmic proteins or 
Pathogen/microbes
Figure 7.2. Schematic diagram showed the therapeutic potential of CBD for Crohn’s Disease 
(CD). CBD may induce a partially non-canonical autophagy (PI3K-Class III independent), 
suggesting that CBD is still capable in enhancing autophagy process when functional 
ATG16L1 is absence in the cell system. With that, CBD increased autophagy may be used as 
the tool for microbial/pathogen clearance in CD.
Cannabinoids reduce lipopolysaccharide-induced STAT3 phosphorylation suggesting a role in 
regulating microbial-induced inflammatory pathways (Kozela et al., 2010a). SOCSj is also up- 
regulated in chronic intestinal inflammation (UC and CD) (Li et ah, 2010). In my model, all 
three cannabinoids were able to reduce endogenous SOCS3 protein, therefore may lepresent 
anti-inflammatory therapeutic potential. Reduction of SOCS3 in an inflammatory setting may
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allow intestinal homeostasis to be restored. CBD also reduced SOCS3 mRNA in microglial 
cells (Juknat et al., 2013), suggesting that this effect may not be intestinal specific. My findings 
showed SOCS3 reduction was not mediated through reduced STAT3 phosphorylation, nor 
ubiquitin-proteasome proteolytic pathway but, suggest that SOCS3 reduction was in fact, 
mediated through the autophagy degradation pathway.
ACEA and AEA induced autophagy were CNR1 mediated and CBD-induced autophagy was 
not CNR1 mediated, Both ACEA and AEA induced SOCS3 reductions were completely 
inhibited in both CNR1 antagonist treated and CNR1 knockdown CaCo2 cells, suggesting that 
ACEA and AEA induced SOCS3 reductions were CNR1 mediated. Interestingly, for CBD, 
there may be additional pathways involved in CBD-induced SOCS3 reduction because there 
was still a modest CBD induced SOCS3 reduction in CNR1 antagonist treated cells, suggesting 
that this could be reminiscent of the canonical versus non-canonical effect of CBD (ie. there is 
some dependence on the canonical autophagy pathway and the CNR1 the non-canonical 
pathway).
SOCS3 is expressed in an oscillatory manner in non-transformed cells (Yoshiura et al., 2007). 
Unusually, for a cancer cell line, basal SOCS3 levels are consistently high in CaCo2 cells and 
my finding that cannabinoids reduce SOCS3 may indicate that they act to increase autophagic 
degradation o f SOCS3 protein, representing a possible mechanism by which cyclic protein 
expression could be regulated. Furthermore, elevated intestinal SOCS3 in UC and CD (Li et 
al., 2010) could be due to compromised autophagosomal degradation of the protein.
As I have shown previously that all cannabinoids increased autophagy and addressed that CBD 
may have therapeutic potential in CD, it is interesting to explore CBD-induced effect in
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autophagy process under inflammatory setting. The use of CBD as a potential therapeutic drug 
for IBD may be through aid of pathogen clearance in CD. Preliminary experiments showed the 
impact of CBD treatment in IL-1 P-induced inflammatory setting (see appendix). IL-1 (3 was 
selected as the pro-inflammatory cytokine to induce inflammation in my model system as IL- 
1(3 production was shown to be increased in inflamed gut mucosa in IBD patients (Reimund et 
al., 1996; Reinecker et al., 1993). My data showed that IL-lp increased LC3-II formation in 
treated cells. CBD at lOpM further enhanced LC3-II formation in IL-1(3 treated CaCo2 cells, 
as compared to CBD and IL-1P treatment alone. This experiment has only been repeated twice 
and more replicates will be required to conclude the statistical significance of this piece of data. 
Based on the results in Chapter 3 (system analysis), I have shown that the IL-1 p-induced effect 
on LC3-II protein was serum dependent, supported by a previous study showing that IL-lp- 
induced autophagy in rat annulus fibrosis cells was serum dependent (Shen et al., 2011), 
suggesting that CBD exerts anti-inflammatory effects in intestinal epithelial cells. Additionally, 
in agreement with a recent study demonstrating that autophagy regulates IL-lp production in 
macrophages by targeting pro- IL-1P for lysosomal degradation (Harris et al., 2011). Use of 
live microbes in my model system will offer us further verification of the possible role of CBD 
in ‘opportunistic-pathogen’ clearance.
Additionally, in correlation to recent studies which have revealed the role of ubiquitylation in 
autophagy regulation (Ohsumi, 2001; Kirkin et al., 2009; Behrends and Fulda, 2012), my study 
showed that the ubiquitin-1 protein expression was correlated to the reduction of SOCS3 
protein in response to CBD treatment, but the ubiquinated-SOCS3 protein did not go through 
degradation via the ubiquitin-proteasome proteolytic pathway. Based on previous findings, a 
range of E3 ubiquitin ligases were discovered to be involved in autophagy regulation. For 
example, the TRIM 13 E3 ligase of p62 adaptor protein and the c-CBI E3 ligase that regulates
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the interaction between Src homology and LC3B protein (Kuang et al., 2013). These E3 ligases 
have been shown to regulate the degradation and stability of the autophagy-related proteins, as 
well as facilitate the regulation of recruited adaptor protein (Kuang et al., 2013). p62 has been 
shown to interact with LC3 protein, as this adaptor protein comprises an LC3-interacting region 
(UR), which facilitates the formation of p62-LC3 complex (Kirkin et al., 2009). Nonetheless, 
the p62 adaptor protein has also been found to interact with ubiquitin (Long et al., 2008). Based 
on these findings, it is rational to suggest a mechanism for autophagy-induced SOCS3 
reduction. It is possible that SOCS3 is ubiquitylated via its internal E3 ligase complex, resulting 
in the recruitment and binding of p62 adaptor protein. p62 bound ubiquitylated SOCS3 protein 
complex will then be recognised by LC3 at the phagophore. This would lead to SOCS3 protein 
being targeted to the autophagolysosomal degradation pathway. Taken together, this suggests 
an interaction between LC3, p62 and ubiquitin protein. However, further experiments will be 
required to validate this hypothesis. This can possibly be done through the generation of p62 
knockdown CaCo2 cells to determine the expression of SOCS3 under the loss of p62 adaptor 
proteins.
In the whole, the research presented in this thesis supports an important role for autophagy in 
homeostatic regulation of cyclic proteins. Furthermore, it also describes a novel role for 
cannabinoids in the intestinal tract that could have therapeutic implications in the treatment of 
CBD.
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I. Stock solution recipes
Following are the recipes for stock solutions that were required for western blotting:
> RIPA Lvsis Buffer 
150mM ofNaCl
1 % of IGEPAL CA-630 
0.5% of Sodium Deoxycholate 
0.1% of SDS 
50mM of Tris
* Buffer to be adjusted to pH  8
> Tris-Glvcine SDS running buffer 
For making up 10X buffer, add:
250mM of Tris
1.92M of glycine 
1% of SDS
> TBS (T Ox)
For making up the buffer intolL, add:
24.2g of Tris Base 
87.6g ofNaCl
* Buffer to be adjusted to pH  7.5
> Stripping buffer 
2mL of 10% SDS 
6.75mL of water
1.25mL of 0.5M Tris HCL (pH 6 .8 )
80uL of 2ME
186 | P a g e
II. P roduct sheet for H uSH shRNA Plasmid, pRS
fj OriGeneMu technology* wc
HuSH shRNA Plasmid. pRS
pRS shR N A  C loning Plasm id
C atalog #  TR200G3
P roduct D escription:
•  Pla sm id vecto r for doming sh RNA  
expression  cassettes
•  D es ign ed  for long term  gene silencing 
stud ies
•  A m picillin  (1 0 Q u g /m l)a n d  Puromycin  
res is tan ce  m arkers  for e a s y  selection  
of transform ed  or transfected cells
•  IJ6 p o lym erase  III prom oter for shR N A  
expression
•  M M L V  L T R  sequ ences  for packaging  
into retroviral particles
•  E c o R I and  H indlll sites oon ven ientfo r  
shuttling existing H u S H  cassettes
Content: Each vial contains 5 ug of dried  
and purified plasm id D NA.
Storage and Stability: T h e  plasm id is 
stable for at least 1 yr at -2 0 ° C  from the  
date of sh ipm ent
Guarantee: This product is guaranteed  for 
the correct sequences and listed functions.
Related Products: Specific H uSH  
constructs a re  availab le  at O riG ene  
covering the full hum an, m ouse and rat 
genom es.
Quality Control A ssays
DNA Quantitation: The concentration of the
purified plasmid was determined at O D jki by a
UV spectrometer.
DNA Sequence Analysis: The final purified
plasmid was sequenced to confirm its identity.
Functional Analysts:
1. Cloning: the pRS plasmid was digested with 
BamHI and Hindlll and the digested fragment 
isolated. Multiple shRNA expression 
cassettes were cloned into this plasmid.
2. Inhibition of target gene: shRNA constructs 
cloned into pRS were verified for inhibition of 
target genes.
3. Stable cell lines: pRS was verified to generate 
stable cell lines using direct transfection.
Figure 1: Map of shRNA Cloning Vector pRS
loop
Taiga: J « ;u c n r e  ’ o  g e tje q u e tx c -f tC '
5V40 *arl/ promoterU6 promoter
pfl5 ahflHA V«.toi 
£3d30b»t]
HC": i ever 3e compfenaeHt
Terms o f U se
By opening the use the product, the purchaser agrees not to distribute, resell modify for resale or use to 
manufacture commercial products without prior written approval from OriGene Technologies Inc. If you do 
not agree with these conditions, please return product to OriGene for 3  ful refuno
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III. Quantitative Real Time PCR (qRT-PCR) generated DNA melting curves for CNR1 
receptor in both CaCo2 CNR1 KD and CaCo2 Scrambled cells.
Quantitative RT-PCR was performed by using extracted RNA samples from the CNR1 
knockdown cells. A single peak of CNR1 melting curve was obtained in both wild type and 
CaCo2 _Scrambled cells but not in CaCo2_CNRlKD cells (Figure 8.1), suggesting that 
CaCo2 _CNRlKD cells have significant low copies of CNR1 gene in the cells and this 
resulted in no single peak for the DNA melt curve in qRT-PCR.
Figure 8.1. DNA melt curve for Cannabinoid receptor(CNR)-l in (A)wild type CaCo2 cells; 
(B)CaCo2_Scrambled cells; and (C)CaCo2_CNRlKD cells.
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IV. The use of D ansylcadaverine (MDC) dye in treated cells
MDC was the fiist autophagiy dye to be optimized in this project. MDC was applied to label 
the autophagic vacuoles in cannabinoid treated cells (Biederbick et al., 1995). However, the 
use o f MDC generated a high background signal with weak fluorescent signal (Figure 8.2), 
resulting in the need to increase the laser power during imaging, which consequently damaged 
the treated cells. Therefore, it was decided that the MDC may not be an appropriate autophagy 
dye to be used in this study.
C o n tro l CBD lO pM  3-MA 3-MA+CBD
Figure 8.2. Fluorescence images with the use o f dansylcadaverine (MDC) dye in treated 
CaCo2 cells.
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V. Preliminary data for CBD action in autophagy process under inflammatory setting
IL-1P, a pro-inflammatory cytokines, is released by immune cells to the site of injury during 
inflammation (Harris et al., 2011). Also, IL-1 p production was increased in inflamed gut 
mucosa in IBD patients (Reimund et al., 1996; Reinecker et al., 1993). Therefore, IL-lp was 
selected as the pro-inflammatory cytokine to induce inflammation in my model system.
The preliminary data showed that both CBD and IL-ip treatments increased LC3-II formation 
and CBD may further enhance IL-ip-induced LC3-II formation in treated cells (Figure 8.4), 
suggesting that CBD exerts anti-inflammatory effects in intestinal epithelial cells. However, 
experiment will need to be repeated in order to confirm the statistical significance of this data.
lh 4h 6h 8h 24h
IL-lp
Figure 8.3. Dose response curve for IL-ip treatment. Immunoblot analysis of LC3-II in fully 
differentiated CaCo2 cells in response to IL-ip (lOng/mL) treatment within 24h. Data plotted 
are relative fold-increase in LC3-II protein expression (adjusted to p-actin, n 1).
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Control CBD IL-1B IL-1B+CBD
Figure 8.4. Cannabidiol (CBD)-induced LC3-II protein expression in IL-ip-induced 
inflammatory setting. CaCo2 cells were pre-treated with IL-1P for lh prior to CBD treatment 
for additional 4h. Data plotted are relative fold-increase in LC3-II protein expression 
(adjusted to p-actin, mean ± SD; n=2)
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